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ABSTRACT 
The purpose of this study was to identify a-adrenoreceptor types and subtypes 
mediating contractile responses to adrenergic agonists in the bovine tail artery and vein and 
to investigate ner\'e-mediated contraction in the bovine tail artery in response to electrical 
field stimulation. Isolated tissue bath methods were used to study isometric contractile 
responses in vessel rings. Electrical field stimulation, under constant current conditions, was 
used to study vessel contraction as a result of neurotransmitter(s) release from sympathetic 
nerve terminals. 
Evidence was obtained for the presence of functional aiA- and aio-adrenoceptors in 
the tail artery. Whether functional aiB-adrenoceptors are present is less certain but it is likely 
that aiB-adrenoceptors do co-exist with other a i-adrenoceptor subtypes. Of the ai-
adrenoceptor subtypes, the aiA-adrenoceptor plays a dominant role in the contractile 
response to adrenergic agonists in the tail artery. 
In the isolated endothelium denuded bovine tail vein both types of a-adrenoceptors 
(ai and a:) are capable of mediating contractile responses to adrenergic agonists, ai-
Adrenoceptors play a significant role in adrenergic-mediated contractile responses in the 
bovine tail vein via activation of both aiA- and ais-adrenoceptors, but not via aio-
adrenoceptors. a2-Adrenoceptor mediated contractions occurred via activation of a2c-
adrenoceptors. The possibility that other a2-adrenoceptor subtypes (a2B and/or aio) 
participate in adrenergic agonist-mediated contraction in the bovine tail vein cannot be 
excluded. 
A purinergic agonist, a,P-meATP, produced contractile responses in the isolated 
endothelium intact bovine tail artery via activation of purinergic receptors (P2x)- The role of 
ATP as a sympathetic neurotransmitter in mediating contractile responses to sympathetic 
nerve stimulation in the bovine tail artery is not clear. Our findings suggest that there is a 
possibility of norepinephrine/purinergic co-transmission in the bovine tail artery. However, 
further experiments which incorporate the direct measurement of ATP release during field 
stimulation along with the use of more selective P2X receptor antagonists will be required to 
resolve this issue. 
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CHAPTER I. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation is written in an alternative thesis format. It contains a general 
introduction, four research papers, a general discussion and a list of references that were cited 
in the general introduction and discussion sections. Chapter I, "General introduction", 
includes research objectives, background information and literature review. Chapter II, "Co­
existence of a,-adrenoceptor subtypes in the bovine tail artery". Chapter III, 
"Characterization of a,A and a,B-adrenoceptor subtypes in the bovine tail vein". Chapter IV, 
"The role of aj-adrenoceptors in contractile responses in the bovine tail vein and artery" and 
Chapter V, "Evaluation of nerve-mediated contraction in the bovine tail artery in response to 
electrical field stimulation" have been submitted for publication to the European Journal of 
Pharmacology. Chapter VI, "General conclusion", includes a general discussion about the 
major findings for this research project. 
This dissertation contains most of the experimental results obtained by the author 
during her graduate study under the supervision of her major professor. Dr. Donald C. Dyer. 
Research Objectives 
Vascular tone as a component of cardiovascular regulation plays an important role in 
the delivery of oxygen and nutrients to the tissues. The skeletal muscle vasculature has a 
great influence on systemic vascular resistance and this in turn has an effect on arterial blood 
pressure regulation. The regulation of vascular tone is a complex process and has at least 
three major elements: neuronal, hormonal and local tissue factors (e.g., autacoids) (Leflcowitz 
et al, 1996). 
The sympathetic nervous system, as a part of the autonomic nervous system, plays a 
significant role in vascular tone regulation. Norepinephrine is a neurotransmitter which is 
released from the sympathetic nerve terminal in response to nerve stimulation and then binds 
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to postsynaptic adrenoceptors to produce the response. According to modem nomenclature 
there are two types of functional a-adrenoceptors (a, and ttj) and each type has three 
subtypes (a,a, aia, oCid oijb, ajc) (Docherty, 1998). The purpose of this research 
was to identify a-adrenoceptor types and subtypes in the bovine tail artery and vein which 
are capable of playing a role in contractile responses to adrenergic agonists and also to 
evaluate the possibility of whether purinergic (ATP) co-transtnission occurs in the isolated 
bovine tail artery when sympathetic nerves are stimulated. Evaluation of the role of 
purinergic receptors and identification of functional a-adrenoceptors was determined by 
studying contractile responses in the isolated bovine tail artery and vein. Evaluation of 
possible ATP co-transmission in the isolated bovine tail artery was studied using electrical 
field stimulation. 
Background and Literature Review 
This section provides background information related to the studies presented in this 
dissertation and includes information about: 1) a-adrenoceptors classification, structure and 
intracellular signaling pathways; 2) pharmacological characterization of a-adrenoceptor (a, 
and subtypes; 3) sympathetic nervous system co-transmitters (norepinephrine, ATP and 
neuropeptide Y); and 4) purinergic receptor mediated contractile responses in smooth muscle. 
a-Adrenoceptors 
Classtncation 
Adrenoceptors mediate the action of the sympathetic nervous system and are found in 
many peripheral tissues and within the central nervous system (Bylund et al., 1994). 
Adrenoceptors are involved in the functioning of all organs and organ systems which are 
under the control of the sympathetic nervous system. Adrenoceptors are cell membrane 
receptors which have seven transmembrane domains and are coupled to guanine nucleotide-
binding regulatory protein (G protein) (Docherty, 1998). There are two large categories of 
J 
adrenoceptors, a and (3 which were originally defined by Ahlquist (1948) based on the 
potency rank of a number of adrenergic agonists in producing a physiological response. The 
main excitatory receptor (except in the intestine) was designated as an a-adrenoceptor while 
the main inhibitory receptor (except in the heart) was named the P-adrenoceptor (Ahlquist, 
1948). Later, in the I970's two types of a-adrenoceptors, a,- and ttj-adrenoceptors, were 
identified (Langer, 1974). 
Initially, a^-adrenoceptors were discovered as prejunctional autoreceptors on 
adrenergic neurons which ftmction to modulate norepinephrine release (Langer, 1974). In 
general, a,-adrenoceptors are characterized by having a higher affinity to prazosin than do 
a2-adrenoceptors (Bylund et al., 1994; Docherty, 1998; Langer, 1999) while a,-
adrenoceptors are characterized by having higher affinity to the agonists, clonidine and UK 
14,304, (5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaIine bitartrate) and to the antagonists 
rauwolscine and yohimbine (MacKinnon et al., 1994). The heterogenity of a,-adrenoceptors 
and the existence of subgroups of a,-adrenoceptors was proposed based on contractile study 
data about differences in tissue sensitivity to norepinephrine (Bevan et al., 1988; Bevan et al., 
1986). However, identification of a-adrenoceptor subtypes became possible with the 
development of radioligand binding assays (Bylund, 1988). Both types of a-adrenoceptors 
(a, and a,) were eventually subdivided into smaller groups, i.e. subtypes (Table 1). 
Table 1. Modem nomenclature of a-adrenoceptors (Docherty, 1998; Langer, 1999). 
Type of a-adrenoceptors 
Characteristics OCt 
Cloned receptors (subtypes) ^la ^Ib ^2A ^2B ^2C 
Native receptors (subtypes) ^IB C'lD CtjA/D *^2B ^2C 
Three a,-adrenoceptors have been cloned (a,j, a,b, a,d) and three functional a,-
adrenoceptor subtypes (a,a, a,B, a,D) have been identified (Bylund et al., 1994; Docherty, 
1998; Langer, 1999). A different kind of a,-adrenoceptor subtype, with a low affinity to 
prazosin has been identified in some tissues but has not been cloned (Langer, 1999). Another 
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classification scheme has divided a,-adrenoceptors into two categories based on their affinity 
to prazosin: a,H-adrenoceptors - those receptors with high affinity to prazosin (ai^, oi,b. a,i,) 
and a,L-adrenoceptors — those receptors with a low affinity to prazosin (Bylund et al., 1994; 
Docherty, 1998; Langer, 1999) (Fig. 1). 
a, - Adrenoceptors 
a IH a IL 
®IA ®IB ^ID 
Figure 1. Subclassification of a,-adrenoceptors (Langer, 1999). 
Four subtypes of aj-adrenoceptors have been cloned (aj^, octb, a^c anda2D)- Current 
classification recognizes three functional (ttjA/o, a2B, o^c) subtypes (Bylund et al., 1994; 
Docherty, 1998). The cl2a- and ttju-adrenoceptor subtypes are species homologues of the 
same receptor subtype (ttjA/o-subtype) (Bylund et al., 1994). a2A-Adrenoceptors are found in 
humans (Guimaraes et a!., 1998), pigs (Trendelenburg et al., 1996) and rabbits 
(Trendelenburg et al., 1994), while ±e azD-adrenoceptor subtype is present in the rat 
(Guimaraes et al., 1998), mouse (Limberger et al., 1995), guinea pig (Guimaraes et al., 1998) 
and cattle (Bylund, et al., 1997). 
Characterization of a-adrenoceptors 
Several methods have been developed to characterize the presence of a-adrenoceptors 
in tissues: functional studies (Furchgott, 1972), radioligand binding assays (Buckner, et al., 
1996), immunostaining assays (Hrometz, et al., 1999) and a variety of molecular biological 
techniques (Perez, et al., 1994). The following includes a brief review of the most commonly 
used methods in receptor characterization. 
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Functional study. In order to produce a response to a ligand (agonist), the ligand has 
to bind to the receptors and form the receptor-ligand (agonist) complex (Furchgott, 1966). 
This process can be described by an equation: 
[Ligand] + [Receptor] ^ [Ligand x Receptor] 
The response to an agonist is proportional to the number of occupied receptors 
(Furchgott, 1966). The ideal system for pharmacological characterization of the receptors is 
when the binding process is in thermodynamic equilibrium, i.e., the free-ligand and the 
receptor-bound ligand are in equilibrium (Furchgott, 1972). However, if the ligand mentioned 
above is norepinephrine there are some parameters that have to be controlled in order to 
achieve equilibrium conditions. The concentration of norepinephrine decreases over time 
from the receptor region due to the removal process which includes not only simple dilution of 
the norepinephrine away from the receptor but also transport (uptake) processes (Furchgott, 
1966; Furchgott, 1972; Lefkowitz et al., 1996). Several uptake processes have been defined 
for norepinephrine (Furchgott, 1966; Lefkowitz et al., 1996). In order to inhibit these removal 
processes when a-adrenoceptors are characterized, it has been proposed that monoamine 
oxidase (MAO), catecholamine-O-methyltransferase, neuronal (uptake,) and tissue uptake 
(uptake^) be blocked with iproniazid, tropolone, cocaine and corticosterone, respectively 
(Furchgott, 1966; Furchgott and Garcia, 1968; Levin and Furchgott, 1970). Concentration-
response relationships to an agonist are usually obtained by adding the agonist cumulatively to 
the tissue bath in half-log increments. Concentration-response relationships to an agonist are 
obtained twice, before and after incubation with one concentration of an antagonist. For each 
experiment a paired tissue not exposed to an antagonist is carried through the procedure to 
permit correction for time-dependent changes in responses to the agonist, as recommended by 
Furchgott (1972) and as used in our laboratory (Zhang and Dyer, 1990; Hill and Dyer, 1997). 
There are some parameters which are commonly acquired in the characterization 
process. The receptor-agonist complex can be described by the effective concentration 
(EC50, molar concentration) of agonist required to produce 50% of the maximal contraction 
("log EC50 = pD,) and by determining the dissociation constant (K^) for the receptor-agonist 
complex as described by Furchgott and Burzstyn (1967). In order to calculate the value 
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for a given agonist, a concentration-response relationship is obtained before and after 
inactivation of a fraction of the receptors with dibenamine. Then a double reciprocal plot is 
constructed of equi-effective concentrations of an agonist before (1/[A]) and after (1/[A]') 
treatment with dibenamine (corrected for the time-dependent changes). The dissociation 
constant (K^ can be calculated by using the equation: = slope - l/intersept (Ruffolo, 
1982). Agonist affinity is a reciprocal of the value (1/K^ (Furchgott, 1972). 
The dissociation constant (Kg) for the receptor-antagonist complex and a 
determination of an antagonist's potency (pAj) can be obtained by methods described by 
Furchgott (1972) and as used in our laboratory (Zhang and Dyer, 1990). This method is 
based on a comparison of shifts of the agonist concentration-response curve at the EC50 in 
control and antagonist treated tissues. Briefly: agonist ECjo values are determined in the 
absence (A) and presence (A*) of each competitive antagonist concentration from agonist 
concentration-response curves. The concentration ratio, CR = A*/A (Furchgott, 1972), and 
the log (CR -1) are calculated after correction for the time-dependent changes in sensitivity to 
the agonist occurring during the course of the experiment. pAj values can be calculated, 
according to Arunlakshana and Schild (1959), by using the equation: log (CR-1) = log[B] -
log Kg (Furchgott, 1972), where [B] is the concentration of the antagonist and Kg, the 
dissociation constant of the receptor-antagonist complex. The calculated log (CR-I) values 
are plotted versus the log [B] as a linear relationship and where the line intercepts the 
abscissa yields the pAz value (pAj = - log K^,). 
Alternatively, the relative potency of antagonists can be determined by calculating 
pKg values (pKg = -logKg) using a single concentration of an antagonist as described by 
Furchgott (1972). For this purpose EC50 values should be calculated from the concentration-
response curves in the absence [A] and in the presence [A'] of each competitive antagonist 
concentration. The concentration ratio, CR = [A']/[A] (Furchgott, 1972), and the log (CR -1) 
should be calculated after correction for the time-dependent changes in sensitivity to the 
agonist. The Kg value can be calculated as: Kb = [B]/CR-1, where [B] is the concentration of 
the antagonist (Furchgott, 1972) and expressed as pKg (-log Kg). However, this method 
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cannot provide information as to whether the antagonism was competitive as can the method 
discussed above by Aruniakshana and Schiid (1959). 
Functional studies have some limitations which are mainly related to the availability of 
selective agonists and/or antagonists. However, an advantage of this technique is that a 
physiologic response (e.g., tissue contraction) is used in the receptor characterization process. 
Radioligand binding assay. Radioligand binding assay is a powerful tool used to 
determine the receptor type(s) on cell membranes. The principle of the radioligand binding 
assays is to measure the bound radioactivity which can be accomplished by three types of 
experiments: saturation, kinetic and/or inhibition (Bylund and Toews, 1993). The saturation 
method allows the determination of the receptor density [B„ J and the affinity of the receptors 
for the radioligand (dissociation constant, Ku). Dissociation rate constants can be estimated 
from kinetic data and the affinity (K,) of the drug for the receptor can be estimated from 
inhibition experiments (Bylund and Toews, 1993). While radioligand binding studies were 
not performed for this dissertation, literature values of agonists or antagonists affinities 
obtained for cloned and native a-adrenoceptors by radiolig£ind binding methods were used for 
comparison with data obtained from functional study experiments. 
Other methods. Fluorescent ligand binding assay allows for the study of a-
adrenoceptors receptors localization in live tissue (Piascik et al., 1997; Daly et al., 1998; 
Daniel et al., 1999). The use of fluorescent ligand binding assay in conjunction with confocal 
laser scanning microscopy allows the data to be quantified (Daly et al., 1998). 
Identification of mRNA distribution of a-adrenoceptor types and subtypes in tissues 
can be used to determine tissue expression of receptors. (Piascik et al., 1994; Zhong and 
Minneman, 1999). 
Molecular cloning techniques permit the study of receptor molecular structure 
(Graham et al., 1996; Schwinn and Price, 1999) and provide a scientific tool to study the 
mechanism of receptor flmction. 
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a,-Adrenoceptors 
This section is a general review of a,-adrenoceptors and includes information about 
tissue distribution, molecular structure and intracellular signaling. Information about a,-
adrenoceptor subtypes and selective agonist and antagonists for these subtypes is also 
presented. 
Tissue distribution, a,-Adrenoceptors have been an extensively studied group of 
receptors. The presence of a,-adrenoceptors has been reported in vascular tissues of different 
species, such as in: rat tail artery (Lachnit et al., 1996; Villalobos-Molina and Ibarra, 1996), 
rat hind limb (Zhu et aJ, 1997), rat mesenteric artery (Stassen et al, 1998; Piascik et al., 
1997), rat aorta (Villalobos-Molina and Ibarra, 1996), rat carotid artery (Villalobos-Molina 
and Ibarra, 1996; Noble et al., 1997), rabbit ear artery (Fagura et al., 1997), pig splenic artery 
(Barbiery et al., 1998) and coronary artery (Yan et al., 1998), equine digital vein (Elliot, 
1997), sheep uterine artery and umbilical vein (Hu and Dyer, 1997) and bovine tail artery 
(Hill and Dyer, 1997) as well as in non-vascular tissues in human (vas deferens, Furukawa et 
al., 1995; prostate, Teng et al., 1994; Chess-Williams et al., 1996; urethra, Taniguchi, et al., 
1997); rabbit heart (Hattori and Kanno, 1997); pig female urethra (Alberts et al., 1999); rat 
liver (Stam et al., 1998), rat heart (Yu and Han, 1994) and vas deferens (Honner and 
Docherty, 1999). 
Interestingly, in human tissues the highest concentration of mRNA for a,^-
adrenoceptors is found in the heart, for a,B-adrenoceptors in spleen and for a,D-adrenoceptors 
in urethra (Langer, 1998). The main physiological role of a,-adrenoceptors in vascular 
tissues is in the control of blood pressure (Bylund et al., 1994). a,-Adrenoceptors are also 
involved in growth of vascular smooth muscle and cardiac muscle (Zhong and Minneman, 
1999). 
Structure, a,-Adrenoceptors are a heterogeneous group of single chain polypeptides 
with a molecular weight of about 65 - 80 kDa (Graham et al., 1996). The polypeptide chains 
of the rat cloned a,,-, a,b-, au-adrenoceptors consist of 561, 515 and 466 amino acids. 
9 
respectively (Graham et al., 1996) (Table 2). Four different variants of human a,y^-
adrenoceptors have been cloned: a,3., (wild type), a,3.2, a,,.3 and a,3^ (Schwiim and Price, 
1999). These variants have differences only in the carboxyl terminals but there are no 
differences in their pharmacology or in their intracellular second messenger systems 
(Schwinn and Price, 1999). 
The helical membrane-spanning domains are composed of an extracellular pocket to 
bind the hydrophilic catecholamines and other adrenergic ligands (Graham et al., 1996; Chen 
et al., 1999). The ligand-binding pockets must be different among the a,-adrenoceptor 
subtypes (Hwa et al., 1995). 
Interestingly, a,B-adrenoceptors can be desensitized. Homologous desensitization 
and phosphorylation of a,B-adrenoceptors by agonists is the result of G-protein kinase-
mediated phosphorylation at Ser^*", Ser^°* and Ser^'" sites, located on the carboxyl terminal of 
the receptor (Scheer et al., 1999; Garcia-Sainz et al., 2000). 
Table 2. Characteristics of cloned a,-adrenoceptors. 
Characteristics 
a,-Receptor Subtypes 
a la  a lb  a Ic  
Molecular weight 
(kDa) 
Amino acids 
Number of amino 
acids on amino 
Glycosylation sites 
(N-terminus) 
G-protein coupling 
Receptor-coupled 
signaling 
80 
466 
25 
3 
«65 
561 
90 
2 
'q / l I /14 Gq/i i / ,4 ,16,  Gh Gq,i i  
Ca'* mobilization, PLC, PLA,, PLD 
80 
515 
42 
4 
Characterization of the cloned a,-adrenoceptors; PLC, phospholipase C; PLAj, 
phospholipase Aj; PLD, phospholipase D, (modified from Graham et al., 1996). 
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Figure 2. Model of a,-adrenoceptors, a,-.Adrenoceptors have seven transmembrane domains 
(D1 - D7) connected by three extracellular (1 - 3) and three intracellular hydrophilic loops (I -
III) (Graham et al., 1996). The extracellular amino termini contain 2-4 glycosylation sites 
(—>) (Graham et al.. 1996). In the a,B-adrenoceptor subtype the essential disulfide bond 
between two amino acids Cys"^and Cys"' is inaccessible for solvents (Graham et al.. 1996). 
Amino acids. Ser^'". Ser"*"* and Ser'"®. located on the carboxyl terminal of the a,B-
adrenoceptors. are substrates for phosphorylation and desensitization of the receptor (Scheer 
et al.. 1999: Garcfa-Sainz et al.. 2000). 
a,-Adrenoceptors belong to the G protein-coupled family of receptors. Each a,-
adrenoceptor has seven transmembrane domains of 20-28 hydrophobic amino acids 
connected by three extracellular and three intracellular hydrophilic loops (Graham et al.. 
1996) (Fig. 2). 
The extracellular amino termini consists of a different number of amino acids 
depending on the a,-adrenoceptor subtype and contains 2-4 glycosylation sites (Graham et 
al.. 1996). The first and the second extracellular loops have a single cysteine which is 
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essential for folding. In the a,B-adrenoceptor subt\'pe the essential disulfide bond between 
Cys'^and Cys"^ is inaccessible for solvents (Graham et al.. 1996). The second and the third 
intracellular loops are involved in intracellular coupling to G-proteins. The third intracellular 
loop and the carboxyl terminal of a,-adrenoceptors may be subtype-specific (Langer. 1998) 
and contain phosphorylation sites for protein kinase A (Graham et al.. 1996) and be involved 
in receptor-mediated phosphoinositol signaling mechanisms (Graham et al.. 1996) (Fig. 2). 
The a,B-adrenoceptor is also a substrate for heterologous desensitization via different 
mechanisms, such as: by phorbol esters (through activation of protein kinase C); via receptors 
coupled to Gq-proteins (such as endothelin receptors - ET^. to G,-proteins and to endogenous 
tyrosine kinase (growth factor receptors) (Scheer et al., 1999; Garcia-Sainz et al.. 2000). 
Signal transduction pathways. The main role of a,-adrenoceptors on vascular 
smooth muscle cell membrane is in mediating contractile responses. The traditional pathway 
of the intracellular reactions is associated with pertussis toxin-insensitive G-proteins (Gq. G,,-
G|4. G,6 and G^) coupled response. However, it has also been demonstrated that a,-
adrenoceptors can be coupled to pertussis toxin-sensitive G-proteins (Gj or G^,) (Graham et 
al., 1996). All a,-adrenoceptors are coupled to Gq and G,, while a,a- and a,B-adrenoceptor 
subtypes are coupled to G,^ and only a,B-adrenoceptors are coupled to G,6 and G^ (Table 2) 
(Graham et al.. 1996). G-protein contains three subunits, which are designated as a. P and y. 
When a ligand bind the a,-adrenoceptors it causes changes in the conformation of the G-
protein: the replacement of GDP by GTP. the dissociation of the a- from the Py-subunit of 
the G-protein and formation of Ga-GTP, which in turn activates phospholipase C (PLC-p) 
(Marshall et al., 1999). Activation of PLC-p results in hydrolysis of phospatidylinositol-4.5-
biphosphate (PIP2) and formation of the cellular second messengers: inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). IP5 stimulates release of Ca"* from 
sarcoplasmic reticulum and DAG activates protein kinase C (PKC) to produce cellular 
responses, (Hieble et al., 1995; Zhong and Minneman, 1999; Varma and Deng, 2000) which 
include activation of gene transcription (Graham et al., 1996). 
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Myosin light chain 
CONTRACTION 
Figure 3. The pathway of intracellular reactions via activation of a,-adrenoceptors. The 
activation of a,-adrenoceptors (a,-AR) causes changes in the conformations of the G-protein 
(G): the replacement of GDP by GTP. dissociation of the a- from the py-subunit of the G-
protein and formation of Ga-GTP, which in turn activates phospholipase C (PLC p) 
(Marshall et al.. 1999). Activation of PLC P results in hydrolysis of phospatidylinositol-4.5-
biphosphate (PIP2) and formation of the cellular second messengers: inositol 1.4.5-
triphosphate (IP3) and diacylglycerol (DAG). IP3 stimulates release of Ca** from 
intracellular store (SR - sarcoplasmic reticulum) and diacylglycerol (DAG) activates protein 
kinase C (PKC) (Hieble et al.. 1995; Zhong and Minneman, 1999; Varma and Deng, 2000). 
Intracellular Ca"* concentration can be increased also via Ca"* influx through voltage-
dependent and independent channels (Zong and Minneman, 1999; Varma and Deng. 2000). 
Intracellular Ca'' binds calmodulin and forms a Ca"*-calmodulin complex which activates 
myosin light chain kinase. Activated myosin light chain kinase along with PK.C initiates 
actin-myosin interaction by phosphorylation of myosin light chain, which in turn produces 
contraction of the smooth muscle cell (Voet and Voet. 1995). Stimulation of a,-
adrenoceptors can activate phospholipase D (PLD) (Zhong and Minneman, 1999; Varma and 
Deng. 2000) which can initiate hydrolysis of phosphatidylcholine (PC) to phosphatidic acid 
(PA) and this pathway leads to additional formation of DAG (Varma and Deng, 2000). 
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The cascade of intracellular reactions leads to an increase in intracellular Ca"* 
concentration and formation of Ca**-calmodulin complex, which is essential to activate 
myosin light chain kinase. Activated myosin light chain kinase along with PKC initiates 
actin-myosin interaction by phosphorylation of myosin light chain which in turn produces 
contraction of the smooth muscle cell (Voet and Voet. 1995) (Fig. 3). 
In addition to the traditional pathways of intracellular signaling several other 
mechanisms have been proposed for a,-adrenoceptor-mediated responses. For example, 
intracellular Ca** can be increased not only via mobilization from intracellular stores but also 
via Ca"* influx through voltage-dependent and independent channels (Zong and Minneman. 
1999; Varma and Deng, 2000). Stimulation of a,-adrenoceptors can activate phospholipase 
D (PLD) (Zhong and Minneman, 1999; Varma and Deng. 2000) and/or phospholipase A, 
(Graham et al.. 1996; Ruan et al., 1998) (Fig. 3). 
Activation of PLD can initiate hydrolysis of phosphatidylcholine to phosphatidic acid 
and this pathway leads to additional formation of DAG (Varma and Deng. 2000). 
Furthermore, activation of a,-adrenoceptors can stimulate accumulation of cAMP via a 
potentiation of adenylyl cyclase through PKC activation and/or via inhibition of cAMP 
degradation (Graham et al., 1996). 
Investigation of the role of a,-adrenoceptors in cell growth and hypertrophy is a 
rapidly developing research area. It has been demonstrated that a,-adrenoceptor agonists can 
activate mitogenic responses in vascular (Xin et al.. 1997) and cardiac (Ramirez et al., 1997) 
muscle cells. Norepinephrine stimulates the growth of vascular smooth muscle cells isolated 
from rat aorta and this occurs via activation of either a,D-adrenoceptors (Xin et al.. 1997) or 
a,Q-adrenoceptors (Chen et al.. 1995). The physiological significance and role of a,-
adrenoceptors in regulating smooth muscle growth and the mechanisms involved in its 
intracellular signaling needs further investigation (Zhong and Minneman, 1999). 
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a,-Adrenoceptor subtypes 
a,A-Adrenoceptor. The a,A-adrenoceptor is the most well characterized subtype 
among the a,-adrenoceptors. The presence of functional a,A-adrenoceptors has been reported 
in various vascular as well as in non-vascular smooth muscle. Activation of a,^-
adrenoceptors causes contraction of smooth muscle such as: rat tail artery (Lachnit et al.. 
1996; Villalobos-Molina and Ibarra. 1996). rat hind limb vasculature (Zhu et al. 1997). rat 
mesenteric arterv" (Stassen et al. 1998), rat aorta (Villalobos-Molina and Ibarra. 1996), rat vas 
deferens (Burt et al., 1998), porcine coronary artery (Yan et al.. 1998). guinea pig nasal 
mucosa vasculature (Tanimitsu et al., 2000). female pig urethra (Alberts, et al.. 1999). human 
urethra (Taniguchi et al.. 1997), human prostate (Marshall et al.. 1995) and human vas 
deferens (Furukawa et al.. 1995). 
The a,A-adrenoceptor subtype has been characterized in experiments which used 
subtype selective agonists or antagonists. There are two commercially available adrenergic 
agonists with a high selectivity to the a,A-adrenoceptors. A61603 ((±N-[5-(4.5-dihydro-l H-
imidazoI-2yI)-2-hydroxy-5.6,7,8-tetrahydronaphthalen-1 -yl] methanesulphonamide 
hydrobromide) and oxymetazoline. In radioligand binding experiments, A6I603 has a high 
affinity (pK,j for native a,A-adrenoceptors in rat vas deferens, canine prostate and for cloned 
a,3-adrenoceptors (Buckner, et al., 1996). A61603 caused a concentration dependent 
contraction of the isolated rat tail artery (pD^ of 7.59) which was inhibited by prazosin and by 
the selective a,A-adrenoceptor antagonist RS-17053 (N-[2-(2-
cyclopror>1methoxyphenoxy)ethyl]-5-chloro-a,a,-dimethyI-lH-indole-3-ethanamine 
hydrochloride) (Lachnit et al., 1996), but not by idazoxan, an a^-adrenoceptor antagonist, or 
by chloroethylclonidine. an irreversible a,B- and a,D-adrenoceptor antagonist (Lachnit et al.. 
1996). Oxymetazoline is reported to be an a,A-adrenoceptor agonist and it produced 
contractions of the isolated female pig urethra (pD, = 6.18; Alberts et al., 1999) and rabbit 
iris dilator (pDj = 6.77. Nakamura et al.. 1999). A61603 exhibits a higher affinity to a,A-
adrenoceptors when compared to that by norepinephrine and phenylephrine (Buckner et al., 
1996). In radioligand binding experiments, oxymetazoline was found to have a higher 
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affinity (pK^) for a,;^-adrenoceptors than for other a,-adrenoceptor subtypes (Buckner et al.. 
1996; Perez et al.. 1994). However, there are conflicting data in the literature about the 
specificity of oxymetazoline. In rat tail artery, oxymetazoline has been sho%vTi to act as a 
serotonin agonist (Lachnit et al., 1996) and it also antagonized contractile responses to 
A61603 (pK^ = 7.6) (Lachnit et al., 1996). 
Two commercially available subtype selective antagonists have been commonly used 
to study a,A-adrenoceptors namely: WB 4101 ((2-(2.6-dimethoxyphenoxyethyl) 
aminomethyi-L4 benzodioxane) (Villalobos-Molina and Ibarra, 1996; Hu and Dyer. 1997; 
Marshall et all, 1995) and 5-methylurapidil (Fagura et al.. 1997; Testa et al.. 1995; Lachnit et 
al.. 1996). WB 4101 has been used to characterize the a,A-adrenoceptor subtype in the rat 
tail artery (pA; = 9.08) (Villalobos-Molina and Ibarra. 1996). in the isolated ovine uterine 
arter>' (pA, = 8.30) and ovine umbilical vein (pA, = 8.45) (Hu and Dyer. 1997). in the rat 
portal vein (pA, = 9.4) (Marshall et all. 1995) and in porcine coronary artery (pA, = 10.67). 
Another a,A-adrenoceptor selective antagonist. 5-methylurapidil. was found to be a potent 
inhibitor of adrenergic-induced contraction in the rat aorta (pA^ = 7.64 - 7.95. Testa et al.. 
1995; Fagura et al.. 1997), in the rat tail artery (pA, = 9.0, Lachnit et al.. 1996) and in the 
female pig urethra (pKg = 8.59, Alberts, et al.. 1999). There are some other antagonists 
which have been shown to have a greater selectivit>' to a,A-adrenoceptor subt>'pes. such as: 
RS 17053 CN-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chIoro-a.a-dimethyl-lH-indole-3-
ethanamine hydrochloride), SNAP 5089 (2.6-dimethyl-4-(4-nitrophenyl)-1.4-
dihydropyridine-3,5-dicarboxilic acid) and REC. 15/2739 (SB 216469. 8-3-[4-(2-
methoxyphenyl)-l-benzopyran dihydrochloride). Contractile responses of the rat tail artery 
via activation of aj^-adrenoceptor were inhibited by RS 17053 (pA, = 9.2). SNAP 5089 
(pA; = 9.3) and REC. 15/2739 (pA, = 10.0) (Lachnit et al.. 1996). However. Marshall and 
colleagues (1995) reported that the relative potency of RS 17053 was significantly lower for 
a,^-adrenoceptors in the rat portal vein (pKe = 7.1) and human prostate (pKe = 7.1) than that 
to a,A-adrenoceptors in rat epididimal vas deferens (pA, = 9.5) (Marshall et al., 1995). The 
differences in RS I7053's relative affinity for these aj^^-adrenoceptors are not clear and 
cannot be explained by species differences. 
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a, B-Adrenoceptors. The role of the a, B-adrenoceptor subtype in contractile 
responses of vascular and non-vascular smooth muscle has been recently studied. Activation 
of a,B-adrenoceptors causes contractile responses in smooth muscle via phosphatidylinositol 
hydrolysis and Ca"* mobilization (Zhong and Minneman. 1999). The presence of a,B-
adrenoceptors has been reported in the rat spleen (Burt et al.. 1995; Noble et al.. 1997). rat 
heart (Yu and Han. 1994), human prostate (Teng et al.. 1994) and in rat mesenteric artery 
(Piascik et al., 1997). 
Table 3. Antagonist potency (pA,) for a,-adrenoceptors reported from ftmctional studies. 
Antagonists ttlA C'lD 
Prazosin 8.78' 8.46*'' 9.04" 9.02' 10.02" 9.35" 
^^''B4101 9.69" 8.87*" 9.48" 9.08' 9.39" 9.36" 9.17' 
5-Methylurapidil 8.39" 8.76*" 8.10" 9.0' 8.19"= 7.17" 7.83" 7.72= 7.95'' 
ARC 239 8.47" 8.98*" 8.86" 9.46" 
Phentolamine 8.01" 7.53^" 1.47' 7.72" 
BMY 7378 6.66" 6.09' 6.3= — 9.08'* 8.72' 
a - Buckner et al.. 1996: a,a* rat vas deferens.a,a- canine prostate*. a,o- rat spleen and a,B -
rat aorta: 
b - Zhu et al.. 1997; a,a- in perfused rat hind limb; 
c - Villalobos -Molina and Ibarra, 1996: a,a* a,D-  rat tail artery; 
d - Fagura et al.. 1997; a,D- rat aorta; 
e - Lachnit et al.. 1996: a,a- rat caudal arter>'. 
Chloroethylclonidine, an irreversible antagonist, has been used to discriminate a,B-
adrenoceptors (Testa et al.. 1995; Hattori and Kanno. 1997; Perez et al.. 1994; O'Rourke et 
al.. 1995) from the a,A-adrenoceptor subtype based on its higher alkylation rate for a,B-
adrenoceptors (Xiao and Jeffries. 1998). 
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Table 4. Radioligand affinities (pK^) for several agonists and antagonists in cloned 
a, -adrenoceptors. 
Agonists a,. Otlb a,d 
Norepinephrine 5.66" 6.38"* 6.54" 7.69" 
Epinephrine 6.62" 6.64''^ 6.91" 7.45" 
Cirazoline 7.02" 7.00"* 6.70" 7.32" 
Phenylephrine 6.03" 5.76"* 5.90" 6.79" 
Oxymetazoline 7.88" 7.86"* 6.69" 6.47" 
A61603 7.52" 7.61"* 5.68" 5.87" 
Methoxamine 5.26" 5.54"* 4.35" 5.24" 
Antagonists 
Prazosin 9.34=" 9.16' 9.69' 
WB 4101 9.28 7.29' 8.42' 
RS-17053 8.59' 7.06' 7.40' 
5-Methylurapidil 8.24=' 6.40' 6.76' 
BMY 7378 6.1 P 6.40' 8.29' 
L-765.314 6.30 = 8.27 = 7.30 = 
a - Zhu et al.. 1997; with "'I-BE2254. in HEK cells; 
b - Buckner et al.. 1996; with [^H]prazosin; a,3- bovine cloned, a,3*- human cloned. a,b-
hamster cloned and a,d - rat cloned; 
c - Patane et al.. 1998; with ['-^]HEAT for the cloned receptors. 
However, chloroethylclonidine does not distinguish betv^'een a,3- and a,D-
adrenoceptor subtypes (O'Rourke et al.. 1997; Xiao and Jeffries. 1998). Complicating the 
issue is that a,B- and a,D-adrenoceptors have a similar aifmity to most adrenergic antagonists 
(Piascik et al.. 1997) and this creates a problem in receptor subtype identification when 
functional methods are used and when tissue contains both a,B- and a,D-adrenoceptor 
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subtypes. In addition, the interactions of chloroethylclonidine with a-adrenoceptors needs 
more study. 
The synthesis of novel a,B-adrenoceptor subtj^pe selective antagonists, cyclazosin ([4-
(4-amino-6.7-dimethox>'quinazolin-2 yl)-c/5-octahydroquinoxaiin-1 -yl]furan-2-yl-
methanone) (Giardina et al.. 1996) and L-765.314 (4-amino-2-[4-[l-(benzyloxycarbonyl)-
2(S)-[[(1.1 -dimethylethyl)amino] carbonyl]-piperazinyl]-6.7-dimethoxyquinazoline), which 
is related to prazosin, has been recently reported (Patane. et al.. 1998). 
Cyclazosin exhibited a higher affinity (pK^ = 9.68). as determined by radioligand 
binding assays, for the a,B-adrenoceptor in rat liver (Stam et al.. 1998) but failed to 
discriminate a,B-adrenoceptors in functional studies. Cyclazosin's relative potency (pKg) 
against phenylephrine-induced contraction was 7.96 for a,B-adrenoceptors in rat spleen while 
the potency (pA,) for a,A,T.-adrenoceptors in rat small mesenteric artery and a,D-
adrenoceptors (pKg) in rat aorta were 7.78 and 6.86. respectively (Stam et al.. 1998). A 
newly described a,B-adrenoceptor antagonist. L-765,314. was found to have a ten-fold 
greater affinity for a,B- over the a,D-adrenoceptors and more than a 100-fold greater affinity 
for the a,B- over the a,A-adrenoceptor (Patane. et al.. 1998). 
a,Q-Adrenoceptors. When aiQ-adrenoceptors were cloned they were mistakenly 
reported to be like the a,A-adrenoceptor. With the discovery of the selective competitive a,D-
adrenoceptor antagonist. BMY 7378 (8-(2-(4-(2-methoxyphenyl)-l-pipera5dnyl)ethyl)-8-
azaspiro(4,5)decane-7.9-dione dihydrochloride) it became possible to pharmacologically 
distinguish the a,D-adrenoceptor subtype (Goetz et al.. 1995; Piascik et al.. 1995). The 
presence of a,D-adrenoceptors has been studied in a number of rat vascular beds including rat 
aorta (Piascik et al.. 1995; Buckner et al., 1996; Villalobos-Molina and Ibarra, 1996). rat iliac 
aner\- (Piascik et al., 1995), rat carotid and mesenteric artery (Villalobos-Molina and Ibarra. 
1996). There are no selective agonists for a,D-adrenoceptors. BMY 7378 exhibits a high 
affinity for the a,D-adrenoceptor subtype in the rat aorta and yielded pA, values of 8.72 
(Villalobos-Molina and Ibarra. 1996) and 9.08 (Fagura et al.. 1997). 
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Affinities and relative potencies of adrenergic agonists and antagonists for different 
a,-adrenoceptor subtypes obtained from functional and radioligand binding experiments are 
presented in the tables 3 and 4. 
a.-Adrenoceptors 
This section is a literature review of a^-adrenoceptors and includes general 
information about tissue distribution, molecular structure, intracellular signaling pathways, 
a.-adrenoceptor subtypes identified primarily in vascular smooth muscle and information 
about affinities of selective agonists and antagonists. In general, a^-adrenoceptors are 
characterized as having a high affinity to the agonists, cionidine and UK 14.304 and to the 
antagonists rauwolscine and yohimbine and by having a low affinity to the a,-adrenoceptor 
antagonist prazosin (see MacKinnon et al.. 1994 for review). 
Tissue distribution. The presence of a2-adrenoceptors has been reported in many 
species and different tissues such as human right atrium (Rump et al.. 1995). rabbit spleen 
(Michel et al.. 1990). rabbit iris (Fuder and Selbach. 1993). opposum kidney (Blaxall et al.. 
1991), rat kidney (Michel et al., 1990). rat cortex (Ho et al.. 1998). rat atrium (Ho et al.. 
1998). mouse brain (Limberger. et al.. 1995). porcine uterus (Kitazawa et al.. 2000). bovine 
ocular tissue (Bylund et al.. 1997) and guinea pig kidney (Uhlen et al.. 1994). a.-
Adrenoceptors have also been found in a variety of vascular beds such as the equine digital 
vein (Elliot. 1997). dog mesenteric artery and vein (Daniel et al.. 1995; Paiva et al.. 1999). 
dog saphenous vein (Hicks et al., 1991: MacLennan et al.. 1997). rat femoral vein (Paiva et 
al.. 1999). human saphenous vein (Smith et al.. 1992; Roberts et al.. 1992; Gavin et al.. 1997) 
and human femoral vein (Glusa and Markwardt. 1983). There are both prejunctional and 
postjunctional a^-adrenoceptors. Prejunctional a,-adrenoceptors are located on the 
membrane of the sympathetic nerve terminal and mediate an inhibition of norepinephrine 
release through a negative feedback in response to a build-up of the norepinephrine 
concentration in the postganglionic sympathetic neuro-effector junction (Docherty 1998, for 
review). Postjunctional ai-adrenoceptors are also located on the membrane of the effector 
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cell (Docherty 1998. for review). Stimulation of a^-adrenoceptors on vascular smooth 
muscle mediates contraction (Elliot. 1997; Daniel et al.. 1995; Paiva et al.. 1999; Hicks et 
al.. 1991; MacLennan et al., 1997; Smith et al.. 1992; Roberts et al.. 1992; Gavin et al.. 1997; 
Glusa and Markwardt. 1983). 
Structure. a2-Adrenoceptors are glycoproteins which have seven transmembrane 
domains connected by three extracellular and three intracellular hydrophilic loops and two 
terminals: an extracellular amino terminal with sites for glycosylation and an intracellular 
carboxyl terminal. The helical structure of the fifth transmembrane domain has been 
demonstrated experimentally (Maijam^ et al.. 1998). 
Three pharmacological subtypes (a^A- oLib a2c) of human a^-adrenoceptors are 
encoded by three genes (a2C10, a,C2 and 0^04. respectively) (MacKinnon et al.. 1994; 
Schaak et al.. 1997). The gene (rg20). found in rat tissue, for the a,D-adrenoceptor and the 
human gene. a,C10 for the human ai^-acirenoceptor. encode a similar protein (MacKinnon et 
al.. 1994). 
It is now accepted that the a^o-adrenoceptor is a species homolog of the human a^^-
adrenoceptor subtype (O'Rourke et al- 1994; MacKinnon. 1994; Schaak et al.. 1997; Bylund 
et al.. 1997) and this is due to a difference in one amino acid located within the fifth 
transmembrane domain. Thus, the a^A-adrenoceptor subtype contains Ser^°' while the a^o-
adrenoceptor subtype contains Cys*°' (MacKinnon. 1994). Variation in the amino acid 
(serine versus cysteine) in this position determines the pharmacological (subt>'pe) differences 
in the ligand binding properties of these homologues receptors (Cockroft, et al.. 2000). 
The second and third intracellular loops of the aj-receptor are responsible for binding 
a specific G-protein (Small et al.. 2000; Nasman et al.. 1997; Eason and Liggett. 1996) which 
initiates the cascade of intracellular reactions. 
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Figure 4. Intracellular reactions initiated by via activation of a^-adrenoceptors. a,-
Adrenoceptors (ttj-AR) are coupled to a pertussis toxin sensitive G, or protein (Gj/J 
(Docherty. 1998). Activation of a,-adrenoceptors is associated with inhibition of adenylyl 
cyclase (AC) which leads to inhibition of cAMP synthesis and which results in contraction of 
vascular smooth muscle. a^-Adrenoceptors coupled to pertussis toxin-sensitive G protein (Gj) 
mediate contraction of the human subcutaneous artery mostly via an influx of extracellular 
Ca"" through voltage-gated calcium channels (Parkinson and Hughes. 1995). 
Signal transduction pathways. a2 -Adrenoceptors are coupled to a pertussis toxin 
sensitive G, or G^ protein (Docherty. 1998) and can also be coupled to G, (Eason and Liggett. 
1996). The general pathway (Fig. 4) of intracellular signaling subsequent to the activation of 
a2-adrenoceptors is associated with an inhibition of adenylyl cyclase which leads to 
inhibition of cAMP synthesis and which results in contraction of vascular smooth muscle. 
However, this is not the only intracellular signaling pathway known for a^-adrenoceptor-
mediated responses (Docherty, 1998). 
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In porcine palmer lateral vein, activation of a2 -adrenoceptors caused a contractile 
response via a reduction of previously elevated (by stimulation of adenylyl cyclase) level of 
cAMP but not in the tissue with a normal level of cAMP (Wright et al.. 1995). 
Postjunctional aj -adrenoceptors 
The presence of fimctional postjunctional a^-adrenoceptors has been reported in 
several vascular beds, such as: equine digital vein (Elliot. 1997). dog mesenteric arter>' (Daniel 
et al.. 1995). dog saphenous vein (Hicks et al.. 1991; MacLennan et al., 1997) and human 
saphenous vein (Roberts et al.. 1992). a,-Adrenoceptor subtype identification, by using 
functional experiments, i.e. vasoconstriction, has some potential difficulties and these are 
related to the lack of potent subtype selective agonists and antagonists. In order to identify the 
subt\'pes of a receptor in a tissue it is often useful to correlate the data obtained from 
functional experiments wth data obtained from radioligand binding experiments for the 
knowTi (native or cloned) ai-adrenoceptor subtype (MacLerman et al.. 1997). 
a , A -Adrenoceptors. The t t j A-adrenoceptor subtype has been identified in isolated 
dog saphenous vein (MacLennan et al.. 1997) and dog mesenteric vein (Paiva et al.. 1999). 
The affinities (pK^) of the following a^A-adrenoceptor subtype selective agonists were: A-
54741 (5.6-dihydroxy-I.2.3.4-tetrahydro-I-naphthyI-imidazoIine) (8.03), oxymetazoline 
(7.67). guanfacine (6.79) and guanabenz (7.02) (MacLennan et al., 1997) and were higher 
than that of norepinephrine (5.74) in the isolated dog saphenous vein (MacLennan et al., 
1997). Contractile responses to norepinephrine were inhibited by a number of antagonists, 
and their affinity (pK^) was calculated as follows: prazosin (5.19), spiroxatrine (6.59), 
tolazoline (6.21), WB 4101 (7.42), rauwolscine (8.66) and idazoxan (7.11). Agonist pK^ 
values and antagonist pKg values were significantly correlated (correlation coefficient, r = 
0.82) with the affinities obtained from radioligand binding assays for the cloned human a;^-
adrenoceptor (MacLennan et al.. 1997) expressed in Chinese hamster lung cells. 
The pA, values of antagonists against the a^-adrenoceptor selective agonist. UK 
14.304 (5-bromo-6-[imidazolin-2-ylamino]-quinoxaline tartrate) (Paiva et al.. 1999) were 
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significantly correlated with pK^ values from radioligeind binding assays obtained on the 
cloned human ajA-adrenoceptor (MacLennan et al.. 1997). 
ajB-Adrenoceptors. The presence of functional -adrenoceptors in human 
saphenous vein were found by Smith and co-workers (1992). They obtained pA^ values for 
the following antagonists: yohimbine (7.37), HV 723 ((a-ethyl-3.4.5-trimethoxy-a-(3((2-(2-
methoxyphenoxy)ethyl)-amino)-propyl)-benzene acetotutrile fumarate) (7.52). ARC 239 ((2-
(2,4-(o-methoxyphenyl)-piperazin-1-yl)-ethyl)-4,4-dimethyl-1,3-(2H.4H)-isoquuinolindine 
chloride) (7.05). prazosin (6.44) and BRL 44408 ((2-((4,5-dihydro-lH-imidazol-2-yl)-
methyl)-2.3-dihydro-l-methyl-IH-isoindole) (5.72) and these pA^ values were correlated (r = 
0.71) with the antagonist's affinity at a,B-Iigand binding sites in rat kidney cells. In contrast, 
the rank of potencies for the a2A-ligand binding site of human platelets was different fi'om 
those in the human saphenous vein and their affinities were not strongly correlated. 
a^c-Adrenoceptors. The presence of functional a^c-adrenoceptors has been reported 
in human saphenous vein (Gavin et al., 1997). The affinities (pK^) for prazosin (6.62) and 
BRL 44408 (5.72) were lower than those for ARC 239 (7.19) and yohimbine (7.23). The 
affinities for the antagonists mentioned above were correlated with the affinities (pK^) for the 
human cloned a^c-adrenoceptor expressed on Sf9 cells, but not with the ajB-ligand binding 
site in rat kidney cells or with the ajA-Hgand binding site in human platelets (Gavin et al.. 
1997). 
ajD-Adrenoceptors. The a^o-adrenoceptor is a species homologue of the a^^-subtype 
("zAD-subtype) (Bylund et al., 1994) but pharmacological differences between and a^D-
adrenoceptor subtypes (Bohmann et al.. 1994; Guimaraes et al., 1998; Ali. et al.. 1998) have 
been reported. ajo-Adrenoceptors are present in the rat (Guimaraes et al.. 1998), mouse 
(Limberger et al., 1995), guinea pig (Guimaraes et al.. 1998) and cottle (Bylund et al., 1997). 
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Prejunctional aj -adrenoceptors 
Prejunctional (i.e.. presynaptic) a2 -adrenoceptors inhibit norepinephrine release from 
the sympathetic nerve terminal (Langer, 1974). 
The presence of functional prejunctional aj-adrenoceptors can be demonstrated in 
experiments by measuring [^H]norepinephrine overflow (Guimaraes et al.. 1998: Molderings 
and Gothert. 1995; Rump et al., 1995) or by measuring the contractile force developed in 
smooth muscle (Ali et al.. 1998) in response to electrical stimulation of sympathetic nerve 
terminals in the presence and absence of selective inhibitors. 
ajA"Adrenoceptors. Prejunctional aT^-adrenoceptors have been foimd in the rabbit 
pulmonary artery and human saphenous vein by measuring overflow of ['H]norepinephrine 
(Molderings and Gothert. 1995) . In their experiment the a2-adrenoceptor antagonist, 
rauvvolscine. but not the a,-adrenoceptor antagonist, prazosin, was very potent and facilitated 
the electrically stimulated release of [^H]norepinephrine in both vessels. The potency of the 
antagonists in increasing [^HJnorepinephrine release was highly correlated with the 
antagonist's affinities (pFs) for the a^A-binding sites in human platelets. 
In the isolated human gastric and ileocolic arteries, the a^-adrenoceptor antagonists 
rauwolscine. RX 821002 (2-[2-methoxy-l,4-benzodioxan-2-yl]-2-imidazoline) and 
yohimibine. were more potent than prazosin in increasing ["HJnorepinephrine overflow 
(Guimaraes et al.. 1998). They found a high correlation between the potencies (EC^o) of the 
eight a,-antagonists, rauwolscine. RX 821002. yohimibine. prazosin, phentolamine. 
idazoxan. WB 4101 and spiroxatrine in human gastric and ileocolic arteries and the affinities 
(pK,) of the same antagonists for the cloned human a^A-subtype expressed in Chinese 
hamster lung cells. 
aiB-Adrenoceptors. Interestingly, that there are no reports, to my knowledge, about 
the presence of prejunctional a^g-adrenoceptors. 
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Table 5. Radioligand affinities (pK^ or pK^) for several agonists and antagonists for cloned 
a2-adrenoceptors cited from radioligand binding studies. 
Agonists ^;D 
Oxymetazoline 7.30a 7.88b g ng 5.70a 6.13b 6.60g 6.67a 7.i4f 8.6<-' 
Norepinephrine 5.56b 6.37g 5.80b 6.68g 
Clonidine 7.71 a 7.23 ^ 6.83a 7 45b 6.81 a 
Guanfacine 7.75a 7.51 b 5.73a 6.01b 6.08a 
Guanabenz 7.9ia 7.88 b 6.34a 6.7ob 6.80a 
UK. 14.304 6.76b 7.46g 6.53 b 6.61 g 6.67a 
Antagonists 
RX 821002 9.87a 9.62b 8.10a 8.89 b 8.96a 8.8C 
Idazoxan 8.69a 8.79b 7.i2g 6.84a 7.76 b 7 29g 7.71 a 8.62f 8.2d 8.0e 
\VB 4101 7.43a 7.26b 7.08C 8.l7g 6.77a 7.80 b 6.94c 8.12a g gof 6.58C7.3'' 8.0e 
Yohimbine 7.39a 7.53b 8.04c 6.67a 8.14b 7.93c 8.25a 9.4of 7.34c 
Prazosin 5.94a 6.42b 5.62C 5.33g 6.89a 7.76b 7 12c 7.22g 6.89a 7 44f 6.24c 6 id 6.3c 
ARC 239 6.41 a 6.47b 5 45c 7.28a 8.II b 7.O6C 7.07a 7 32f 5,54c 6 7d 6.6e 
Phentoiamine 7.61C 7.78g 7.24c 7.97g 7.3ic 8.5^ 8.0^ 
SK.F 104078 6.56b 7.00g 6.83 b 6.96g 7.4d 7.4c 6.6e 
Rauwolscine 7.56a 7.69b 8.06g 6.66 a 8.88 b 8.12a lo.iof 8.0d 8.3e 
a - pKp values published by Uhlen et al., 1995, with[^H]-MK: and a^c in guinea 
pig cerebral cortex, in guinea pig kidney; 
b - pKp values published by Renouard et al., 1994. with [^H]RX821002: a^A in rat cerebral 
corte.x cells and in neonatal rat lung cells. 
c - pK, values published by Smith et al., 1995, with [^H]yohimbine: a;^ human platelet. 
a2B in rat kidney and a2D in rat submandibular gland; 
d - pKp values published by Limberger et al.. 1995. with [^H]norepinephrine: in mouse 
brain cortex; 
e - pKp values published by Wahl et al., 1996. [^HJnorepinephrine: in mouse heart atria; 
f - pK, values published by Blaxall et al., 1991, ['H]rauwolscine: a^c in opossum kidney cell; 
g- pK, values published by Michel et al.. 1990, [^HJrauwolscine: in rabbit spleen and a2B 
in rat kidney. 
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a2c-Adrenoceptors. Prejunctional a^c-adrenoceptors have been found in the human 
right atrium (Rump et al.. 1995). Their presence was based upon: 1) the similar rank of 
antagonist affinities (rauwolscine > WB 4101 > phentolamine > prazosin) in response to the 
non-selective a-adrenoceptor agonist, norepinephrine, and the selective a^-adrenoceptor 
agonist. UK 14.304. 2) A high correlation (r = 0.909) of antagonist potency (ECjo) with the 
affinity (pKo) of those antagonists was obtained from radioligand binding experiments at a^c-
binding sites of opossum kidney cells. 
a2D-Adrenoceptors. Prejunctional aio-adrenoceptors were found in the rat kidney 
(Bohmann et al.. 1994) and in the rat heart (Smith et al.. 1995) and these resembled the a^p-
adrenoceptor binding site in rat submandibular gland. 
Non-subtype selective a^-adrenoceptor agonists and antagonists 
Two non-subtype selective ai-adrenoceptor agonists have been used to study a.-
adrenoceptors (Table 5). The non-subtype selective a^-adrenoceptor agonist, UK 14.304 (5-
bromo-6-[2-imidazolin-2-ylamino]-quinoxaIine bitartrate) is a potent vasoconstrictor in the 
isolated equine digital vein (Elliot. 1997) and in the isolated porcine thoracic aorta (pD, = 
6.24) and marginal ear vein (pD, = 7.51. Wright et al.. 1995). UK 14.304 has a higher 
affinity for all cloned a^-adrenoceptor subtypes (pK, values; 6.3 - 6.7) than does 
norepinephrine (pK, values: 4.9 - 5.8) (Renouard et al.. 1994; Uhlen et al., 1992). Clonidine 
also has been used as a non-subtype selective a,-adrenoceptor agonist. The direct application 
of clonidine in vivo caused concentration (10 nM - ImM) dependent contractions in canine 
pial arter\' and vein (Ishiyama et al.. 1998) via postjunctional receptors. Activation of 
prejunctional aj-adrenoceptors by clonidine has been demonstrated to produce concentration 
dependent inhibition of electrically-evoked contractions in rat vas deferens (pD, = 9.29), rat 
tail artery (pD, = 7.98) and guinea-pig ileum (pD, = 7.28, Ali et al.. 1998). These responses 
to clonidine were almost as potent as those to UK 14,304 and were inhibited by phentolamine 
and rauwolscine (Ali et al., 1998). 
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There are no available a^-adrenoceptor subtype selective antagonists because ail of 
ihem are able to bind all a^-adrenoceptor subtjpes. However, some a,-adrenoceptor 
antagonists have a slight selectivity to one of the a;-adrenoceptor subtypes and this can be 
used for subtype identification. 
For example, prazosin can discriminate a^B- and a^c-adrenoceptor subtypes from 
adrenoceptors because prazosin has a higher affinity (pK^) for a^B- and/or a^c-adrenoceptor 
subtypes (Uhlen et al., 1994. MacLenann et al.. 1997) and a lower affinity (pK,) for 
adrenoceptors (Trendelenburg et al., 1994. Bohmann et al., 1994, Limberger et al.. 1995. 
Wahl et al.. 1996). 
However, prazosin is unable to discriminate between a^B* and a^c-adrenoceptor 
subtypes. For this purpose the antagonist potencies of ARC 239 and rauwolscine can be 
compared. Even though ARC 239 and rauwolscine exhibit affinity for all a2-adrenoceptor 
subtypes. ARC 239 has a slightly greater selectivity for a^B'^^^rsnoceptors (Blaxall et al.. 
1991. Uhlen et al.. 1994, Renouard et al., 1994) while rauwolscine is more selective for a2c-
adrenoceptors (Blaxall et al., 1991, Uhlen et al.. 1994). In order to discriminate between a^e-
and a^c-adrenoceptor subtypes, the relative potencies (Blaxall et al.. 1991. Fuder and 
Selbach. 1993) of ARC 239 and rauwolscine for a^B* and a^c-adrenoceptors can be 
compared. 
An antagonist's potency to a2 -adrenoceptors. in functional studies, is a very useful 
piece of information in characterizing the receptor subtype. The following literature values 
of antagonist potency (pA,). determined from functional studies for a^-adrenoceptors. has 
been reported: yohimbine (8.22) in equine digital vein (Elliot, 1997) and in human saphenous 
vein (7.23 - 7.40) (Connaughton and Docherty, 1990; Smith et al., 1992; Gavin et al., 1997); 
for rauwolscine (6.09) in porcine thoracic aorta (Wright et al., 1995) and in dog saphenous 
vein (6.0) (Low et al, 1999); for RX 812002 (2-[2-methoxy-1.4-benzodioxan-2-yl]-2-
imidazoline) in equine digital vein (9.04) (Elliot, 1997); and for RS-15385-197 
((8aR. 12aS. 13aS)-5,8.8,a,9.10,11,12.12a, 13.13a,decahydro-3-methoxy-12-
(methyIsulphonyl)6H-isoquino[2,l-g][I,6]-naphthyridine) in dog saphenous vein (10.0) 
(Brown et al., 1993). 
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Sympathetic neurotransmitters 
The hypothesis that the sympathetic nervous system regulates organ functions via 
chemical neurotransmission where adrenaline-like substance might be released from 
sympathetic nerve was expressed almost a century ago (Elliott, 1905). The fact that 
norepinephrine is the primarily neurotransmitter released from the sympathetic nerve 
terminal which in turn produces the effect was identified by Euler (1946). It is now 
commonly accepted that regulation of vascular tone by sympathetic nerves depends on 
neurotransmitter(s) release from the nerve terminal and also by the presence of functional 
receptors. Substances such as neuropeptide Y (NPY) (Lundberg et al. 1982) and adenosine 
5'-triphosphate (ATP) (Lagercrantz and Stjame. 1974: Bumstock, 1976) can be stored and 
released from the adrenergic nerve terminal along with norepinephrine and are thought to be 
involved in producing the physiological response. The ATP co-transmission process has 
been demonstrated in dog mesenteric arter>' (Muramatsu. 1986). rabbit ear artery (O'Connor 
et al.. 1990). rabbit aorta (Sedaa et al.. 1990). canine splenic artery (Ren et al.. 1996). guinea-
pig and rat vas deferens (Fedan et al., 1981), guinea-pig taenia coli and rat duodenum 
(Windscheif et al.. 1995). Investigation of possible ATP co-transmission in the bovine tail 
artery was a part of the experimental work for this dissertation. 
Neurotransmitter(s) release or physiological responses mediated by 
neurotransmitter(s) can be studied in vitro by using transmural electrical field stimulation of 
sympathetic nerve terminals (Bumstock, 1976; Levitt and Westfall. 1982; Machaly et al.. 
1988; Evans and Kennedy, 1994; Lundberg, 1996). Depolarization of the sympathetic nerve 
ending by an electrical field causes Ca"* influx through voltage-dependent Ca** channels, an 
event essential for neurotransmitter release (Lefkowitz et al.. 1996). Depolarization of the 
nerve terminal can be abolished by tetrodotoxin, a voltage-dependent Na*-chaimel blocker 
(Bao and Stj^e,1993; Lundberg, 1996). Tetrodotoxin (1 (xM) or guanethidine. an inhibitor 
of norepiphrine release, have been commonly used to determine whether the response 
produced by field stimulation occurred via neurotransmitter release or was due to the direct 
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Stimulation of smooth muscle by field stimulation (Ren and Bumstock. 1997; Bao and 
Stjame. 1993). 
The use of electrical procedures which incorporate a constant current bervveen a pair 
of electrodes in the tissue bath has been proposed as the best method to use to stimulate the 
nerve and not the smooth muscle (Duckies and Silverman, 1980). A frequency-response 
relationship is usually obtained to field stimulation in such experiments (Duckies and 
Silverman. 1980; Ren and Bumstock, 1997). 
Norepinephrine as a neurotransmitter 
Norepinephrine is synthesized in the sympathetic neuron from the amino acid 
tyrosine, stored in vesicles and ultimately released from the sympathetic ner\'e in response to 
neuron stimulation (Lefkowitz et al.. 1996). The effect of norepinephrine occurs when it 
diffuses across the sympathetic cleft and binds to the adrenergic receptors on the membrane 
of the effector cell. Once released, the concentration of norepinephrine in the sympathetic 
cleft decreases because of several removal processes. These processes lead to a termination 
of norepinephrine's action and include simple dilution of the norepinephrine concentration in 
the receptor region and by active transport (uptake,) of norepinephrine back into the neuron 
and by diffusing into the effector tissues (uptakcj) (Furchgott. 1966; Lefkowitz et al.. 1996). 
Neuronal uptake (uptake,) of norepinephrine can be blocked by cocaine while non-neuronal 
uptake (uptake,) can be blocked with corticosterone. Norepinephrine can be deaminated by 
the intracellular neuronal enzyme monoamine oxidase (MAO) and be degraded within non-
neuronal tissue by both catechol-O-methyltransferase (COMT) and MAO (Furchgott. 1966). 
Since these four processes are constantly removing norepinephrine from the receptors site, 
equilibrium conditions never occur for norepinephrine and receptors. That is why Furchgott 
(1966) recommended that removal processes be blocked when considering the 
characterization of receptors using agonists and antagonists. 
As a neurotransmitter, norepinephrine can inhibit its own release through the 
activation of prejunctional aj-adrenoceptors (Langer, 1974; Guimaraes et al., 1998; 
Molderings and Gothert, 1995; Rump et al.. 1995). 
30 
ATP as a neurotransmitter in sy mpathetic transmission 
ATP as a neurotransmitter is released from the sympathetic neuron terminal 
(Lagercrantz and Stjame, 1974; Bumstock, 1976; Levitt and Westfall. 1982; Sedaa et al.. 
1990) and through activation of purinergic receptors causes physiologic responses (Ralevic 
and Bumstock. 1998). Evaluation of whether ATP is a neurotransmitter can be studied b>' 
measuring [^HJpurine outflow from ["HjATP-labeled sympathetic nerve terminals (Levitt and 
Westfall, 1982; Sedaa et al., 1990 ) and/or by monitoring contractile responses (Windscheif 
et al., 1994; Ziyal et al. 1997) to field stimulation. ATP co-transmission has been reported in 
several vascular beds (Muramatsu, 1986; O'Connor et al.. 1990; Sedaa et al.. 1990; Ren et 
al., 1996) but information concerning whether ATP co-transmission occurs in skeletal muscle 
vasculature is limited (Sajag et al.. 1990; Bumstock and Warland, 1987; Dzielak. 1983). 
Some difficulties exist in determining whether ATP is involved in a particular co-
transmission process. The major problem is related to the chemical properties of ATP as a 
neurotransmitter. Thus, neuronally released ATP is a very unstable compound and is rapidly, 
within 100 milliseconds (Bao and Stj^e, 1993), enzymatically inactivated by adenosine 5'-
triphosphatase (ecto-ATPase) to adenosine (Gordon. 1986). Adenosine can cause cellular 
responses on its own via activation of adenosine receptors and thereby mask the role of ATP 
(Ralevic and Bumstock, 1998). The second major problem is related to the possibility that 
multiple purinergic receptors can be present in the same tissue. 
Different approaches have been used in order to eliminate the potential problems in 
evaluating the role of ATP as a neurotransmitter. For example, contractile responses to field 
stimulation can be conducted on intact (Ziyal et al.. 1997) or endothelium denuded blood 
vessels (Sedaa, et al.. 1990; Evans and Kennedy, 1994). The use of endothelium denuded 
isolated vessels has been proposed as a way to eliminate the effect of the endothelium on 
vascular smooth muscle contraction (Furchgott and Zawadski, 1980). An ecto-ATPase 
inhibitor. ARL 67156 (6-N,N-diethyl-D-P,Y-dibromomethyleneATP. Westfall et al.. 1996). 
has been used to slow down the rapid breakdown of the released ATP within the synaptic 
cleft. To eliminate the possible effect of adenosine, a non-selective PI receptor inhibitor. 8-
sulphophenyltheophylline (O'Connor et al.. 1990; Crack et al., 1994), has been included in 
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the experimental design. In some preparations cyclooxygenase inhibitors (e.g. indomethacin) 
have been used to inhibit prostaglandin synthesis (Crack et al.. 1994). 
Neuropeptide Y (NPY) as a neurotransmitter in sympathetic transmission 
It has been demonstrated that neuropeptide Y might be a sympathetic co-transmitter 
released from the sympathetic nerve terminal (Lundberg et al, 1982) and which might 
modulate contractile responses to sympathetic nerve stimulation by inhibiting 
neurotransmitter (norepinephrine and/or ATP) release from the nerve terminal (Lundberg. 
1996). Neuropeptide Y is a peptide consisting of 36 amino acids and can be synthesized 
within the sympathetic nerve and stored in vesicles. Neuropeptide Y can cause 
vasoconstriction through activation of its own receptors (Lundberg. 1996). Three types of 
neuropeptide Y receptors have been identified (Y,. Y^ and Yj) and all of them are linked to 
increases in intracellular Ca** concentration and stimulation of cAMP synthesis (Lundberg. 
1996). Activation of the Y, receptors causes vasoconstriction, presumably by acting 
postsynaptically. while the Y, receptors act presynaptically to modulate neurotransmitters 
release. The Yj receptor mediates inhibition of secretion in bovine chromaffin cells by 
inhibiting adenylyl cyclase (Lundberg, 1996). 
Although neuropeptide Y may function in the bovine tail arter\' as a co-transmitter, 
this possibility was not investigated in this research project. 
Purinergic receptors 
A part of this dissertation concerned the role of purinergic receptors in contractile 
responses in the bovine tziil artery and was necessitated by the results obtained when the 
sympathetic nerves in the tail artery' were stimulated. The following review covers the 
classification of purinergic receptors, their structures, intracellular signaling mechanisms and 
possible involvement in regulation of vascular tone and a discussion of agonists and 
antagonists. 
Current classification of purinergic receptors divides them into two categories: PI 
(adenosine receptors) and P2 (ATP receptors) (Ralevic and Bumstock. 1998; Fredholm et al.. 
1997). Purinergic receptors are cell-surface membrzuie-bound receptors and have been found 
in various tissues including the heart and vasculature (Ralevic and Bumstock. 1998). 
Adenosine receptors. Adenosine receptors (PI) are G-protein coupled receptors 
(Table 6). Adenosine receptors have been found in the following tissues: heart, brain, kidney 
and blood vessels. Adenosine receptors are divided into four subtypes. A,. A^^. A^g and A-,, 
based on molecular structure, tissue distribution and pharmacological characteristics. A2-
receptors are the most common subtype of adenosine receptors and are found in vascular 
tissues where they mediate relaxation of the blood vessels. 
Table 6. Classification, general intracellular signaling mechanisms and effects in blood 
vessels of adenosine receptors (modified from Ralevic and Bumstock. 1998). 
Receptors A, Aja Aj b  •A3 
G-protein-coupling G.o G, G, G, G, 
Intracellular effects icAMP TCAMP tcAMP icAMP 
TIP3 TIP ,, ca--
Predominant effect Direct effect is rare Rela.xation Relaxation Contraction 
in the blood vessels Relaxation via prejunctional or 
inhibition of sympathetic Relaxation* 
neurotransmitter release 
* - The physiological role of Aj-receptors is not completely understood. Activation of A3-
receptors on mast cells causes degranulation of the mast cells and the release of vasoactive 
substances (i.e., histamine) which in turn causes the vascular response (Ralevic and 
Bumstock. 1998). 
In general, the activation of A, causes inhibition of cAMP level through protein-
coupled response, while activation of A^ receptors causes stimulation of cAMP synthesis 
though stimulation of adenylyl cyclase via a G, protein-coupled mechanism. However, A j b  
can be coupled to G, and G, proteins. Aj-receptors are predominantly G^ coupled and their 
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mRNA has been found in many tissues, including: lung, brain, heart, spleen, uterus, bladder, 
kidney and liver. However, the physiological role of Aj-receptors is not completely 
understood (Ralevic and Bumstock. 1998). 
ATP receptors. ATP receptors (P2) are subdivided into two classes: P2X and P2Y. 
where P2X receptors are ATP-gated ion channels (Na*. K* and Ca"*) and P2Y receptors are 
G-protein coupled receptors (Table 7). In addition, seven subtypes of P2X and five subtypes 
of P2Y receptors have been cloned (Ralevic and Bumstock. 1998; Kennedy and Leff. 1995; 
Fredholm et al.. 1997). ATP receptors have been found in many tissues, especially in the 
central nervous system and in vascular tissues. Activation of P2X receptors causes 
contraction of vascular (Ren and Bumstock. 1997; Windschief et al.. 1994; Ziyal et al.. 1997) 
and non-vascular (Westfall et al.. 1996; Tuluc et al.. 1998; Najbar-Kaszkiel and Rand. 1996) 
smooth muscle while activation of P2Y receptors on endothelial cells causes relaxation of 
vascular smooth muscle via the endothelium-dependent mechanisms (Malmsjo et al.. 1999: 
Thapaliya et al., 1999). General characteristics of ATP receptors are given in Table 7 
(Ralevic and Bumstock. 1998; Kennedy and Leff, 1995). 
P2X receptors. P2X receptors are proteins and their structiu-e has been predicted 
based on cloned P2X receptors. P2X receptors consist of 379 - 472 amino acids, which form 
an ion channel with two hydrophobic transmembrane domains and one hydrophilic 
extracellular loop (Fig. 5). The extracellular loop has 10 conserved (for all P2X receptor 
subtypes) cysteine and 14 glycine residues and there are 2 to 6 potential glycosylation sites 
(Ralevic and Bumstock, 1998). 
Activated P2X receptors mediate the influx of Na*. K* and Ca"* and this produces 
cellular responses due to an increase in intracellular Ca"* concentration and cell 
depolarization (Ralevic and Bumstock, 1998). Some P2X receptor subtypes, but not all, can 
be desensitized by ATP (Ralevic and Bumstock, 1998; Fredholm et al., 1997). The 
mechanism of desensitization is not completely understood. Different portions of P2X 
receptors have been suggested to be involved in the desensitization process, i.e. hydrophobic 
domains, carboxyl (P2X2) or amino terminal (P2X3) (Ralevic and Bumstock, 1998). 
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Table 7. Characterization of purinergic receptors. 
P2X P2Y 
Receptor type ATP-gated ion channel G-protein coupled: 
G q l l -  G, 
Number of amino acids 379 - 472 308 -377 
Intracellular enzymes not applicable PLC. AC. PLD. PKC. 
involved MAPK 
Effectors Ca-* > Na* > K* tiPj, TDAG. tCa-
i'CAMP 
Subtypes P2X„ P2X.. P2X3, P2X„ P2Y,. P2Y,. P2Y,. P2Y,. 
P2X5. PIX^. P2X, P2Y„ 
Effect on vascular tone Contraction Relaxation* or Contraction 
Phospholipase C (PLC); phospholipase D (PLD); proteinkinase C (PKC). mitoge-activated 
protein kinase (MAPK.). adenylyl cyclase (AC), diacylglycerol (DAG) (modified from 
Ralevic and Bumstock. 1998). * - Activation of P2Y receptors on the endothelial cell causes 
endothelium-dependent relaxation of vascular smooth muscle. 
Based on its ability to be desensitized. P2X receptors are divided into three 
categories: rapidly (within 100 -300 msec) desensitizing, slowly desensitizing and non-
desensitizing (Ralevic and Bumstock. 1998). 
In addition, non-desensitizing P2X receptors might be either a,p-meATP-sensitive or 
a.p-meATP-insensitive. Desensitization of P2X receptors can be used as a method to 
inactivate these receptors in order to study their functional role (Ren and Bumstock, 1997). 
In vascular smooth muscle both categories of a.p-meATP-sensitive, desensitizing and non-
desensitizing receptors, have been found (Ralevic and Bumstock, 1998). 
All seven subtypes of P2X receptors (P2X„ P2Xj, P2X3, P2X„ P2X5, P2X^, P2X,) 
have been cloned (Fredholm, et al., 1997; Ralevic and Bumstock. 1998). All subtypes are 
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Figure 5. Diagram of a proposed PlXj receptor structure. The diagram shows that both the 
N- and C-terminals are intracellular. There are two transmembrane hydrophobic spanning 
segments (M1 and M2) and one extracellular hydrophilic loop with two disulfide-bond (-s-s-) 
and three glycosylation sites (—>) (modified from Ralevic and Bumstock. 1998). 
widely spread in spinal cord and peripheral neurons. P2X, is one of the most 
significant subtypes present in vascular smooth muscle (Ralevic and Bumstock. 1998). 
P2Y receptors. P2Y receptors belong to a large group of G-protein coupled receptors. 
Their primary pathway of intracellular responses is associated with Gq ,,-protein coupled 
activation of phospholipase C which leads to the formation of IP3 and increases in 
intracellular Ca'* concentration. However, some P2Y receptor subtypes can be negatively 
coupled to adenylyl cylclase through Gj protein (Ralevic and Bumstock. 1998). In addition, 
intracellular signaling mechanisms of P2Y receptors have been described which link them to 
multiple intracellular effectors such as. phospholipases (C. D. A,), diacylglycerol. protein-
kinase C and voltage-dependent Ca** channels (Ralevic and Bumstock, 1998). P2Y receptors 
have been found in various tissues and P2Y, is the primary subtype presented in blood 
vessels. P2Y receptors have been found on endothelial and vascular smooth muscle cells. 
Activation of P2Y receptors mediates vasodilatation via Ca'*-dependent synthesis of nitric 
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oxide and/or synthesis of endothelium-derived relaxing or hyperpolarizing factors. P2Y 
receptors can also play a role in vascular smooth muscle proliferation via activation of 
mitogenic-activated protein kinase (MAPK) (Ralevic and Bumstock. 1998). P2Y receptors 
can be desensitized through phosphorylation of intracellular regions of the receptor but the 
mechanisms of desensitization are not completely understood (Ralevic and Bumstock. 1998). 
Purinergic agonists and antagonists 
There are no selective agonists for P2X or P2 Y receptors and most agonists can 
couple to both receptor types. All purinergic receptors can be activated by ATP. which is not 
a stable compound. Several synthetic ATP analogs are commercially available to study the 
effects of purines on biological processes. 2MeSATP (2-methylthio ATP), a synthetic 
agonist, can stimulate both P2X and P2Y receptors (Malmsjo et al.. 1999) and exhibits a 
higher potency than ATP for some P2X receptor subtypes (Liu et al.. 1999; Ralevic and 
Bumstock. 1998). a.p-meATP and p.y-meATP have been used to study P2X receptors 
(Kennedy and Leff. 1995; Ralevic and Bumstock. 1998). a.p-MeATP causes contraction of 
vascular (Ren and Bumstock. 1997; Windschief et al.. 1994; Ziyal et al.. 1997) and non­
vascular (Westfall et al., 1996) smooth muscle via activation of P2X receptors and is more 
potent than 2meSATP in rat perfused mesenteric arteries (Windschief et al.. 1994). in rabbit 
ear arter\' (OXonnor et al.. 1990) and in rat urinary bladder (Bo and Bumstock. 1990). ATP 
was less potent than a,P-meATP and 2meSATP in rat mesenteric arteries (Windschief. et al.. 
1994) and in rabbit ear artery (O'Connor et al.. 1990) while in the rat urinary bladder the rank 
of potencies was different: a,p-meATP > ATP> 2-MeSATP (Bo and Bumstock. 1990). 
There are no subtype selective P2X and P2Y receptor antagonists. Suramin and 
PPADS (pyridoxalphosphatte-6-azophenyl-2'.4'-disulphonic acid) are the most commonly 
used antagonists to study P2X and P2Y receptors (Ohara, et al., 1998; Bao and Stjame. 1993; 
McLaren et al.. 1994; Windscheif et al.. 1995). 
Suramin is a slow-equilibrating antagonist (Leff et al.. 1990) and exhibited 
competitive antagonism to a,p-meATP-induced contraction (Leff et al., 1990; Ziayl et al.. 
1997). Suramin inhibited contractile responses to a,P-meATP via P2X receptors in rabbit ear 
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aner\' (pKg = 4.79; Leff et al., 1990), in rabbit saphenous artery (pA. = 4.79; Ziayl et al.. 
1997) and inhibited relaxant responses via P2Y receptors in rabbit aorta (Ziayl et al.. 1997). 
Suramin did not affect contraction to KCl (Leff et al.. 1990: Bao and Stjame. 1993) or to 
norepinephrine in guinea pig small cutaneous artery (Morris. 1999) and in rat tail arter\- (Bao 
and Stjame, 1993) but inhibited contractile responses to phenylephrine and histamine in 
rabbit ear anery (Leff et al.. 1990). Suramin's effect on contractile responses to 
phenylephrine and histamine contraction is not completely understood- Even though suramin 
is a competitive purinergic antagonist, it is also a G protein inhibitor whereby it inhibits the 
activation of the G„ subunit (Freissmuth et al.. 1996; Hohenegger et al.. 1997). 
NF023 (3'-urea of 8-(benzamido)naphthalene-1.3.5-trisulphonic acid), another 
purinergic antagonist (Raievic and Bumstock. 1998), exhibited a higher potency (pA2= 5.69) 
than suramin in inhibition of a,p-meATP-induced contraction but it had no effect on relaxant 
responses to a,p-meATP in the rabbit aorta (Ziayl et al.. 1997). 
PPADS is not a selective purinergic antagonist (Ziganshin et al.. 1993; Windschief et 
al.. 1994; McLaren et al.. 1994) and has been shown to inhibit contractile responses to a,P-
meATP via P2X receptors (Ziganshin et al.. 1993) and via P2Y receptors in guinea-pig taenia 
coli and rat duodenum (Windschief et al.. 1995). Some other purinergic antagonists such as 
reactive blue 2. reactive red (Raievic and Bumstock, 1998; Bumstock and Warland. 1987). 
diadenosine pentaphosphate (ApjA) (Van der Giet et al.. 1999) and its product, diinosine 
pentaphosphate (IpsI) (King, et al.. 1999) have been used to study purinergic receptors. 
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CHAPTER 11. CO-EXISTENCE OF a,-ADRENOCEPTOR SUBTYPES IN THE 
BOVINE TAIL ARTERY. 
A paper submitted to European Journal of Pharmacology. 2000 
Marina V. loudina and Donald C. Dyer 
ABSTRACT 
The purpose of this study was to identify the a,-adrenoreceptor subtypes present in 
the bovine tail artery which mediate contractions to adrenergic agonists, a,-Adrenergic 
agonists caused concentration-dependent contraction of the isolated bovine tail artery. 
A61603, an a,A-selective agonist, was more potent (pD, = 7.7 ±0.15; n=9) in causing 
contraction of the bovine tail artery compared to that of norepinephrine (6.0 ± 0.07. n=6) and 
phenylephrine (5.9 ±0.13, n=8). The calculated dissociation constant (K^) of A61603 was 
0.149 ± 0.04 fiM (n= 6). Antagonists, ARC 239. BMY 7378, WB 4101 and 5-
methylurapidil. caused a parallel shift to the right of the concentration-response curve to 
.A.61603 with pA^ values of 9.29, 6.62, 9.27 and 8.86, respectively. Prazosin. BMY 7378 and 
WB 4101 shifted the concentration-response curve to phenylephrine to the right with pA^ 
values of 9.47, 7.17 and 9.73. respectively. WB 4101. a selective a,;^-adrenoceptor 
antagonist, was equally potent against phenylephrine and A61603. The affinities (pA; value) 
obtained for 5-methylurapidil, WB 4101, BMY 7378 and prazosin against a,-adrenoceptor 
agonists were significantly correlated with pK, values (Zhu et al., 1997) for the cloned ot,a-
adrenoceptor (r=0.99. P < 0.05), but not with the a,b-adrenoceptor (r=0.78. n.s.) or the cloned 
ttij-adrenoceptor (r=0.43. n.s.). BMY 7378. a selective a,D-adrenoceptor antagonist, was 
significantly more potent against the non-subtype selective agonist phenylephrine than to 
A61603. Chloroethylclonidine (50 |^M for 10 min) did not affect contractile responses (at 
EC30 and ma.ximum) to A61603, but caused a significant (P<0.05) inhibition of contractile 
responses to phenylephrine. In conclusion, it appears that all three subtypes (ttjA-, ajB" and 
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a,D) of a,-adrenoceptors may play a role in adrenergic mediated contraction in the bovine tail 
arter\-. However. a,A-adrenoceptors play a dominant role in the contractile response to 
adrenergic agonists in this tissue while the other two a-adrenoceptor subtN^pes (a,B- and a,D-) 
ver>' likely co-exist in the bovine tail artery but have less of an impact on contractile 
responses. 
Keywords: a (-adrenoceptor subtypes, vascular smooth muscle, bovine, median caudal arter\'. 
FNTRODUCTION 
Modem classification divides a-adrenoceptors into two types: a, and a^. a,-
Adrenoceptors have three native subtypes: a,^, a,B and a,D (Docherty, 1998). Three 
recombinant a,-adrenoceptor subtypes have been cloned and current classification 
determines them as a,a. a|b and a,d (Hieble et al., 1995: Docherty, 1998). Three native 
(a2,v2D"- ^;b"- and four cloned "a"- oc2c" oc^d) subtypes of a^-adrenoceptors 
have been identified (Docherty, 1998) by modem classification. 
The presence of functional a,-adrenoceptors has been reported in vascular tissues 
(Lachnit et al., 1996; Villalobos-Molina and Ibarra, 1996; Zhu et al, 1997; Stassen et al, 
1998; Hu and Dyer, 1997; Hill and Dyer. 1997; Fagura et al.. 1997) as well as in non­
vascular (Fumkawa et al.. 1995; Yu and Han. 1994; Teng et al.. 1994; Alberts et al.. 1999; 
Marshall et al.. 1995; Hattori and Kanno. 1997) tissues, a,-Adrenoceptors have been 
extensively studied in a variety of species such as rat (Lachnit et al.. 1996; Villalobos-Molina 
and Ibarra. 1996; Zhu et al, 1997; Stassen et al, 1998). rabbit (Fagura et al.,1997, Hattory and 
Kanno. 1997). cattle (Hill and Dyer, 1997), sheep (Hu and Dyer, 1997), human (Teng et al.. 
1994; Fumkawa et al., 1995; Marshall et al., 1995) and pig (Alberts et al., 1999). 
The a,^- subtype is the most well defined adrenoceptor subtype and has been studied 
with selective a,A-adrenoceptor agonists and/or antagonists. There are at least two 
commercially available agonists with high selectivity to the a,A-adrenoceptor subtype: 
A61603 ((±N-[5-(4,5-dihydro-l H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-l-
yl] methanesulphonamide hydrobromide) and oxymetazoline (Buckner et al., 1996). WB 
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4101 ((2-(2.6-dimethoxyphenoxyethyl) aminomethy 1-1.4 benzodioxane) and 5-
methylurapidil are two subtv-pe selective a,A-adrenoceptor antagonists, which discriminate 
for the a,A-adrenoceptor (Marshall et all. 1995; Zhu et al.. 1997; Furukawa et al.. 1995; 
Faguraetal.. 1997). 
Limited information is available about the a,B-adrenoceptor subtype, which has also 
been found in both vascular and non-vascular smooth muscle. The presence of a,B-
adrenoceptors has been reported in the rat aorta (Han et al.. 1990; Testa et al.. 1995), rat heart 
(Yu and Han. 1994). rat mesenteric artery (Piascik et al.. 1997). rabbit heart (Hattori and 
Kanno. 1997) and human prostate (Teng et al.. 1994). Unfortunately, there are no selective 
competitive antagonists for the a,B-adrenoceptor. Chloroethylclonidine has been employed 
to distinguish between a,A-adrenoceptors and a,B-adrenoceptors (Teng et al.. 1994; Testa et 
al.. 1995; Hattori and Kanno. 1997). Chloroethylclonidine alkylates the a,B-adrenoceptor 
subtype and serves as an irreversible antagonist (O'Rourke et al.. 1995). However, the 
interactions of chloroethylclonidine and a-adrenoceptors have not been fully studied. Thus, 
it has been demonstrated that chloroethylclonidine can cause contraction of the dog 
saphenous vein (Nunes and Guimaraes, 1993) and the rabbit ear artery (Fagura et al.. 1997). 
O'Rourke and co-workers (1997) demonstrated using radioligand binding methods that 
chloroethylclonidine significantly inhibited the maximum binding of ["HJprazosin to a,B-
adrenoceptors in rat spleen membranes to 21% and the binding of [^H]yohimbine to a2D-
adrenoceptors in rat submandibularv' gland membranes to 35%. In addition, they reported 
that chloroethylclonidine (100 ^M) irreversibly bound ajp-adrenoceptors in rat aorta and 
produced contraction only in combination with norepinephrine, acting as "a silent irreversible 
agonist" (O'Rourke etal.. 1997). 
The presence of aip-adrenoceptors has been studied in a number of rat vascular beds 
including rat aorta (Fagura et al.. 1997; Buckner et al.. 1996; Villalobos-Molina and Ibarra, 
1996), rat renal artery (Villzdobos-Molina et al.. 1997), rat carotid and mesenteric artery 
(Villalobos-Molina and Ibarra, 1996). BMY 7378 ((8-(2-(4-(2-methoxyphenyl)-l-
piperazinyl)ethyl)-8-azaspiro(4.5)decane-7,9-dione dihydrochloride)) is reported to be 
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selective for the cloned a,d-adrenoceptor subtyp>e (Goetz et al..l995) and has been used to 
study a,0-adrenoceptors (Fagura et al.. 1997; Villalobos-Molina et al.. 1997). 
Adrenergic induced contractile responses in the isolated bovine tail arter>' were 
investigated by Hill and Dyer (1997). They reported that norepinephrine and phenylephrine 
caused contractions of the isolated bovine tail artery which were significantly inhibited by 
prazosin, an a,-adrenoceptor antagonist. Whereas, the selective a^-adrenoceptor agonist. B-
HT 920 (5.6,7,8-tetrahydro-6-(2-propenyl)-4H-thiazolo[4.5-d]azepin-2-amine 
dihydrochloride), failed to cause contraction. They concluded that adrenergic agonists 
caused contraction of isolated bovine tail artery primarily through a,-adrenoceptors and not 
through a^-adrenoceptors. No attempt was made to characterize the subtype(s) of the a,-
adrenoceptors present in the bovine tail artery. 
The purpose of this study was to identify the a,-adrenoreceptor subtypes present in the 
bovine tail arter\' which mediate contractions to adrenergic agonists. 
MATERIALS AND METHODS 
Tissue preparation 
Bovine tails (steers) were obtained from a local abattoir. The tissue was transported 
to the laboratory on ice where the median caudal artery was dissected from the tail. Tissue 
preparation protocol was similar to that described by Hill and Dyer (1997). Dissected artery 
was placed in a modified Krebs" solution of the following composition (mM): NaCl. 115.21; 
KCl 4.70; CaCl,, 1.80; MgSO„ 1.16; KH^PO^, 1.18; NaHCO,. 22.14; dextrose, 7.88; and 
0.03 sodium EDTA. Endothelium was removed by the careful rotation of a blunt wooden 
stick inside the lumen of the vessels. Vessels were cut into rings 4-5 mm long. Each ring 
was placed in a 10 ml tissue bath filled with FCrebs' solution at 38.5" C and continually 
aerated by bubbling O,: CO; (95:5) from the bottom of the bath. The tissue rings were 
suspended in the bath by two stainless steel wires passing through the lumen of each ring. 
One wire was stationary and secured near the bottom of the tissue bath while the second wire 
was connected to the force transducer. Up to 8 rings were studied per experimental day. 
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Isometric contraction was continually monitored by using a MacLab system connected to a 
computer. The arter>' rings were initially stretched to a tension of 15 g and then allowed to 
relax over a 60 min period. Before beginning the experiments baseline tension was 
established by adjusting the tension to 2 g. During the equilibration period all tissues were 
incubated with 0.36 mM iproniazid in order to inhibit monoamine oxidase (MAO). 
Endothelium removal was confirmed by absence of a relaxation response to 1 ^ M 
acetylcholine in rings contracted by 45 mM KCl. The artery rings were then washed with 
fresh Krebs' solution every 10 minutes for 30 minutes until the basal tension of 2 g was re­
established. Artery rings were treated with 10 fiM tropolone. 1 fiM cocaine and 10 fiM 
corticosterone for 15 minutes, prior to obtaining concentration-response relationships to an 
a-adrenoceptor agonist, in order to block catechoIamine-O-methyltransferase, neuronal 
(uptake,) and tissue (uptake,) uptake, respectively (Furchgott and Garcia, 1968; Levin and 
Furchgott. 1970; Hill and Dyer, 1997). All concentrations of agonists, norepinephrine (10 
nM - 0.1 mM), phenylephrine (10 nM - 0.1 mM) and A61603 (1 nM - 0.1 mM). were added 
to the bath cumulatively in half-log increments. In each experiment with an antagonist, 
concentration-response relationships to an agonist were obtained twice, before and 1 hour 
after incubation with one concentration of an antagonist. The maximal contraction to an 
agonist obtained during the first concentration-response relationship was set as the 100% 
response for that tissue. The effective concentrations of an agonist required to produce 30% 
and 50% (when mentioned) of the maximal contraction (ECjo and EC;o-. respectively) 
obtained from the control and the antagonist treated tissues were determined. The negative 
log molar concentration of agonist inducing 50% of the maximal response (-log EC50) was 
expressed as pD,. Shifts in agonist EC30 values by antagonists were used to calculate 
antagonist potencies (Schild, 1949). For every experiment a tissue not exposed to an 
antagonist was carried through the procedure to permit corrections for time-dependent 
changes in the response of the tissues to the agonist and not due to the antagonist, as 
recommended by Furchgott (1972) and as used in our laboratory (Zhang and Dyer, 1990; Hill 
and Dyer, 1997). 
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Analysis of responses to agonists and antagonists 
The dissociation constant (K^ of the a,A-selective agonist. A61603. was determined 
for the artery using the procedure described by Furchgott and Burzstyn (1967) and as used in 
our laboratory (Hill and Dyer. 1997). Briefly, the tissues were prepared as described above 
and a concentration response relationship to A61603 (1 nM - 30 fiM) was obtained. In order 
to inactivate a fraction of the a,A-adrenoceptors. tissues were incubated with dibenamine 
(0.3 nM). an irreversible a-adrenoceptor antagonist, for 20 min followed by washing the 
tissues 4-5 times over 30 min. Responses to A61603 before (A) and after (A') treatment with 
dibenamine were plotted after the corrections were made to account for time-dependent 
changes in the response of the tissue to A61603. A double reciprocal plot of equi-effecive 
concentrations of A61603 yielded a slope of I/q and an abscissa intercept of (l-q)/q K^. The 
dissociation constant (K^). where q is the fraction of inhibited receptors, was calculated by 
using the equation: 1/[A] = l-q/q[A'] + 1/q (K^). or = slope - 1/intercept (Furchgott and 
Burzst>n. 1967). 
The antagonist potencies for each adrenoceptor antagonist. pA^. W'as obtained as 
described by Furchgott (1972) and as used in our laboratory (Zhang and Dyer. 1990). Artery-
rings were prepared as described above. Antagonists. WB 4101 (1-30 nM) and BMY 7378 
(0.3-30 JJ.M) were tested against A61603 and phenylephrine; 5-methylurapidil (10 nM -
0.1 |j.M) and ARC 239 (10 nM - 0.1 |j.M) were tested against A61603; prazosin (1-30 nM) 
was tested against phenylephrine and norepinephrine. Antagonist potencies (pA,) were 
calculated based on shifts of the agonist concentration-response curves at the EC30. Briefly : 
EC 30 was calculated in the absence (A) and presence (A*) of each competitive antagonist 
concentration from the concentration-response curves. The concentration ratio. CR = A*/A 
(Furchgott, 1972). and the log (CR -1) was calculated after correction for the time-dependent 
changes in sensitivity to the agonist. The Kg value is inversely related to affinity and can be 
calculated as: Kg = [B]/CR-1, where [B] is the concentration of the antagonist. The pA, 
values were calculated according to Arunlakshana and Schild (1959) by using the equation: 
log (CR-1) = log[B] - log Kb (Furchgott, 1972), where [B] is the concentration of the 
antagonist and Kg the dissociation constant of the receptor-antagonist complex, is inversely 
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related to affinit\' (pA, = - log Kg). The calculated log (CR-I) values were plotted versus the 
log [B] as a linear relationship and where the line intercepts the abscissa yields the pA, value. 
Chloroethylclonidine was used to study a,B-adrenoceptors (Villalobos- Molina et al.. 
1997; Zhu et al., 1997; Marshall et al.. 1995). Tissues were prepared as described above. 
After the first concentration-response relationship to phenylephrine, artery rings were 
incubated with 50 fiM of chloroethylclonidine for 10, 20 or 30 min or with 100 jiM of 
chloroethylclonidine for 30 min. Then tissues were rinsed thoroughly with fresh Krebs' 
solution for 30 min. A second concentration-response relationship to phenylephrine or a 
concentration-response relationship to A61603 was obtained. The EC,o and maximal 
responses in the absence and presence of chloroethylclondine treatment were determined for 
each agonist. The response to A61603 was plotted as a percentage of the original response to 
phenylephrine. 
Drugs 
The following drugs were used: (-)-norepinephrine bitartrate. cocaine hydrocholride. 
corticosterone 21-acetate, ipronizid (phosphate salt), acetylcholine chloride, phenylephrine 
hydrochloride, idazoxan (Sigma Chemical. St. Louis, MO). A61603 ((N-[5-(4.5-dihydro-lH-
imidazol-2yl)-2-hydroxy-5,6.7,8-tetrahydronaphthalen-l-yl]methanesulfonamide 
hydrobromide). ARC 239 ((2-[2.4-(methoxyphenyl)piperazin-l-yl]-ethyl)-4.4-dimethyl-1.3-
(2H.4H)-isoquinolindine dihydrochloride) (Tocris. Ballwin. MO), chloroethylclonidine. WB 
4101 ((2-(2.6-dimethoxyphenoxyethyl) aminomethyl-1.4 benzodioxane) hydrochloride). 
5-methylurapidil. BMY 7378 (8-[2-[4-(2-methoxyphenyl)-l-piperazinyl]ethyl]-8-
azaspiro[4,5]decane-7,9-dione dihydrochloride) (Research Biochemical International. Natick. 
MA), prazosin (Pfizer. Brooklyn. NY), tropolone (Aldrich, Milwaukee), dibenamine HCl 
(Smith. Kline and French, Philadelphia, PA). Prazosin was initially prepared in lactic acid 
and then diluted in isotonic saline solution. Norepinephrine and phenylephrine solutions 
were prepared in isotonic saline which was acidified with hydrochloric acid. Dibenamine 
and corticosterone were dissolved in ethanol. All other drugs were dissolved in isotonic 
saline. 
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Statistical Analysis 
The results are presented as mean ± S.E.M. and n is the number of animals used for 
each experiment. ECjo values for agonists, were calculated from their concentration-response 
relationships by using the GraphPad Prism computer program (GraphPad Software Inc. San 
Diego, CA). EC30 values of agonists, were calculated by using linear function between two 
of the closest points which overlap the 30% response. Student's unpaired t-test was 
performed to define the differences between two group means. A P value of 0.05 or less was 
considered significant. 
RESULTS 
a,-Adrenergic agonists caused concentration-dependent contractions of the isolated 
bovine tail artery. The potency of norepinephrine, expressed as pD,. w'as 6.0 ± 0.07 (n=6) 
and was not different from the potency of phenylephrine 5.9 ±0.13 (n=8). A61603. an a,A-
seiective agonist, was more potent (pD^ = 7.7 ± 0.15; n=9) in causing contraction of the 
bovine tail artery. The calculated dissociation constant (K^) of A61603 was 0.149 ± 0.04 
(n= 6). 
The potency of antagonists, prazosin. BMY 7378. WB 4101 and 5-methylurapidil. in 
blocking a-adrenoceptor agonists is presented in Table 1. All antagonists shifted the 
concentration-response curves to these a-adrenoceptor agonists to the right (Fig. I and 2) and 
exhibited the characteristics of competitive antagonism since the slopes of the Schild plots 
were not different from unity. BMY 7378, an a,D-adrenoceptor antagonist, was more p)otent 
against phenylephrine (pA, = 7.17) than A61603 (pA^ = 6.62). 
Chloroethylclonidine caused inhibition of contractile responses to a,-adrenoceptor 
agonists (Fig. 3). and was more potent against contractile responses to phenylephrine than 
those to A6I603. Thus, incubation with 50 |iM chloroethylclonidine for 10 min did not 
affect contractile response (at EC30 and maximum) to A61603. but caused significant 
(P<0.05) inhibition of contractile responses to phenylephrine. However, incubation with 50 
I^M of chloroethylclonidine for 20 min (data not shown) or 30 min or with 100 of 
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chloroethylclonidine for 30 min caused significant inhibition of contractile responses when 
determined at the EC30 and the maximal contraction to both agonists. 
DISCUSSION 
Our results support data published by Hill and Dyer (1997) that adrenergic agonists 
cause contraction of the bovine tail artery through activation of a,-adrenoceptors. We 
extended their study and evaluated the involvement of a,-adrenoceptor subtypes in the 
vasoconstriction response. We used endothelium denuded bovine tail artery rings to avoid 
possible interference by the endothelium on the contractile response. The a,;^-adrenoceptor 
subtype has been identified and extensively studied in vascular smooth muscle (Lachnit et al.. 
1996; Villalobos-Molina and Ibarra. 1996; Stassen et al.. 1998). We used A61603. an 
adrenoceptor selective agonist (Buckner et al.. 1996). to investigate the possible role of the 
aiA-adrenoceptor subt>'pe in contractile responses in bovine tail artery. A61603 caused 
concentration dependent contractions and was more potent than the non-selective a,-
adrenoceptor agonists, norepinephrine and phenylephrine, based on a comparison of EC50 
\ alues. These findings are consistent with those of Buckner and co-workers (1996). In 
radioligand binding experiments, using bovine cloned a,,-adrenoceptor, they found the 
following affinities (pK,): A61603 (7.52), norepinephrine (6.36) and phenylephrine (6.03). 
The affinity of A6I603 for hamster clonal a,t,-adrenoceptors (5.68) and rat clonal a,j-
adrenoceptors (5.87) was less than those of norepinephrine and phenylephrine. Data from 
our study is consistent with theirs since we found that the potency of A61603. expressed as a 
value, was higher (K^ = 0.149 ^M) than that of norepinephrine (K^ = 3.11 (iM; Hill and 
Dyer. 1997). 
The affinities of four a,-adrenoceptor antagonists (5-methylurapidil. WB 4101. BMY 
7378 and ARC 239) were determined against A61603. 5-Methylurapidil (Table 1). an a,A-
adrenoceptor selective antagonist, inhibited A61603 induced contraction with a higher 
potency (pA, = 8.86 ± 0.05) than that of BMY 7378 (pA, = 6.62 ± 0.15). an a,D-adrenoceptor 
selective antagonist. The affinities (pA, value) obtained for 5-methylurapidil, WB 4101. 
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BMY 7378. ARC 239 and prazosin against a,-adrenoceptor agonists were significantly 
correlated (Fig. 4) \\ith pK^ values (Zhu et al.. 1997) for the cloned a,a-adrenoceptor (r = 
0.99. P < 0.05). but not with the a,b-adrenoceptor (r=0.78. P > 0.05) or the cloned a,(j-
adrenoceptor (r=0.43, P > 0.05). Our data suggest that the a,A-adrenoceptor subtype plays a 
significant role in contractile responses to adrenergic agonists in the bovine tail arter\'. 
.A.dditional support for the dominance of the aj^-adrenoceptor in adrenergic mediated 
contractions of the bovine tail artery comes from the finding that the affinity of BMY 7378 
(pA; = 7.17 ± 0.05) against phenylephrine was significantly higher than against A61603 
(pA, = 6.62 ± 0.15). BMY 7378, a selective a,D-adrenoceptor antagonist has higher affinity 
to a,D- than to a,A-adrenoceptors (Goetz et al., 1995; Zhu et al.. 1997) and has been 
commonly used to discriminate the a,D-adrenoceptor subtype (Fagura et al.. 1997; 
Villalobos-Molina et al.. 1997; Zhu et al.. 1997). Greater antagonism by BMY 7378 against 
phenylephrine, a non-subtype selective a,-adrenoceptor agonist when compared to that 
against A61603. a selective a,;^^-agonist. can be taken as evidence for the presence of 
functional a,D-adrenoceptors in the bovine tail artery. 
We used chloroethylclonidine to study the presence of a,B-adrenoceptors by 
evaluating the differences in alkylation rate of a,-adrenoceptors subt>'pes. Our method was 
based on previous e.xperiments by Xiao and Jeffries (1997) concerning the kinetics of 
alkylation of cloned a,-adrenoceptors. Xiao and Jeffries (1997) reported that the lowest 
alkylation rate was for the a,3-adrenoceptors when compared to a,b- or a,j-adrenoceptors. 
We found that treatment with a low concentration of chloroethylclonidine (50 |iM) for 10 
min significantly inhibited contractile responses to phenylephrine, but had no affect on the 
concentration-response relationship to A61603. Increasing the concentration of 
chloroethylclonidine (to 100 fiM) or increasing the incubation time (to 20 or 30 min) 
significantly inhibited contractions to both, phenylephrine and A61603. These findings 
suggest that alkylation of a,-adrenoceptors with 50 ^M (10 min) of chloroethylclonidine 
caused inactivation of other than a,A-adrenoceptor subtypes. Unfortunately, alkylation of a,-
adrenoceptors with chloroethylclonidine is unable to discriminate between a,B- and a,D-
adrenoceptor subtypes and therefore our data cannot exclude the possibility of the presence of 
48 
both functional a,B- and a,D-adrenoceptors. Defining the presence of ftinctional a,B-
adrenoceptors in the bovine tail artery awaits the disclosure of more specific 
agonist/antagonists for a,B-adrenoceptors. 
In summary, it appears that all three subtypes (a, A -, am" a I D ) of a,-adrenoceptors 
may play a role in adrenergic mediated contraction in the bovine tail artery, 
a, Adrenoceptors play a dominant role in contractile responses to adrenergic agonists in this 
tissue. This conclusion is based on the high potency of the a,A-adrenoceptor agonist A61603 
in bovine tail artery and a significant correlation of antagonist affinities (pA^ values) with 
literature radioligand binding affinities (pK^ values) for the cloned a,a-adrenoceptor. The 
other two a-adrenoceptor subtypes (a,B- and a,D-) very likely co-exist in the bovine tail 
artery but have less of an impact on contractile responses to adrenergic agonists than the a,A-
adrenoceptors. 
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Figure 1. Concentration-response relationships to phenylephrine in endothelium denuded 
bovine tail arter\' rings in the absence of antagonists (control (•) and time-matched (O) 
control tissue) and in the presence of adrenergic antagonists: (A) prazosin (•) InM. 
(V) 3 nM. (A) 10 nM. (A) 30 nM. n=6; (B) WB 4101 (•) InM. (A) 10 nM. (A) 30 nM. n=5 
and (C) BMY 7378 (•) 0.3 |iM, (•) 1 (xM. (O) 30 (iM. n=5. Each point on the 
concentration-response curve represents the mean ± S.E.M. Schild plots were constructed 
for each antagonist. 
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Figure 2. Concentration-response relationships to A61603 in endothelium denuded bovine 
tail artery- rings in the absence of antagonists (control (• ) and time-matched (O) control 
tissue) and in the presence of adrenergic antagonists: (A) 5-methylurapidil (A) 10 nM, 
(A) 30 nM. (•) O.l^iM. (=) 0.3 ^M; n=4; (B) WB4101 (•) InM. (V) 3 nM. (A) 10 nM. 
(A) 30 nM. n=4; (C) BMY 7378 (Z) 0.3 ^iM. (•) 1 ^M. (O) 30 hM. n=5 and (D) ARC 239 
(A) 10 nM, (A) 30 nM. (• ) 0.1 fiM. n=5. Each point on the concentration-response curve 
represents the mean ± S.E.M. Schild plots were constructed for each antagonist. 
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Figure 3. Concentration-response relationships in isolated bovine tail artery rings to 
phenylephrine and A61603 alone and in experiments with chloroethylclonidine. (A) The 
effect of incubation with 50 |aM of chloroethylclonidine for 10 min and (B) the effect of 
incubation with 50 ^iM and 100 of chloroethylclonidine for 30 min. 
(A). Explanation of symbols: (•) the first concentration-response relationship to 
phenylephrine (control tissue), (O) the second concentration-response relationship to 
phenylephrine for the untreated tissue (time-matched control), (I) concentration-response 
relationship to phenylephrine after exposure to chloroethylclonidine (50 fiM) for 10 min. 
(•) concentration-response relationship to A61603 in untreated (control) tissue and 
(O) concentration-response relationship to A61603 in chloroethylclonidine (50 ^M. 10 min) 
treated tissues. Each point on the concentration-response cur\'e represents the mean ± S.E.M. 
n=4. 
(B). Explanation of symbols: concentration-response relationship to phenylephrine in 
(• ) control tissue. (O) time-matched control, and after exposure to (A) 50 fiM and 
(A) 100 }j.M chloroethylclonidine for 30 min. Concentration-response relationship to A61603 
in (•) untreated (control) tissue and in tissues treated with (•) 50 jiM and (V) 100 fiM 
chloroethylclonidine for 30 min. Each point on the concentration-response curve represent 
the mean ± S.E.M. n=4. 
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Figure 4. Correlation between the potencies (pAi) of a i-adrenoceptor antagonists 
(1 - BMY 7378. 2 - 5-methylurapidil. 3 - WB 4101.4- prazosin) against contractile 
responses induced by A61603 in the isolated endothelium denuded bovine tail artery and 
bindings affinities (pKi) reported for cloned aia, cxjb, and aid — adrenoceptors by Zhu and 
co-workers (1997). There was a significant correlation for au-adrenoceptors, n.s means not 
significant. 
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Table 1. pAi values for ai-adrenoceptor antagonists in the bovine tail artery*. 
Agonist Antagonist pAi Slope It 
Phenylephrine Prazosin 9.47 ±0.21 -0.89 ± 0.09 6 
Phenylephrine BMY 7378 • 7.17 ±0.05 -1.21 ±0.13 5 
Phenylephrine WB4I0I 9.73 ±0.18 -1.04 ±0.05 5 
A61603 ARC 239 9.29 ± 0.26 -1.05 ±0.09 5 
A61603 BMY 7378 6.62 ±0.15 -1.16±0.14 5 
A61603 WB4101 9.27 ± 0.09 -0.93 ± 0.06 4 
A61603 5-methylurapidiI 8.86 ± 0.05 -0.98 ± 0.05 4 
Data are expressed as mean ± SEM of the number (n) of animal used. Slopes are not 
different from unity. * pAi values are significantly different from that found for A61603, 
^<0.05. 
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CHAPTER III. CHARACTERIZATION OF a,^- AND a,g-ADRENOCEPTOR 
SUBTYPES IN THE BOVINE TAIL VEIN 
A paper submitted to European Journal of Pharmacology. 2000 
Marina V. loudina and Donald C. Dyer 
ABSTRACT 
Limited research has been done concerning the fimctional role of a,-adrenoceptors in 
vein. The bovine tail vein possesses a higher affinity for norepinephrine (loudina and Dyer. 
2000 a) than the bovine tail artery and this could be explained, in part, by a difference in a-
adrenoceptor types and/or subtypes involved in contractile responses to adrenergic agonists 
in these vessels. The purpose of this study was to identify functional a,-adrenoceptor 
subtypes in the isolated endothelium denuded bovine (steer) tail vein, incorporating the novel 
aiQ-adrenoceptor selective antagonist L-765,314 in this endeavor. Adrenergic agonists, 
norepinephrine, phenylephrine and A61603, caused concentration dependent contraction of 
the isolated bovine tail vein with following potency (pD,) range: A61603 (7.0 ± 0.09) > 
norepinephrine (6.5 ± 0.09; n=4) > phenylephrine (5.9 ±0.13; n=8). The dissociation 
constant (K^ for norepinephrine was (0.40 ± 0.07 fiM: n=4) and for A61603 was (0.52 ± 
0.11 fiM; n=4). Contractile responses to phenylephrine and A61603 were significantly 
inhibited (pK-g) by prazosin (8.8 and 8.7), BMY 7378 (6.7 and 6.6). WB 4101 (8.8 and 9.4). 
L-765.314 (7.0 and 6.4) and 5-methylurapidil (6.0 and 7.0), respectively. The potencies of 
WB 4101 and 5-methylurapidil, were higher against A61603 than to phenylephrine while 
L-765.314 was more potent in inhibiting phenylephrine-induced contractions than those of 
A61603-induced contractions. 
Chloroethylclonidine (50 ^.M) after 10 min incubation significantly inhibited the 
maximum (but did not affect ECso) contractile response to phenylephrine but not that to 
A61603. However, incubation with 50 nM chloroethylclonidine for 20 min or 30 min or 
with 100 nM chloroethylclonidine for 30 min caused a significant inhibition of the maximal 
67 
contractile response to both agonists. Our data suggests that a,-adrenoceptors play a 
significant role in contractile responses to adrenergic agonists in the bovine tail vein via 
activation of both and a,B-adrenoceptor subtypes. 
Keywords: a,-adrenoceptors, a,a - and a, B -adrenoceptor subtypes, vein, vascular 
smooth muscle, bovine species 
INTRODUCTION 
According to modem classification there are two types of a-adrenoceptors (a, and a^) 
and both are G-protein coupled receptors (Dochert>'. 1998). The presence of a-adrenoceptors 
has been reported in a number of sfjecies, such as: rat (tail artery. Lachnit et al.. 1996; 
Villalobos-Molina and Ibarra, 1996; hind limb. Zhu et al. 1997; mesenteric artery. Stassen et 
al. 1998; Piascik et al., 1997; aorta, Villalobos-Molina and Ibarra. 1996; carotid artery. 
Villalobos-Molina and Ibarra, 1996; spleen, Buckner et al.. 1996; heart. Zhang et al.. 1999; 
vas deferens. Buckner et al., 1996; Honner and Docherty. 1999; cerebral cortex. Chess-
Williams et al.. 1996; kidney. Chess-Williams et al.. 1996). human (vas deferens. Furukawa 
et al.. 1995; prostate. Teng et al.. 1994; saphenous vein. Connaughton and Docherty. 1990; 
Smith et al.. 1992; Gavin et al., 1997; Roberts et al.. 1992; gastric and ileocolic arteries. 
Guimaraes et al.. 1998). dog (saphenous vein, Nunes and Guimaraes. 1993; Low et al, 1999; 
mesenteric arter\'. Daniel et al., 1995), rabbit (ear artery. Fagura et al.. 1997). equine (digital 
vein. Elliot. 1997), porcine (thoracic aorta and marginal ear vein, Wright et al., 1995) and 
cattle (tail artery. Hill and Dyer, 1997). 
Both types of a-adrenoceptors (a, and a,) take part in contractile responses in 
vascular tissues. Thus, activation of a-adrenoceptors vascular smooth muscle cell membrane 
causes contraction (Hill and Dyer. 1997; Buckner et al., 1996; Lachnit et. al.. 1996; 
Villalobos-Molina et.al., 1997), while activation of a-adrenoceptors on the membrane of the 
endothelial cell modulates the contractile response of vascular smooth muscle via 
endothelium-derived factors (MacLean et al., 1993; Zschauer et al., 1997). a,-
Adrenoceptors. located on the sympathetic neuron terminal membrane affect the contractile 
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response to nerve stimulation via regulation of neurotransmitter release (Trendelenburg et.al. 
1997). The present study was designed to examine the role a,-adrenoceptors play in 
contraction of bovine tail vein smooth muscle and to evaluate the a,-adrenoceptor subt>pes 
present in this tissue. 
Three native (a,^-. a,B- and a,D-) a,-adrenoceptor subtypes are recognized by modem 
classification and three a,-adrenoceptor (a,j-, an,- and a,d-) subtypes have been cloned 
(Langer. 1998). The presence of all a,-adrenoceptor subtypes have been demonstrated in 
vascular smooth muscle. Pharmacological characterization of a,A-adrenoceptor-induced 
contractile responses in vascular smooth muscle (Fagura et al.. 1997; Lachnit et. al., 1996; 
Furukawa et al., 1995; loudina and Dyer, 2000c; Marshall et all, 1995) was accomplished 
using commercially available a,A-adrenoceptors selective agonists. A61603 ((±N-[5-(4.5-
dihydro-1 H-imidazol-2yl)-2-hydroxy-5.6,7,8-tetrahydronaphthalen-1 -yl] 
methanesulphonamide hydrobromide) and/or oxymetazoline (Buckner et al.. 1996) and 
antagonists. 5-methylurapidil and/or WB 4101 ((2-(2,6-dimethoxyphenoxyethyl) 
aminomethyl-1,4 benzodioxane) (Zhu et al.. 1997; Buckner et al., 1996). Characterization of 
functional a,D-adrenoceptors (Villalobos-Molina and Ibarra. 1996; Buckner et al.. 1996; 
loudina and Dyer. 2000b) became possible because of the availability of an a,D-adrenoceptor 
subtype selective antagonist, BMY 7378 ((8-(2-(4-(2-methoxyphenyl)-l-piperazinyl)ethyl)-8-
azaspiro{4.5)decane-7.9-dione dihydrochloride)). However, pharmacological 
characterization of a,B-adrenoceptors is more difficult because of the absence of 
commercially available selective agonists and antagonists. Chloroethylclonidine. an 
alkylating agent, has been used to discriminate the fimctional a,B-adrenoceptors (Testa et al.. 
1995; Hattori and Kanno. 1997) from the a,A-adrenoceptor subtype because of its higher 
alkylation rate for a,B-adrenoceptors (Xiao and Jeffries. 1998). However, 
chloroethylclonidine does not distinguish between a,B- and a,D-adrenoceptor subtypes (Xiao 
and Jeffries. 1998) and this might become a problem when a,B- and a,D-adrenoceptors are 
both present in a tissue. A novel a,B-adrenoceptor subtype selective competitive antagonist. 
L-765.314 (4-amino-2-[4-[l-(benzyloxycarbonyl)-2(S)-[[(l, 1 -dimethylethyl)amino] 
carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline), related to prazosin, has been recently 
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synthesized (Patane. et al.. 1998). The affinit\' (pK,) of L-765.314 to the a,B-adrenoceptor 
subtype was about 10 times greater than to a,D-adrenoceptors and more than 100 times 
greater than to a,A-adrenoceptors (Patane, et al.. 1998). Thus. L-765.314 appears to be a 
useful pharmacological tool for the characterization of a,-adrenoceptors due to its high 
affinity for a,B-adrenoceptors. 
We have studied adrenergic receptors in the bovine tail arterv' (Hill and Dyer. 1997; 
loudina and Dyer. 2000a.b) and vein (loudina and Dyer. 2000 a, c). Adrenergic agonists 
cause contraction of the bovine tail artery by activation of predominantly a,-adrenoceptors 
(Hill and Dyer, 1997) primarily by an action on a,A-adrenoceptors (loudina and Dyer. 2000 
b). However, the role of a,-adrenoceptor subtypes in the bovine tail vein has not been 
determined. In contrast to the artery, the bovine tail vein possesses a higher affinity to 
norepinephrine (loudina and Dyer, 2000 a) and this may be explained, in part, by the 
presence of different a-adrenoceptor types (a^-adrenoceptors) in the vein (loudina and Dyer. 
2000 c). In contrast to the artery, only a limited number of studies has been reported about 
the functional role of the a,-adrenoceptors in vein (Schuiz and Westfall. 1982; Leech and 
Faber. 1996; Elliot, 1997; Marshall et al.. 1996; Hu and Dyer, 1997; Low et al.. 1999). 
The purpose of this study was to identify and characterize functional a,-adrenoceptor 
subtypes in the isolated endothelium denuded bovine (steer) tail vein, incorporating the new 
and novel a,B-adrenoceptor selective antagonist L-765.314 in this endeavor. 
MATERIALS AND METHODS 
Tissue preparation 
Bovine tails (steer) were obtained from a local abattoir and transported to the 
laboratory' on ice. The caudal vein was dissected from the tail and placed in a modified 
Krebs" solution of the following composition (mM): NaCl, 115.21; KCl 4.70; CaCL, 1.80; 
MgSO,. 1.16; KH.PO,, 1.18; NaHCOj. 22.14; dextrose, 7.88; and 0.03 mM EDTA. which 
was continually aerated (95% O,: 5% COj). The vein was cut into rings 4-5 mm long. The 
endothelium was carefiilly removed by rotating a wooden stick inside the limien. The tissue 
70 
rings were suspended in lO-ml tissue baths filled with aerated Krebs' solution at 38.5° C b\^ 
passing two stainless steel wires through the lumen of each ring. One wire was fixed near the 
bottom of the tissue bath while the second wire was connected to the force transducer. 
Isometric contraction was continually recorded by using a MacLab system connected to a 
computer. An initial tension of 4 g was applied to the vein rings and the tissues permitted to 
relax during the 60- min equilibration period. All tissues were incubated with 0.36 mM 
iproniazid during equilibration period in order to inhibit monoamine oxidase (MAO). Prior 
to beginning the experiments a baseline tension of 1 g was established. Initially each tissue 
was contracted by 120 mM K.C1 in order to establish tissues viability. The absence of 
relaxation to 1 |j.M acetylcholine in rings contracted by 120 mM KCl was used to confirm 
endothelium removal. Tissues which developed a tension of less than 2 g in response to 
120 mM KCl or which relaxed in response to acetylcholine were discarded. The vein 
segments were then washed with fresh Krebs' solution every 10 minutes for 30 minutes until 
the basal tension of Ig was re-established. Vein rings were treated with 10 fiM tropolone. 
1 i^M cocaine and 10 ^iM corticosterone for 15 minutes in order to block catecholamine-O-
methyltransferase. neuronal (uptake,) and tissue (uptake;) uptake, respectively (Furchgott and 
Garcia. 1968; Levin and Furchgott. 1970; Hill and Dyer. 1997) prior to obtaining a 
concentration-response relationships to an a-adrenoceptor agonist. All concentrations of 
agonists, norepinephrine (10 nM - 0.1 mM). phenylephrine (10 nM - 0.1 mM) and A61603 
(1 nM - 0.1 mM). were added to the bath cumulatively in half-log increments. 
Concentration-response relationships to an agonist were obtained twice, before and after 
incubation with one concentration of an antagonist. The maximal tension developed to an 
agonist obtained during the first concentration-response relationship was set as the 100% 
response for that tissue. For every experiment a paired tissue not exposed to an antagonist 
was carried through the procedure to permit correction for time-dependent changes in 
responses to the agonist, as recommended by Furchgott (1972) and as used in our laboratory 
(Zhang and Dyer. 1990; Hill and Dyer. 1997). 
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Analysis of responses to agonists 
The dissociation constants (K^J of the non-subtype selective agonist, norepinephrine, 
and the a,A-selective agonist, A61603, were determined for the bovine tail vein using the 
procedure described by Furchgott and Burzstyn (1967) and as used in our laboratory (Hill 
and Dyer. 1997). Briefly, the vein rings were prepared as described above and a 
concentration- response relationship to norepinephrine (10 nM - 100 jiM) or A61603 (1 nM -
30 fiM) was obtained. Following wash out and return to basal tone the tissues were 
incubated v\ith 0.3 ^.M dibenamine, an irreversible a-adrenoceptor antagonist, for 20 min in 
order to inactivate a fraction of the a-adrenoceptors. After incubation with dibenamine all 
tissues were extensively washed with fresh Krebs' solution 4-5 times over 30 min before 
obtaining a second concentration-response relationship to an agonist. 
Analysis of responses to antagonists 
Antagonist potencies (pKg = -logKa) were calculated from a single concentration of 
an antagonist. For this purpose the concentration-response relationship to an agonist, 
phenylephrine (10 nM - 100 fiM) or A61603 (1 nM - 30 nM). was obtained before and after 
I hour incubation with one concentration of an antagonist: WB 4101 (10 nM). BMY 7378 
(1 IJ.M), 5-methylurapidil (30 ^M), L-765.314 (1 fj.M) or prazosin (30 nM). 
Experiments with chloroethylcionidine 
The irreversible a-adrenergic antagonist, chloroethylcionidine. was used to study a,B-
adrenoceptors (Villalobos- Molina et al., 1997; Zhu et al.. 1997; Marshall et al.. 1995). 
Tissues were prepared as described above. An initial concentration-response relationship to 
phenylephrine was obtained for all vein rings and the maximum contraction was set as the 
100% response. Following washout and return to baseline tension the vessels segments were 
incubated with either 50 nM of chloroethylcionidine for 10, 20 or 30 min or with 100 (iM of 
chloroethylcionidine for 30 min. Then all tissues were rinsed extensively with fresh Krebs* 
solution 4-5 times for 30 min. A second concentration-response relationship was then 
acquired for phenylephrine and A61603. A tissue not exposed to chloroethylcionidine was 
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carried through the experiment and served as a time-matched control. An EC50 value was 
determined only for control tissues and for tissues treated with 50 mM chloroethylclonidine 
for 10 min. 
Data calculation. 
The effective molar concentration of an agonist required to produce 50% maximal 
contraction, i.e. EC50 (-log EC50 = pDj) was calculated from its concentration-response 
relationship curve using the GraphPad Prism computer program (GraphPad Software Inc. San 
Diego. CA). The effective concentration of an agonist required to produce 30% (EC30) of 
maximal contraction were calculated by using linear fimction between the two closest points 
which overlap the 30% response. 
The dissociation constant (K^J for the receptor-agonist complex was calculated as 
described Furchgott and Burzstyn (1967). Briefly: a double reciprocal plot of equi-effective 
concentrations of an agonist before (1/[A]) and after (1/[A]') treatment with dibenamine 
corrected for the time-dependent changes was made. The dissociation constant (K^) was 
calculated by using the equation: = slope - 1/intercept (Ruffolo. 1982). The agonist 
affinity can be calculated as a reciprocals of value (LTC^) (Furchgott. 1972). 
Antagonist potency (pKg value) for antagonists was obtained as described by 
Furchgott (1972). EC30 values were calculated as described above from the concentration-
response curves in the absence [A] and in the presence [A'] of each competitive antagonist 
concentration. The concentration ratio. CR = [A']/[A] (Furchgott. 1972). and the log (CR -1) 
was calculated after correction for ±e time-dependent changes in sensitivity to the agonist. 
The Kg value was calculated as: Kg = [B]/CR-1, where [B] is the concentration of the 
antagonist (Furchgott, 1972) and expressed as pKg (-log Kg) 
Statistical Analysis 
The results are presented as mean ± S.E.M. and n is the number of animals used for 
each experiment. Student's unpaired t-test was performed to define the differences between 
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two group means. ANOVA test was performed in order to compare differences among the 
groups. A P value of 0.05 or less was considered significant. 
Drugs 
The following drugs were used: (—)-norepinephrine bitartrate. cocaine hydrocholride. 
corticosterone 21-acetate, ipronizid (phosphate salt), acetylcholine chloride, phenylephrine 
hydrochloride, idazoxan (Sigma Chemical. St. Louis. MO). A61603 ((±N-[5-(4.5-dihydro-l 
H-imidazol-2yl)-2-hydroxy-5.6.7.8-tetrahydronaphthalen-l-yl] methanesulphonamide 
hydrobromide), (Tocris. Ballwin. MO), chloroethylclonidine. WB 4101 ((2-(2.6-
dimethoxyphenoxyethyl) aminomethyl-1,4 benzodioxane). 5-methylurapidil. BMY 7378 (8-
(2-(4-(2-methoxyphenyl)-l-piperazinyl)ethyl)-8-azaspiro(4.5)decane-7.9-dione 
dihydrochloride) (Research Biochemical International. Natick. MA), prazosin (Pfizer. 
Brooklyn, NY), tropolone (Aldrich. Milwaukee. WI), dibenamine HCI (Smith. KJine and 
French, Philadelphia, PA). L-765,314 (4-amino-2-[4-[l-(benzyloxycarbonyI)-2(S)-[[(l.l-
dimethylethyl)amino] carbonyl]-pipera2dnyI]-6,7-dimethoxyquinazoline) (Merck, Rahway. 
NJ). Prazosin was initially prepared in lactic acid and then diluted in isotonic saline solution. 
Norepinephrine and phenylephrine solutions were prepared in isotonic saline which was 
acidified with hydrochloric acid (0.0001 N, final concentration). Dibenamine and 
corticosterone were dissolved in ethanol and no more than 10 (j.1 was added to a 10-ml bath. 
All other drugs were dissolved in isotonic saline. 
RESULTS 
Adrenergic agonists, norepinephrine, phenylephrine and A61603, caused 
concentration dependent contraction of the isolated bovine tail vein. The potency (pDi) of 
phenylephrine in the bovine tail vein was (5.9 ±0.13; n=8) and was significantly different 
from the potency of norepinephrine (6.5 ± 0.09; n=4) and A61603 (7.0 ± 0.09; n=4). Thus, 
the order of agonist potency (pD, values) order was: A61603 > norepinephrine > 
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phenylephrine. The dissociation constant (K^) of norepinephrine (0.40 ± 0.07 ^M; n=4) was 
not different from that of A61603 (0.52 ± 0.11 |iM; n=4) (Fig.l). 
Antagonists, prazosin, BMY 7378, WB 4101. L-765,314 and 5-methylurapidil. 
inhibited contractile responses to phenylephrine and A6I603 (Fig. 2) and their potency (pKg) 
is presented in Table 1. The potencies of antagonists. WB 4101 and 5-methylurapidiI, were 
higher against A61603 than to phenylephrine. L-765.314 was more potent in inhibiting 
phenylephrine-induced contractions than those of A61603-induced contractions. 
Chloroethylclonidine inhibited contractile responses to phenylephrine and A61603 in 
the bovine tail vein (Fig. 3). Chloroethylclonidine (50 jiM) after 10 min incubation 
significantly inhibited the maximum (but did not affect ECjo) contractile response to 
phenylephrine but not that to A61603. However, incubation with 50 jaM 
chloroethylclonidine for 20 min (data not shown) or 30 min or with 100 fiM 
chloroethylclonidine for 30 min caused a significant inhibition of the maximal contractile 
response to both agonists. 
DISCUSSION 
The purpose of this study was to evaluate the role of a,-adrenoceptors in contractile 
responses in the isolated endothelium denuded bovine tail vein by studying the affinit>' of 
adrenergic agonists and antagonists. The adrenergic agonists, norepinephrine, phenylephrine 
and .A61603. caused concentration dependent contractions in the endothelium denuded 
bovine tail vein. A61603 had a significantly greater potency (pD;) to a-adrenoceptors 
compared to that of norepinephrine or phenylephrine. Their potency (pD^) order was: 
A61603 > norepinephrine > phenylephrine. A high potency for A61603. a selective ttiA,-
adrenoceptors agonist suggests, the presence of a,A-adrenoceptors. The potency (pD,) order 
of tti-adrenergic agonists. A61603. norepinephrine and phenylephrine, determined in the 
bovine tail vein was similar to the affinity (pK,) order of the same agonists determined by 
radioligand binding assay for native a,a- (rat submaxillary) and cloned a,3-adrenoceptors 
(bovine and human) (Buckner et al., 1996). The other two a,-adrenoceptor subtypes. a,<j-
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and a,d-adrenoceptors. had a higher affinity (pK^) to norepinephrine than to A61603 (Buckner 
et al.. 1996). The agonist-receptor dissociation constant (K^) was determined using the 
alkylating agent dibenamine which appears to have similar affinity to all (a,a-- cXib* 
a,D-) a,-adrenoceptor subtypes. This assumption is based on the experimental findings that 
dibenamine was equally potent in inhibiting a,-adrenoceptors at both low and high affinity* 
[^HJPrazosin binding sites in bovine prostate tissue (Maruyama et al.. 1992). The affinity 
(l/K^) of A61603 in the endothelium denuded bovine tail vein was not significantly different 
from that of norepinephrine. Interestingly, the value (0.40 (iM) for norepinephrine in the 
endothelium denuded bovine tail vein was lower than that determined for the endothelium 
intact bovine tail artery (3.11 ^M) (Hill and Dyer. 1997). These findings are in agreement 
with our previous observations that the bovine tail vein exhibits a higher sensitivity (EC50) to 
norepinephrine than does the artery (loudina and Dyer. 2000 c). The differences in values 
for norepinephrine in the vein and arter>' might be explained by differences in the a-
adrenoceptor types and subtypes present in each tissue. Contractile responses in the bovine 
tail arter\- to adrenergic agonists occurs via activation of predominantly a,-adrenoceptors 
(Hill and Dyer. 1997) of which the a,A-adrenoceptor subtype appears to play a significant 
role (loudina and Dyer. 2000 b). In addition, a^-adrenoceptors play an important role in 
contractile responses to adrenergic agonists in the bovine tail vein (loudina and Dyer. 2000 c) 
but not in the artety (Hill and Dyer. 1997). The adrenergic agonist potency data suggests the 
presence of an ttj^-adrenoceptor subty'pe in the bovine tail vein. 
In order to investigate the possibility of the presence of other a,-adrenoceptor 
subtypes in the tail vein, the potencies (pKg) of antagonists. WB 4101. BMY 7378. 5-
methylurapidil. L-765,314 and prazosin, were determined against phenylephrine and A61603 
(Table 1). As expected, the a,A-adrenoceptor subtype selective antagonists. 5-methylurapidil 
and 4101, were significantly more potent in inhibiting A61603-induced contraction (7.02 
and 9.40. respectively) than that to phenylephrine (6.01 and 8.76, respectively). These data 
provide additional evidence for the presence of functional a,A-adrenoceptors in the bovine 
tail vein. 
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In order to ascertain if the a,D-adrenoceptor subtype is present in the bovine tail vein 
we used the potent a,D-adrenoceptor subt>'pe selective competitive antagonist. BMY 7378. 
The affinit>' of BMY 7378 determined by radioligand binding methods (pK, = 8.2 -9.4; Goetz 
et al., 1995; Zhu et al., 1997) for the cloned a,d-adrenoceptor was similar to those reponed 
from functional studies (pA, = 8.9 - 10.1; Goetz et al.. 1995; Noble, et al.. 1997) for the 
native ttio-adrenoceptor in rat aorta and was higher than affinities for either a,a- or a,B-
adrenoceptors (Goetz et al., 1995; Zhu et al.. 1997; Noble, et al., 1997). In the bovine tail 
vein BMY 7378 inhibited contractile responses to phenylephrine and A61603 with similar 
potency (pK^ = 6.64 and 6.71, respectively). The low affinity of BMY 7378 suggests the 
lack of functional a,D-adrenoceptors in the bovine tail vein. 
For a,B-adrenoceptor subt>'pe identification we used L-765.314, a novel a,B-
adrenoceptor subtype selective antagonist, and chloroethylclonidine. L-765.314 exhibited a 
significantly higher affinity' (pKg) against phenylephrine than against A61603 (7.0 and 6.4. 
respectively) induced contraction. The affinity (pK^) of L-765.314 determined by radioligand 
binding methodology for the cloned a,3-. a,b- and a,d-adrenoceptors was 6.7, 8.5 and 7.7. 
respectively (Patane et al.. 1998). The difference in L-765.314 antagonism against 
phenylephrine, a non-subtype selective agonist, versus A61603. an a,A-adrenoceptor subtype 
selective agonist, suggests the presence of the ttiB-adrenoceptor subtype in the bovine tail 
vein. This result was supported by experiments with chloroethylclonidine. Determination of 
the presence of a,B-adrenoceptors can be obtained by evaluating the alkylation rate of a,-
adrenoceptors subt>'pes by chloroethylclonidine (Xiao and Jeffries, 1997). We found that 
treatment with a low concentration of chloroethylclonidine (50 |iM) for 10 min significantly 
inhibited the maximum contractile response to phenylephrine, but had no effect on that to 
A61603. However, increasing the concentration of chloroethylclonidine (to 100 ^iM) or 
increasing the incubation time (to 20 or 30 min) significantly inhibited the maximum 
contraction to both phenylephrine and A61603. These data suggest that incubation of the 
bovine tail vein with 50 fiM chloroethylclonidine (10 min) caused inactivation of a,B-
adrenoceptors. 
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In summan'. our data suggest that a,-adrenoceptors play a significant role in 
contractile responses to adrenergic agonists in the bovine tail vein via activation of a, a- and 
a,B-adrenoceptor subtypes. 
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Figure 1. Determination of the dissociation constant Ka for norepinephrine and A61603 
acting on a-adrenergic receptors in endothelium denuded bovine tail vein rings. 
Concentration-response relationships to an agonist were obtained in tissues not exposed to 
dibenamine (control. •) tissue and time-matched control tissue (O) and after incubating the 
tissues with 0.3 fiM dibenamine for 20 min (•). A double reciprocal plot of equi-active 
concentrations before and after incubation was used to determine the Ka of agonists (see 
Methods). 
(A). Concentration-response relationship to norepinephrine before and after 
treatment with dibenamine and a double reciprocal plot of equi-active concentrations was 
plotted for the Ka determination. (n=4). 
(B). Concentration-response relationship to A61603 before and after treatment with 
dibenamine and a double reciprocal plot of equi-active concentrations was plotted for the Ka 
determination, (n=4). 
Each point on the concentration-response curves represents the mean ± S.E.M. 
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Figure 2. Concentration-response relationships to phenylephrine (A) and A61603 (B) in 
endothelium denuded bovine tail vein rings in the absence of antagonists (control. • ) tissue 
and time-matched control tissue (O) and in the presence of adrenergic antagonists. Each 
point on the concentration-response curve represents the mean ± S.E.M. 
(A). Concentration-response relationships to phenylephrine in the absence and in the 
presence of 10 nM WB 4101 (•, n=7); 1 |a.M BMY 7378 (O. n=7); 30 fiM 5-methylurapidil 
(•. n=5); 1 f^M L-765.314 (•. n=4) and 30 nM prazosin (•. n=7). 
(B). Concentration-response relationships to A61603 in the absence and in the presence of 
10 nM WB 4101 (•, n=6); 1 jiM BMY 7378 (O, n=5); 30 fiM 5-methylurapidil (•. n=6); 
1 |aM L-765.314 ( •. n=4) and 30 nM prazosin (•. n=7). 
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Figure 3. Concentration-response relationships in isolated bovine tail vein rings to 
phenylephrine and A61603 alone and in experiments with chloroethylclonidine. (A) The 
effect of incubation with 50 |j,M of chloroethylclonidine for 10 min and (B) the effect of 
incubation with 50 jiM and 100 |j,M of chloroethylclonidine for 30 min. 
(A). The first (•) concentration-response relationship to phenylephrine (control 
tissue). (O) the second concentration-response relationship to phenylephrine for the 
untreated tissue (time-matched control). (•) concentration-response relationship to 
phenylephrine after exposure to chloroethylclonidine (50 jiM. 10 min). (•) concentration-
response relationship to A61603 in untreated (control) tissue and (A) concentration-response 
relationship to A61603 in chloroethylclonidine (50 f^M. 10 min) treated tissues. Each point 
on the concentration-response curve represent the mean ± S.E.M. n=4. (*) Maximal 
contraction to phenylephrine in chloroethylclonidine treated vein rings was different from 
that in time-matched control tissue. 
(B). Concentration-response relationship to phenylephrine in (• ) control tissue. 
(O) time-matched control, and after exposure to (A) 50 |.iM and (A) 100 |iM 
chloroethylclonidine for 30 min. Concentration-response relationship to A61603 in 
(•) untreated (control) tissue and in tissues treated with (^) 50 jiM and (O) 100 |j.M 
chloroethylclonidine for 30 min. Each point on the concentration-response curve represent 
the mean ± S.E.M. n=4. 
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Table 1. pKs values for ai-adrenoceptor antagonists in the endothelium denuded bovine tail 
vein. 
Agonist Antagonist PKb n 
Phenylephrine WB4101 8.77 ±0.16* 1 
Phenylephrine BMY 7378 6.71 ±0.08 1 
Phenylephrine Prazosin 8.84 ±0.14 1 
Phenylephrine 5-methylurapidil 6.01 ±0.15* 5 
Phenylephrine L-765.314 7.0 ±0.12* 4 
A61603 WB4101 9.40 ±0.11 6 
A61603 BMY 7378 6.64 ±0.11 5 
A61603 Prazosin 8.74 ± 0.08 7 
A61603 5-methyliuapidil 7.02 ±0.41 6 
A61603 L-765J14 6.4 ± 0.02 4 
Data are expressed as mean ± SEM of the number («) of animals used. * Mean of pKe value 
determined against phenylephrine was significantly different (/'<0.05) from the mean 
determined against A61603. 
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CHAPTER IV. THE ROLE OF aj-ADRENOCEPTORS IN CONTRACTILE 
RESPONSES IN THE BOVINE TAIL VEIN AND ARTERY. 
A paper submitted to European Journal of Pharmacology. 2000 
Marina V. loudina and Donald C. Dyer 
ABSTRACT 
The purposes of this study were to compare contractile responses to a^-adrenoceptor 
agonists in the isolated endothelium denuded bovine tail artery and vein and to identify the 
a^-adrenoceptor subtypes present. UK 14,304, an aj-adrenoceptor selective agonist, caused 
concentration-dependent contraction of the bovine tail vein with a pD; of 6.9 ± 0.10 and a 
maximum tension developed 3.3 ± 0.3 g or 62.8 ± 5.2 % (n=9) of that to 120 mM KCl. The 
maximum tension developed to UK 14,304 in the bovine tail artery was only 6 ± 1.1% (n=4) 
of that to 120 mM KCl. The potencies (pKg ± S.E.M) for aj-adrenoceptor antagonists 
calculated against UK 14.304 in the bovine tail vein were: rauwolscine (8.2 ± 0.20). WB 
4101 (7.8 ± 0.26). idazoxan (7.9 ± 0.13), prazosin (7.7 ± 0.50). yohimbine (7.6 ± 0.27) and 
.A.RC 239 (6.4 ± 0.17). The potency of prazosin (7.7) against UK 14.304 in the vein suggests 
the presence of a^e- and/or a^c-adrenoceptor subtypes rather than the presence of a2A.t>* 
adrenoceptors. To discriminate between a,B- and a^c-adrenoceptor subtypes we determined, 
using pKg values, the relative potency ratio of pK^ values for ARC 239/rauwolscine in the 
bovine tail vein and found it to be 0.77. This ratio was not different from a similar ratio (0.83 
± 0.03. n=5) using literature pK^or pKo values for ajc-adrenoceptors. Norepinephrine was 
more potent in producing contractions in the bovine tail vein (pD, = 6.5 ± 0.07) than in the 
tail artery (pD, = 6.1 ± 0.16, n=4) P<0.05. Idazoxan pKg values against norepinephrine were 
(6.6 ± 0.08, n=8) in the bovine tail artery and (6.8 ±0.12, n=7) in the vein. This was 
significantly (P<0.05) lower than the pKe (7.9) for UK 14,304 in vein. In conclusion, 
functional a^-adrenoceptors in the bovine tail vein play a significant role in contractile 
94 
responses to adrenergic agonists. UK 14.304, an a^-adrenergic agonist, caused contraction in 
the isolated endothelium denuded bovine tail vein via activation of a^c-adrenoceptors. 
However, the possibility that other functional a^-adrenoceptor subt\'pes (a,B and/or a,D) in 
the bovine tail vein participate in adrenergic agonist mediated contraction cannot be excluded 
and needs further study. Contraction mediated by aj-adrenoceptors in the endothelium 
denuded bovine tail artery is ver>' small. 
Keywords: a2-adrenoceptor subtypes, vascular smooth muscle, bovine, tail artery, tail vein. 
INTRODUCTION 
There are two types of a-adrenoceptors (a,- and a^-) and both are found in vascular 
smooth muscle (see Dochert>'. 1998, for review). Both a,- and a,-adrenoceptors can 
participate in vascular contraction to adrenergic agonists (Elliott 1997; Leech and Faber. 
1996). a,-Adrenoceptors appear to play a dominant role in vascular contraction (Hill and 
Dyer. 1997). but not always (Guimaraes and Nunes. 1990). In general, it is accepted that 
functional a^-adrenoceptors can be characterized by their high affinity to the a^-adrenoceptor 
agonists, clonidine and UK 14.304, (5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline 
bitartrate), and to the a^-adrenoceptor antagonists, rauwolscine and yohimbine and by a low 
affinity to the a,-adrenoceptor antagonist, prazosin (see MacKinnon et ah. 1994 for review). 
The presence of functional aj-adrenoceptors has been reported in several vascular beds such 
as equine digital vein (Elliot. 1997). dog mesenteric artery (Daniel et al., 1995), dog 
mesenteric vein (Paiva et a!.. 1999), dog saphenous vein (MacLennan et al., 1997). rat 
femoral vein (Paiva et al.. 1999) and human saphenous vein (Roberts et al.. 1992; Gavin et 
al.. 1997). According to current classification, fimctional a^-adrenoceptors are divided into 
three subtypes (ajA/jD'- "zb"- ^ZC) (Docherty, 1998) while four recombinant a^-adrenoceptor 
subtypes have been cloned and identified as, a2A-, otze*- ci:d adrenoceptors (Bylund et 
al.. 1994; Docherty, 1998). The and a^o-adrenoceptor subtypes appear to be species 
homologues of the same receptor subtype (a2A,T3-subtype) (Bylund et al., 1994) but 
pharmacological differences between ajA- and ajQ-adrenoceptor subtypes (Bohmann et al.. 
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1994; Guimaraes et al.,1998; Ali. et al..l998) have been reported. ajA-Adrenoceptors are 
found in humans (Guimaraes et al.. 1998), pigs (Trendelenburg et al.. 1996) and rabbits 
(Trendelenburg et al., 1994), while the ajo-adrenoceptor subtype is present in the rat (Ho et 
al.. 1998), mouse (Limberger et al., 1995), guinea pig (Ali. et al.. 1998) and cattle (Bylund et 
al.. 1997). 
.All three subtypes (aiA/^o"' ocib"- of a^-adrenoceptors have been found in vein 
smooth muscle. aj^-Adrenoceptors have been identified in dog saphenous vein (MacLennan 
et al.. 1997). dog mesenteric vein (Paivaetal., 1999) while a3-adrenoceptors (Smith et al.. 
1992) and a2c:-adrenoceptors (Gavin et al., 1997) are found in human saphenous vein. It has 
been reported that activation of both a,- and a^-adrenoceptors causes contraction of human 
femoral vein (Glusa and Markwardt, 1983), equine digital vein (Elliot, 1997) and porcine 
carotid arteriovenous anastomoses (Willems et al., 1999). The expression of contractile 
responses is dependent on the densities of a,- and a^-adrenoceptors on the cell membrane of 
vascular smooth muscle (Wright et al., 1995). 
The type of adrenergic receptors in the endothelium intact bovine tail arterj' has been 
studied in our laboratory (Hill and Dyer. 1997) and it was reported that contractile responses 
in the bovine tail artery occur predominantly through activation of a,-adrenoceptors. There 
is no information to our knowledge concerning functional a-adrenoceptor types and subtypes 
in the bovine tail vein and in comparison with those in the tail artery. The bovine tail artery 
and vein exhibit different sensitivities to norepinephrine (loudina and Dyer, 1999) which 
might be explained in part on differences in adrenoceptor types/subtypes involved in 
contractile responses in these vessels. The purposes of this study were to compare contractile 
responses to a^-adrenoceptor agonists in the bovine tail artery and vein and to identify the a,-
adrenoceptor subtypes. 
a-Adrenoceptors (a,-and a,-) on the endothelial cell membrane (MacLean, et al.. 1993; 
Zschauer et al.. 1997) can modify the contractile responses to adrenergic agonists via 
endothelium-dependent mechanisms. In order to avoid the possible effect by the 
endothelium on contractile responses to adrenergic agonists in the bovine tail artery and vein 
we used endothelium denuded vessels. 
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MATERIALS AND METHODS 
Tissue preparation 
Bovine tails (steers) were obtained from a local abattoir and delivered on ice to the 
laboratory. The median caudal artery jmd vein were isolated from the tail and placed in an 
aerated modified Krebs' solution. The composition of the Krebs' solution was (mM): NaCl. 
115.21; KCl 4.70; CaCU. 1.80; MgS04, 1.16; KH,PO„ 1.18;NaHC03. 22.14; dextrose. 7.88; 
and 0.03 mM EDTA. The procedure used in preparing the tissue was similar to that 
described by Hill and Dyer (1997). Artery and vein were cut into rings 4-5 mm long. The 
endothelium was denuded by careful rotation of a blimt wooden stick inside the vessel lumen. 
Each vessel ring was placed in a 10 ml tissue bath filled with continually aerated (95% O;: 
5% COj) Krebs" solution maintained at 38.5°C. The tissue rings were mounted between two 
stainless steel wires passing through the lumen of each ring. One wire was stationary and 
was attached near the bottom of the tissue bath while the second wire was connected to the 
force transducer. Isometric contraction was continually monitored by using a MacLab 
sN'stem connected to a computer. The ring segments were initially stretched to a tension of 
15g (artery) and 4g (vein) and then allowed to relax over a 60-min period. Baseline tension 
was adjusted to 2g for artery and to Ig for vein rings before beginning the experiments-
Evaluation of contractile response to UK 14^04 in the bovine vessels 
Arter\' and vein rings were prepared as described above. At the end of the 
equilibration period the vessel rings were contracted to 120 mM K.C1. This contractile 
response was set as the 100% response to which all other agonist-induced contractile 
responses were compared. The absence of a relaxation response to the addition of 1 fi.M 
acetylcholine to the bath was used to confirm endothelium removal. Tissues which relaxed 
to acetylcholine were not used. Vessel rings were then washed with fresh Krebs" solution 
ever\' 10 minutes for 30 minutes until the basal tension of 2 g for artery and 1 g for vein was 
re-established. A concentration-response relationship to UK 14,304 (1 nM - 10 fj.M) was 
obtained without or in the presence of an antagonist. UK 14,304 was added cumulatively to 
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the tissue baths in half-log increments. The vein segments were incubated for 1 hour with 
one concentration of an a-adrenoceptor antagonist: rauwolscine (0.3 |iM). WB 4101 
(0.3 m-M). idazoxan (0.3 ^M), prazosin (0.3 (aM). yohimbine (0.3 jaM) or ARC 239 (3 (iM). 
A tissue not exposed to an antagonist was used as a control tissue for each experiment. 
Evaluation of contractile response to norepinephrine in the bovine vessels 
Tissues were prepared as described above. During the initial 60-min equilibration 
period, artery and vein segments were incubated with 0.36 mM iproniazid in order to inhibit 
monoamine oxidase (MAO). Absence of a relaxation response to acetylcholine (IjiM) in 
arter\' and vein rings contracted by KCl (45 and 120 mM. respectively) was used to confirm 
endothelium removal. The vessel rings that did relax to acetylcholine were not used. Tissues 
were then extensively washed with fresh Krebs" solution for 30 minutes until the basal 
tension was re-established. Prior to obtaining a concentration-response relationship to 
norepinephrine all tissues were treated with 10 ^M tropolone, 1 fiM cocaine and 10 fiM 
corticosterone for 15 minutes in order to block catecholamine-O-methyltransferase. neuronal 
(uptake,) and tissue (uptake,) uptake, respectively (Furchgott and Garcia. 1968; Levin and 
Furchgott. 1970; Hill and Dyer. 1997). 
Concentration-response relationships to norepinephrine (10 nM - 0.1 mM) were 
obtained twice, before and 1 hour after incubation with one concentration of idazoxan (1 or 
3 )iM). The maximum contraction to norepinephrine obtained during the first concentration-
response relationship was set as the 100% response for that tissue. One tissue not exposed to 
idazoxan was carried through each experiment in order to correct for time-related changes in 
tissue sensitivity to norepinephrine. 
Calculation of data 
The effective concentration of an agonist which produced 50% of the ma.\imal 
contraction, i.e. ECjo (-log EC50 = pD,) was calculated based on concentration-response 
relationships to an agonist using non-linear regression (GraphPad computer program; 
GraphPad Software Inc, Szm Diego, CA). The effective concentration of an agonist to 
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produce 25% (EC^s) or 30% (EC30) of maximal contraction were calculated by using linear 
function between two the closest points on either side of the 25% or 30% response. EC.s and 
EC30 values were used to calculate antagonist potencies (pKg) as described by Furchgott 
(1972). Briefly: EC^j or EC30 were calculated in the absence [A] and in ±e presence [A ] of 
each competitive antagonist concentration from the concentration-response curves. The 
concentration ratio, CR = [A']/[A] (Furchgott, 1972). and the log (CR - 1) was calculated 
after correction for the time-dependent changes in sensitivity to the agonist. The Kg value 
was calculated as: Kg = [B]/CR-1. where [B] is the concentration of the antagonist 
(Furchgott. 1972) and expressed as pKg = -log Kg 
Drugs 
The following drugs were used: (—)-norepinephrine bitartrate. cocaine hydrocholride. 
corticosterone 21-acetate, iproniazid (phosphate salt), acetylcholine chloride, yohimbine, 
idazoxan (Sigma Chemical. St. Louis. MO), ARC 239 ((2-[2.4-(methoxyphenyl)piperazin-l-
yl]-ethyl)-4.4-dimethyl-1.3-(2H.4H)-isoquinolindine dihydrochloride). UK 14,304, (5-
bromo-6-[2-imidazolin-2-ylamino]-quinoxaline bitartrate) (Tocris, Ballwin, MO). WB 4101 
((2-(2.6-dimethoxyphenoxyethyl) aminomethyl-1.4 benzodioxane) hydrochloride), 
rauwolscine (Research Biochemical International. Natick. MA), prazosin (Pfizer. Brooklyn. 
NY), tropolone (Aldrich. Milwaukee . WI). UK 14.304 was initially dissolved in DMSO and 
then diluted in isotonic saline. Prazosin was initially prepared in lactic acid and then diluted 
in isotonic saline solution. Norepinephrine solutions were prepared in isotonic saline which 
was acidified with hydrochloric acid. All other drugs were dissolved in isotonic saline. 
Statistical Analysis 
The results are presented as mean ± S.E.M. and n is the number of animals used for 
each experiment. The group differences among the treatments were determined by using 
ANOVA test. The differences between two group means were examined by using Student's 
unpaired t-test. A P value of 0.05 or less was considered significant. 
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RESULTS 
UK 14.304. an tti-adrenoceptor selective agonist, caused concentration-dependent 
contraction of the bovine tail vein (Fig.l) with a pD, of 6.9 ±0.10 and a maximum tension 
developed 3.3 ± 0.3 g or 62.8 ± 5.2 % (n=9) of that to 120 mM KCl. Tension developed in 
response to UK 14.304 in the bovine tail artery was only 0.4 ± 0.12 g and was 6 ± 1.1% (n=4) 
of that to 120 mM KCI (data not shown). 
a."Adrenoceptor antagonists, rauwolscine (0.3 jiM), WB 4101 (0.3 jaM). idazoxan 
(0.3 fiM). prazosin (0.3 ^iM), yohimbine (0.3 ^ M) and ARC 239 (3 f^M). caused inhibition of 
contractile responses to UK 14,304 in the bovine tail vein (Fig.l). The antagonist potencies 
(pKg values) are presented in Table 1. Potencies for the same antagonists in the bovine tail 
arter>' were not obtained because of ±e small contraction developed to UK 14.304. 
Norepinephrine produced concentration-dependent contractions of the bovine tail 
vessels (Fig. 2) and was more potent in producing contractions in the bovine tail vein (pD; = 
6.5 ± 0.07. n=8) than in the artery (pD^ = 6.1 ± 0.16. n=4) P<0.05. Idazo.xan (1 and 3 ^M) 
(Fig.2) inhibited concentration-dependent contraction to norepinephrine with similar potency 
(pKe) in the bovine tail artery (6.6 ± 0.08, n=8) and vein (6.8 ±0.12, n=7). The antagonist 
potency of idazoxan was significantly (P<0.05) higher against UK 14,304 in vein (pKg = 7.9 
±0.12, n=7) as compared to that of norepinephrine. 
DISCUSSION 
The purpose of this study was to investigate the role of a^-adrenoceptors in contractile 
responses in the isolated endothelium denuded bovine tail artery and vein. In order to 
evaluate the role of a^-adrenoceptors we used the non-subtype selective a^-adrenergic 
agonist, UK 14,304. Based on radioligand binding methods, UK 14,304 seems to have a 
higher affinity to all cloned a^-adrenoceptor subtypes (pK^ values: 6.3 - 6.7) as compared to 
that of norepinephrine (pK, values: 4.9 - 5.8) (Renouard et al., 1994; Uhlen et al., 1992). In 
our study UK 14.304 caused a significant contractile response in the endothelium denuded 
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bovine tail vein with a maximal tension developed of 3.3 g which was 63 % of the 120 mM 
KCl response. a,-Adrenoceptor antagonists, prazosin, idazoxan. ARC 239. WB 4101. 
rauwolscine and yohimbine inhibited contractile responses to UK 14.304. Antagonist 
potencies were calculated from a single concentration of antagonist and expressed as a pKg 
value (Table 1). We found that prazosin inhibited contractile responses to UK 14.304 with a 
relatively high potency (pKg = 7.7) which suggests the presence of ajB- and/or ttjc* 
adrenoceptor subtypes rather than aio-adrenoceptors. A higher potency (pK,) for prazosin 
has been demonstrated for a^e- and/or a^c-adrenoceptor subtypes (Uhlen et al.. 1994. 
MacLenann et al.. 1997) and a lower (pK^) for a2A,Tj-adrenoceptors (Trendelenburg et al.. 
1994. Bohmann et al., 1994. Limberger et al.. 1995, Wahl et al.. 1996). However, prazosin is 
unable to discriminate between ttiB- and ajc-adrenoceptor subtypes. For this purpose we 
compared antagonist potency of ARC 239 and rauwolscine. These antagonists exhibit 
affinity for all a^-adrenoceptor subtypes. However, ARC 239 has a slightly greater 
selectivity for ajB-adrenoceptors (Blaxall et al.. 1991. Uhlen et al.. 1994, Renouard et al.. 
1994) while rauwolscine is more selective for ajc-adrenoceptors (Blaxall et al.. 1991. Uhlen 
et al.. 1994). In order to discriminate between ttie- and a^c-adrenoceptor subtypes we 
calculated relative potencies (Blaxall et al.. 1991. Fuder and Selbach. 1993) of ARC 239 and 
rauwolscine for a2B- and a^c-adrenoceptors. For example, the pKg value for ARC 239 (6.4) 
in the bovine tail vein was relatively small compare to that of rauwolscine (8.2) (Table 1) and 
the calculated relative potency ratio (ARC 239/rauwolscine) was 0.77. This ratio was 
compared with similar ratios (ARC 239/ rauwolscine) from the literature. These values were 
determined from a number of radioligand binding experiments (pK^ or pKp) for a^a- and a^c-
adrenoceptors (Table 2). The calculated mean potency ratio for a^c-adrenoceptors (0.83 ± 
0.03. n=5) was significantly lower than that for a^e-adrenoceptors (0.98 ± 0.03. n=6). This is 
in agreement with the higher selectivity of ARC 239 for aig-adrenoceptors and of 
rauwolscine for ajc-adrenoceptors, discussed above. The relative potency ratio of ARC 
239/rauwolscine calculated for the bovine tail vein (0.77) was not different from the ratio 
calculated for literature values for a^c-adrenoceptors. These results suggest the presence of 
functional a^c-adrenoceptors in the bovine tail vein. No significant correlation of our data 
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(pKg values) with antagonist potencies reported in the literature from radioligand binding 
(pK, or pKo values) experiments for known ai-adrenoceptor subt>T3es (Uhlen et al.. 1992. 
Uhlen et al.. 1994, Blaxall et al., 1991) was found. A lack of potent subtype selective a,-
adrenergic agonists and antagonists makes the identification of receptor subtype difficult 
especially in ftmctional studies. The majority of commercially available a^-adrenoceptor 
antagonists have an affinity for all a^-adrenoceptor subtypes (Uhlen et al., 1994, MacLenann 
et al., 1997. Blaxall et al.. 1991, Trendelenburg et al., 1994, Limberger et al., 1995. Wahl et 
al.. 1996) but with a limited selectivity for one specific a^-adrenoceptor subtype (Blaxall et 
al.. 1991. Uhlen et al., 1994, Renouard et al., 1994, MacLenann et al.. 1997). We conclude 
that UK 14,304 caused contractile responses in the bovine tail vein through activation of a,-
adrenoceptors which resemble the a^c-adrenoceptor subtype. However, our data do not 
permit us to exclude the possibility of ajB- and/or aiQ-adrenoceptors participating in the 
contractile response to an adrenergic agonist. 
In the isolated endothelium denuded bovine tail arter>' UK 14,304 caused a very small 
contractile response which was only 6% of that to 120 mM KCI. The artery rings developed 
a much smaller tension in resp>onse to UK 14,304 (0.4 g) when compared to vein rings 
(3.3 g). A small contractile response to a^-adrenoceptor agonists in the tail artery is in 
agreement with previously published data (Hill and Dyer, 1997). They found that in intact 
isolated bovine tail artery medetomidine, a selective a^-adrenoceptor agonist, caused 
contraction but with low potency (pD, = 5.6) and low maximal response. Another a;-
adrenoceptor agonist, B-HT 920 (5,6,7,8-tetrahydro-6-(2-propenyl)4H-thiazolo [4,5-
d]azepin-2-amine dihydrochloride) failed to produce a contractile response. In their study 
idazoxan and rauwolscine did not inhibit the contractile response to medetomidine which 
suggests that the large concentration of medetomidine required to elicit a contraction may not 
have been via a^-adrenoceptors. We found that norepinephrine had a similar potency to 
produce contractile responses in the endothelium denuded (pD, = 6.1) tail artery when 
compared to the endothelium intact (pD, = 5.9) (Hill and Dyer. 1997) bovine tail artery. The 
bovine tail vein was more sensitive to norepinephrine (pD, = 6.5) than the tail artery (pD, = 
6.1). These findings might be explained by differences in the a-adrenoceptor types (a, - in 
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arten; a, and a; - in vein) contributing to response to norepinephrine in those vessels. A 
higher norepinephrine potency was reported by Blaylock and Wilson (1995) for those vessel 
with a larger population of a^-adrenoceptors. Idazoxan caused inhibition of contractile 
responses to norepinephrine in the isolated denuded bovine tail artery and vein (Fig. 2). The 
potency (pKg) of idazoxan against the non-subtype selective a-adrenoceptors agonist, 
norepinephrine, was similar in the artery and vein (6.6 and 6.8, respectively) and was 
significantly lower than that found for idazoxan in vein (pKb= 7.9) against a selective a^-
adrenoceptors agonist. UK 14.304. Idazoxan is a potent non-subtype selective a,-
adrenoceptors antagonist. The potency (pK, or pKp) of idazoxan obtained from radioligand 
binding studies has been published in a number of reports and varied from 7.3 to 8.7 (Blaxall 
et al.. 1991. McLennan et al., 1997; Renouard et al., 1994) for different a,-adrenoceptor 
subtypes. This range encompasses the potency (pKg = 7.9) of idazoxan against UK 14.304 in 
the bovine tail vein. Low idazoxan potency (pKg) in the bovine tail artery and vein against 
norepinephrine may indicate affinity of idazoxan for a,-adrenoceptors. We speculate that a 
high concentration of idazoxan (1-3 |aM) may cause inhibition of contractile responses to 
norepinephrine, in part, via inhibition of a,-adrenoceptors. The role of fiinctional a,-
adrenoceptors in the bovine tail vessels is under current investigation. 
In summary, fiinctional a2-adrenoceptors in the bovine tail vein play a significant role 
in contractile responses to adrenergic agonists. UK 14.304. a^-adrenergic agonist, caused 
contraction in the isolated endothelium denuded bovine tail vein via activation of a^c* 
adrenoceptors. However, the possibility that other functional a^-adrenoceptor subtypes (a;B-
and/or ajc-) in the bovine tail vein participate in adrenergic agonist mediated contraction 
cannot be excluded and needs fiirther study. The role of a^-adrenoceptors in the bovine tail 
artery is very small, because UK 14.304 caused only a ver>' small contraction. 
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Figure 1. Concentration-response relationships to UK 14,304 in endothelium denuded 
bovine tail vein rings in the absence of antagonists (control ( • ) tissue) and in the presence of 
adrenergic antagonists: 0.3 (iM WB 4101 (A) (n=4); 0.3 |iM rauwolscine (A) (n=6); 
0.3 idazoxan (•) (n=7); 0.3 jiM prazosin (•) (n=5); 3 (iM ARC 239, (O) (n=5) and 
0.3 |j.M yohimbine (V) (n=5). Each point on the concentration-response curve represents the 
mean ± S.E.M. 
Figure 2. Concentration-response relationships to norepinephrine in endothelium denuded 
bovine tail vessels in control (•), time-matched control (O) tissue, and in the presence of 
1 j^M (•) and 3 fiM (•) idazoxan. (A). Contractile responses in the isolated bovine tail 
arter\-. n=4. (B). Contractile responses in the isolated bovine tail vein. n=8. Each point on 
the concentration-response curve represents the mean ± S.E.M. 
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Table 1. Antagonist potencies in the isolated endothelium denuded bovine tail vein. 
Antagonist PKb Number of 
animals (n) 
WB4101 7.8 ± 0.26 4 
Prazosin 7.7 ±0.50 5 
ARC 239 6.4 ±0.17 5 
Rauwolscine 8.2 ± 0.20 6 
Idazoxan 7.9 ±0.13 7 
Yohimbine 7.6 ± 0.27 5 
-Ajitagonists potencies were obtained against UK 14.304. an a2-adrenoceptor selective 
agonist. Data are expressed as mean ± SEM of the number (n) of animal used. 
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Table 2. Relative potencies of ARC 239 and rauwolscine for a2B- and aic-adrenoceptors 
calculated as a ratio of potencies reported from radioligand binding studies. 
Subtype of a^-adrenoceptors 
and literature source 
Relative potency 
(ARC 239/rauwolscine ratio) 
2B. rat neonatal kidney, Uhlen et al.. 1992 
2B. rat neonatal lung, Uhlen et al.. 1992 
2B. guinea pig cerebral kidney, Uhlen et al.. 1995 
2B. rat neonatal lung, Blaxall et al.. 1991 
2B. cloned human receptors, Uhlen et al., 1994 
2B. rat neonatal lung, Renouard et al., 1994 
mean 
2C. rat cerebral cortex, Uhlen et al.. 1992 
2C. cloned rat pA2d cells. Uhlen et al.. 1992 
2C, guinea pig cerebral cortex receptors. Uhlen et al.. 1995 
2C. opossum kidney cells. Blaxall et al.. 1991 
2C, cloned human receptors, Uhlen et al., 1994 
mean 
1.00 
0.98 
1.09 
0.94 
0.92 
0.91 
0.98 ± 0.03 * 
0.83 
0.81 
0.87 
0.72 
0.82 
0.83 ± 0.03 
TTie calculated mean ratio of data obtained from the literature and presented in this table for 
a2B-adrenoceptors and for aac-adrenoceptors. The relative potency for ARC 239 and 
rauwolscine (ARC 239/rauwolsine ratio) based on pKe values obtained in the present study 
for the isolated bovine tail vein is 0.77. * Mean value is significantly different (P<0.05) from 
that ratio (0.77) found for bovine tail vein. 
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CHAPTER V. EVALUATION OF NERVE-MEDIATED CONTRACTION IN THE 
BOVINE TAIL ARTERY IN RESPONSE TO ELECTRICAL FIELD STIMULATION 
A paper to be submitted to European Journal of Pharmacology. 2000 
Marina V. loudina and Donald C. Dyer 
ABSTRACT 
The purpose of this study was to investigate the possibility of a purinergic component 
in nerve-mediated contractile responses in a bovine skeletal muscle (tail) artery when 
subjected to field stimulation. The isolated bovine tail arter>' was used as the tissue model. 
We found, that contractile responses of the isolated bovine tail artery subjected to electrical 
field stimulation were frequency dependent and were abolished by tetrodotoxin (1 mM). The 
maximum contraction to field stimulation was 43% - 50% of the maximum to that of 
norepinephrine. Phentolamine and prazosin caused concentration-dependent inhibition of 
contractile responses to exogenous norepinephrine. Phentolamine (1.3 and 10 ^iM) and 
prazosin (10. 30 and 100 nM) both effectively inhibited frequency-dependent contractions to 
field stimulation. However. 15% of the maximum contraction to norepinephrine remained at 
32 Hz in the presence of the high antagonist concentration. 
a,P-MeATP (0.1 - 10 |iM) caused concentration-dependent contractions of the 
isolated bovine tail artery. The maximum contractile response obtained from a non-
cumulative concentration-response relationship to a,P-meATP (102 ± 7.4 %) was 
significantly higher then that obtained when the a,P-meATP was added to the bath in a 
cumulative manner (64 ± 5.6). Desensitization of purinergic receptors with a,P-meATP (1 
nM) was not long-lasting and did not permit this method to be used as a to inactivate the 
purinergic receptors. Suramin (300 |iM) but not prazosin (100 nM) significantly inhibited 
contractile responses to a,P-meATP in the bovine tail artery. Suramin (300 jiM) did not 
affect the contraction to KCl but unexpectedly antagonized contractions to norepinephrine. 
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Contractile responses to field stimulation at 8 - 32 Hz were significantly inhibited by suramin 
(300 |J.M) but the degree of inhibition by a combination of prazosin (100 nM) and siu-amin 
(300 (J.M) was not different from inhibition produced by prazosin alone. PPADS 
(pyridoxalphosphatte-6-azophenyl-2'.4'-disulphonic acid) (100 nM) had no effect on either 
a,P-meATP-evoked contractions nor contractions to field stimulation. 
In conclusion, our data suggest that there are fimctional purinergic (P,^) receptors in 
the bovine tail artery and their activation causes a contractile response. There is a possibility 
of norepinephrine/purinergic co-transmission in the bovine tail artery but additional 
experiments will be required to resolve this problem. 
Keywords: bovine tail artery, field stimulation, nerve-mediated contraction, 
a,P-meATP. 
INTRODUCTION 
The co-transmission concept, established since the 1970's and well-accepted today, 
states that norepinephrine can be stored and released fi-om the sympathetic nerve terminal 
alone or in combination with ATP (adenosine 5'-triphosphate) and/or neuropeptide Y (see 
Lunberg. 1996). ATP can be stored and released fi"om the adrenergic nerve terminal along 
with norepinephrine (Lagercrantz and Stjame. 1974: Bumstock. 1976). ATP released from 
the nerve terminal (Lagercrantz and Stjame. 1974: Bumstock. 1976: Levitt and Westfall. 
1982: Sedaa. et al.. 1990) activates purinergic receptors (see Ralevic and Bumstock. 1998) 
and causes contraction (Muramatsu et al.. 1989; Ziyal et al., 1997; Ziganshin et al.. 1994) or 
relaxation of vascular smooth muscle (Ziganshin et al.. 1994; Ziyal et al.. 1997). ATP co-
transmission has been demonstrated in vascular tissues, such as dog mesenteric arterv-
(Muramatsu. 1986), rabbit ear artery (O'Connor et al.. 1990). rabbit aorta (Sedaa et al.. 
1990). canine splenic artery (Ren et al.. 1996) as well as in non-vascular tissues, such as 
guinea-pig and rat vas deferens (Fedan et al., 1981), guinea-pig taenia coli and rat duodenum 
(Windscheif et al., 1995). However, information about the co-transmission process in 
skeletal muscle vessels is limited. For example, ATP co-transmission has been reported in 
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the rat tail and femoral arteries and dog saphenous vein (Sajag et al.. 1990) and in rabbit 
saphenous artery (Bumstock and Warland. 1987). Limited research has been done 
concerning the regulation of vascular smooth muscle contraction in cattle (Dzielak. 1983). 
Some difficulties exist in determining whether ATP is involved in the co-transmission 
processes. In general, those problems can be divided into two major categories. The first 
group of problems is related to the chemical properties of ATP as a neurotransmitter and the 
second group is related to the number and types of purinergic receptors present in the tissue. 
For example, neuronally released ATP is a very unstable compound and is rapidly, within 
100 milliseconds (Bao and Stjame. 1993), enzymatically inactivated by adenosine 
5'-triphosphatase (ecto-ATPase) to adenosine (Gordon, 1986). Adenosine can cause cellular 
responses on its own via activation of adenosine receptors and thereby mask the role of ATP 
(Ralevic and Bumstock, 1998). Current classification divides purinergic receptors into two 
categories: PI (adenosine receptors) and P2 (ATP receptors) (Ralevic and Bumstock, 1998). 
ATP receptors (P2) are subdivided into two classes, Pjx and Piy. where P^x receptors are 
.ATP-gated ion channels and P^y receptors are G-protein coupled receptors. In addition. 
seven subtypes of P^x (P2X1 * ^2x7) and five subtypes of P^y (P2Y1 - P2Y5) receptors have been 
cloned (see Ralevic and Bumstock. 1998). Lack of subtype selective agonists and 
antagonists for Pjx and P,y receptors makes it impossible to determine purinergic receptor 
subtypes by studying contractions in smooth muscle. 
Electrical field stimulation (Levitt and Westfall, 1982; Machaly et al.. 1988; Evans 
and Kennedy. 1994) has been commonly employed to stimulate the sympathetic nerve 
terminal in order to produce effects via neurotransmitter(s) release. ATP release from the 
sympathetic nerve terminal can be directly studied by measuring [^H]-purine outflow from 
the sympathetic nerve terminal (Levitt and Westfall. 1982; Sedaa et al.. 1990). Measuring 
contractile responses to field stimulation in isolated tissue can be employed as a method to 
evaluate whether ATP co-transmission occurs when it is coupled with the use of appropriate 
pharmacological chemicals. 
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The purpose of this study was to investigate whether there is a purinergic component 
in contractile responses in a bovine skeletal muscle arter>' subjected to field stimulation by 
using the isolated bovine tail artery as the tissue model. 
MATERIALS AND METHODS 
Tissue preparation 
Bovine tails from steers were obtained from a local abattoir. The tissue was 
transported to the laboratory on ice where the tail arteries were dissected from the basal part 
(upper third) of the tail. Dissected vessels were placed in a modified Krebs" solution with the 
following composition (mM): NaCl. 115.21; KCl 4.70; CaCl,, 1.80; MgS04. 1.16; KH2PO4. 
1.18; NaHCO,. 22.14; dextrose, 7.88 and EDTA. 0.03 mM. Intact vessels were cut into rings 
4-5 mm long and each ring was mounted on two stainless steel wires passing through the 
lumen of the ring. Each ring was placed in a 10 ml tissue bath filled with Krebs" solution at 
38.5° C and continually aerated by bubbling O,: CO, (95;5) from the bottom of the bath. 
Indomethacin (2.8 }iM) was added to the Krebs' solution to inhibit cyclooxygenase and 
prevent the synthesis of prostaglandins in all experiments. No attempt was made to remove 
the endothelium. 
One wire was stationary and secured near the bottom of the tissue bath while the 
second wire was connected to the force transducer. Up to 8 rings were studied per 
experimental day. Isometric contractions were continually monitored by using a MacLab 
system connected to a computer. The ring segments were initially stretched to a tension of 
15 g and then allowed to relax over a 60-min period. Then the ring segments were adjusted 
to a basal tension of 2g and maintained at the basal tension for 20 - 30 min before being 
exposed to drugs. 
Field stimulation experiments 
The tension developed in the isolated artery rings in response to field stimulation 
were obtained as a frequency-response relationship (Duckies and Silverman, 1980; Ren and 
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Bumstock. 1997) with a frequency range of 1 - 32 Hz. Field stimulation was delivered by a 
Grass SD9 stimulator which was connected to a Med-Lab Stimu-Splitter II (Med Lab 
Instruments. Fort Collins, Co) to create a constant current between a pair of electrodes in the 
tissue bath. A constant current method has been proposed as the best technique to use in field 
stimulation experiments in order to stimulate the nerve terminals and not the smooth muscle 
(Duckies and Silverman. 1980). Tissues were stimulated for 20 sec at each frequency with an 
electrical pulse duration of 1 msec at a constant current of 150 mA in the tissue bath. A 
constant current of 150 mA was mziintained through the stimulation period and was manually 
adjusted when required. 
An initial series of experiments were conducted to confirm that: 1) the chosen 
electrical parameters caused contraction due to neurotransmitter(s) release, and were not the 
result of direct stimulation of vascular smooth muscle, and 2) repeated field stimulation did 
not change the tissues excitability to norepinephrine or to field stimulation over the 
experimental time period. 
Tissues were prepared as described above. An initial concentration-response 
relationship to norepinephrine was followed by a 30-min washout period. A set of three 
consecutive frequency-response relationships (1-32 Hz) to field stimulation was then 
obtained. A 15-min interval between two frequency-response relationships was sufficient 
and allowed the tissues to relax to the baseline tension (2 g) before the next stimulation 
session occurred. Then artery rings were washed with fresh Krebs' solution and 2 or 3 
tissues per experiment were incubated (I hour) with 1 mM tetrodotoxin in order to block the 
voltage-gated Na'-channels. A second set of three consecutive frequency-response 
relationships to field stimulation was then obtained and this was followed by a concentration-
response relationship to norepinephrine. 
The following experiments were conducted for the purpose to investigate and 
compare the role of adrenergic and purinergic components in contractile responses to field 
stimulation. 
Frequency-response relationships to field stimulation (1-32 Hz) were obtained 
before and after 1 -hour incubation with one concentration of phentolamine (0.1, 1, 3 or 
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10 fiM) and prazosin (10. 30 or 100 nM). An arter\' ring not exposed to an antagonist, which 
sen. ed as a time-matched control tissue, was carried through each experiment. Contractile 
responses to field stimulation were compared to a concentration-response relationship to 
norepinephrine (10 nM - 100 jiM) which was obtained twice, before and after determining a 
frequency-response relationship to field stimulation. 
Frequency-response relationships to field stimulation (1-32 Hz) were obtained 
before and 1-hour after incubation with one concentration of PPADS (100 |iM) 
(pyridoxalphosphatte-6-azophenyl-2'.4'-disulphonic acid), prazosin (100 nM). suramin 
(300 jaM) or a combination of prazosin and suramin (100 nM and 300 jj,M. respectively). 
Contractile responses to a,|3-meATP 
.A. stable ATP analogue. a,P-meATP. was used to ascertain if it would contract the 
isolated bovine tail artery in order to confirm the presence of fiinctional purinergic receptors 
in this blood vessel. 
Tissues were prepared as described above. The maximum contractile response 
obtained during the determination of a concentration-response relationship to norepinephrine 
(10 nM - 100 faM) was set as the 100% response and was used for comparison to contractile 
responses to a,P-meATP. We compared cumulative vs. non-cumulative concentration-
response relationship to a,{3-meATP. A cumulative concentration-response relationship to 
a,P-meATP (0.1 |iM - 10 nM) was obtained by adding it in half-log increments to the tissue 
bath. For the non-cumulative concentration-response relationship, a,p-meATP (0.1 ^ M -
10 uM) was added to the tissue bath in single increasing concentrations, where every 
successive concentration was one-half log higher than preceding concentration. A twenty-
minute washout inter\'al was sufficient between the two consecutive concentrations for tissue 
tension to return to basal conditions (2 g). 
In order to evaluate the effectiveness of desensitization of purinergic receptors by the 
cumulative application of a,p-meATP we used a single concentration of a,p-meATP (1 ^M). 
Immediately after obtaining the cumulative concentration-response to a,P-meATP tissues 
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were extensively washed three times over a 5 min period and then I |aM a,P-meATP was 
added to the bath. An addition 1 jiM a,P-meATP was added to the bath 20 min later. 
The effects of the purinergic antagonists, suramin and PPADS. as well as an 
a,-adrenergic antagonist, prazosin, were evaluated for their effects on contractile responses to 
a,p-meATP. Tissues were prepared as described above. After the equilibration period, all 
tissues were challenged with a single (3 |j,M) concentration of a,3-meATP. which produced a 
standardized contractile response. The tissues were then washed with fresh Krebs' solution 
for 30 min before adding the antagonists: prazosin (100 nM), suramin (300 ^iM). a 
combination of prazosin and suramin (100 nM and 300 ^M. respectively) or PPADS (100 
I^M). A tissue not exposed to an antagonist was carried through each experiment and it 
ser\'ed as a time-matched control tissue. Cumulative concentration-response relationships to 
a,P-meATP (0.1 |j,M - 10 jiM) were obtained 1 hour after incubation with antagonists. The 
effect of suramin on contractile responses to norepinephrine and KCl were also obtained 
1 hour after incubation with 300 |i.M suramin. 
Statistical Analysis 
The results are presented as mean ± S.E.M. and n  is the number of animals used for 
each experiment. EC50 values for agonists, were calculated from their concentration-response 
relationships using the GraphPad Prism computer program (GraphPad Software Inc. San 
Diego, CA). The group differences among the treatments were analyzed by using ANOVA. 
Student's unpaired t-test was performed to define the differences between two group means. 
Values are given as means ± S.E.M. A P value of 0.05 or less was considered significant. 
Drugs 
The following drugs were used in this study: norepinephrine, phentolamine. suramin. 
a,p-meATP, indomethacin, tetrodotoxin (Sigma Chemical, St. Louis. MO), PPADS 
(pyridoxalphosphatte-6-azophenyl-2',4'-disulphonic acid) (Research Biochemical 
International. Natick, MA), prazosin (Pfizer. Brooklyn. NY). Indomethacin was dissolved in 
10% Na2C03 and solutions were made fresh daily. Prazosin wzis initially dissolved in lactic 
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acid and then diluted in isotonic saline solution. Norepinephrine solutions were prepared in 
isotonic saline which was acidified with hydrochloric acid. All other drugs were dissolved in 
isotonic saline. 
RESULTS 
Contractile responses in the isolated bovine tail arter>' to electrical field stimulation 
were frequency dependent (Fig. 1 A). Tetrodotoxin (1 mM), significantly inhibited 
contractile responses to field stimulation (Fig. I A) but had no effect on the concentration-
response relationship to exogenous norepinephrine (Fig. IB). Repeated field stimulation did 
not change the tissue excitability to norepinephrine or to field stimulation during the course 
of the experiment (Fig. 1). The maximum contraction to field stimulation was found to be 
43% - 50% (Fig. 2A and Fig. 3 A) of the maximum to norepinephrine. 
Phentolamine (1.3 and 10 jaM) and prazosin (10, 30 and 100 nM) significantly 
decreased contractile responses to field stimulation (Fig. 2A and Fig. 3A. respectively) and to 
norepinephrine (Fig. 2B and Fig. 3B. respectively). Phentolamine and prazosin caused 
concentration-dependent inhibition of contractile responses to norepinephrine. However, 
inhibition of contractile responses to field stimulation by prazosin and phentolamine was not 
concentration-dependent. Different concentrations of phentolamine (1.3 and 10 fiM) and 
prazosin (10. 30 and 100 nM) were equally potent in inhibiting frequency-dependent 
contractions to field stimulation, and approximately 15% of the maximum contraction to 
norepinephrine remained at 32 Hz (Fig.2A and Fig 3A. respectively) in the presence of these 
antagonists. 
a,p-MeATP (0.1 (iM - 10 |j.M) caused concentration-dependent contractions of the 
isolated bovine tail artery (Fig. 4). The maximum contractile response obtained from the 
non-cumulative concentration-response relationship to a,P-meATP was significantly higher 
(102 ± 7.4 %) then that obtained from the cumulative (64 ± 5.6%) concentration-response 
relationship (n=4). A single concentration (1 hM) of a,P-meATP did not cause contraction 
of the tail artery when it was applied immediately after the washout period following the 
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cumulative concentration-response relationship to a,P-meATP. After an additional 20-min 
interval an addition I (xM of a,P-meATP in the bath produced a contraction of the arter>' 
(data not shown). 
Suramin (300 (iM) but not prazosin (100 nM) significantly inhibited contractile 
responses to a,P-meATP in the bovine tail artery (Fig. 5). PPADS (100 fj.M) did not inhibit 
a,P-meATP-evoked contractions in the bovine tail artery (data not shown). The same 
concentration of suramin (300 fAM) did not affect the contraction to KCl (Fig. 6A) but 
unexpectedly antagonized contractions to norepinephrine (Fig. 6B). 
Contractile responses to field stimulation at 8 - 32 Hz were significantly inhibited by 
suramin (300 ^M) in the bovine tail artery rings (Fig. 7). However, the degree of inhibition 
by a combination of prazosin (100 nM) and suramin (300 jiM) was not different from the 
inhibition produced by prazosin alone (Fig. 7). PPADS (100 |j.M) did not affect the 
contractile response to field stimulation (data not shown). 
DISCUSSION 
We used field stimulation to study contractile responses to sympathetic nerve terminal 
stimulation and to evaluate the possibility that purinergic co-transmission processes occur in 
the isolated bovine tail artery. An electrical field stimulation with a constant current between 
two parallel platinum electrodes was used in all experiments (Duckies and Silverman. 1980). 
Tetrodotoxin (1 mM), a voltage-gated Na*- channel blocker, abolished the contractile 
responses to electrical field stimulation in the bovine tail artery but had no effect on 
contractile responses to norepinephrine. These findings indicated that the contractions 
observed were due to neurotransmitter(s) release and were not the result of direct stimulation 
of vascular smooth muscle. 
If norepinephrine is the only neurotransmitter released from sympathetic nerve 
terminals then an equivalent response will be produced by both ner\'e stimulation and 
exogenous norepinephrine when an equivalent number of adrenergic receptors are occupied. 
To test this hypothesis we compared contractile responses to norepinephrine and field 
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stimulation in the presence of a-adrenergic antagonists, prazosin and phentolamine. 
Contractile responses to field stimulation were frequency-dependent with the maximum 
response being about 43 - 50% of that to the maximum obtained to norepinephrine (100 |iM). 
Prazosin and phentolamine, as expected, significantly inhibited contractile responses to 
exogenous norepinephrine and caused a right shift of the concentration-response relationship 
curve for norepinephrine (Fig. 2A and 3 A). Prazosin (30 and 100 nM) and phentolamine 
(3(j.M and 10 )j.M) completely inhibited contractile responses to exogenous norepinephrine at 
concentrations lower than the EC50 of norepinephrine in time-matched control tissue (Fig. 2 
and 3). However, responses to field stimulation at 32 Hz in the presence of prazosin (30 and 
100 nM) and phentolamine (3fiM and 10 (iM) were about 15% of the maximal contraction to 
norepinephrine. These data suggest that prazosin and phentolamine were more potent in 
inhibiting contractile responses to exogenous norepinephrine than those to field stimulation 
in the bovine tail artery. Based on these findings we concluded that there was a possibility of 
more than one neurotransmitter, besides norepinephrine, being involved in the contractile 
response to sympathetic ner\'e terminal stimulation. We then sought to determine whether 
purinergic (ATP) co-transmission occurred in this tissue. 
There are no reports to our knowledge about the presence of purinergic receptors in 
the bovine tail artery. Contractile responses to the purinergic agonist a,P-meATP, a 
synthetic stable ATP analogue, which activates purinergic (P2x) receptors have been 
demonstrated in rat mesenteric artery (Windschief et al.. 1994). rabbit ear artery (O'Connor 
et al.. 1990) and rat urinary bladder (Bo and Bumstock, 1990). We found that a,p-meATP 
caused concentration-dependent contraction of the bovine tail artery, which suggests the 
presence of fianctional purinergic (P2x) receptors. A comparison of concentration-response 
relationships to a,P-meATP when applied in single concentrations versus cumulatively 
indicated that some desensitization occurred during the cumulative approach for obtaining a 
concentration-response relationship. The maximal response to cumulatively applied a,P-
meATP was about 40% less than when it was applied in a non-cumulatively manner. After 
obtaining a cimiulative concentration response relationship to a,p-meATP, followed by a 
5-min washout period, the addition of a single concentration (1 |iM) of a,P-meATP did not 
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produce a contraction. However, at 20 min. a,p-nieATP (1 ^M) did produce a contraction. 
Thus, the desensitization was not long-lasting. Based on these findings, desensitization did 
not prove to be an effective method to inactivate purinergic receptors in the isolated bovine 
tail artery. In contrast to our findings. Ziyal and co-workers (1997) did not find differences 
benveen cumulative and non-cumulative concentration response relationships to a,P-meATP 
in rabbit saphenous artery. 
Contractile responses to a,p-meATP were significantly inhibited by suramin 
(300 p-M) but not by prazosin (100 nM) in the bovine tail artery. These findings were 
expected and in agreement with others (Bao and Stjame. 1993: Leff et al.. 1990; Ziyal et al.. 
1997; Morris. 1999). It has been shown that suramin, as a purinergic (P^x) competitive 
antagonist, inhibited contractile responses to a,p-meATP in the isolated rabbit ear artery (pA, 
= 4.79) (Leff et al.. 1990) and rabbit saphenous artery (pA, = 4.79) (Ziyal et al.. 1997). 
Similar to that reported earlier (Bao and Stjame, 1993). suramin (300 |iM) did not affect 
contractions to KCl in the isolated bovine tail artery. However, we found that suramin (300 
pM) slightly, but significantly, inhibited contraction to norepinephrine. These findings are 
not in agreement with previously published reports about suramin's effect on contractile 
responses to exogenous norepinephrine. For example, 30 |iM suramin did not affect 
contractile responses to submaximal (10 |iM) concentration of norepinephrine in guinea pig 
small cutaneous artery (Morris. 1999) and 500 (iM suramin did not interfere with the 
concentration-response relationship to norepinephrine (10 nM - 100 (iM) in rat tail artery 
(Bao and Stj^e. 1993). The antagonism by suramin to low concentrations of 
norepinephrine was not expected and cannot be clearly explained. There are no reports, to 
our knowledge, about suramin inhibition of contractile responses to norepinephrine. 
However, it has been recently discovered that suramin (100 |iM) is a G protein inhibitor and 
inhibits the activation of the subunit (Freissmuth et al.. 1996; Hohenegger et al., 1997). 
Norepinephrine is known to produce contraction of bovine tail artery through activation ofa-
adrenoceptors (predominantly a,-adrenoceptors. Hill and Dyer. 1997) which are coupled to G 
proteins (for review see Docherty, 1998). The possibility of cross-talk interactions between 
G," and G^-coupled receptors has been discussed in the literature (Selbie and Hill, 1997). We 
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speculate that inhibition of the activation of the G„ subunit by suramin would be expected to 
inhibit contractile responses to norepinephrine in the bovine tail arter>'. These findings 
clearly need further study. 
PPADS, a purinergic (P^x) receptor antagonist, has been reported to effectively inhibit 
the contractile responses to a,P-meATP in some vascular tissue preparations, such as isolated 
rabbit ear artery (Ziganshin et al., 1994), isolated splenic artery (Ren and Bumstock. 1997) 
and perfused rat mesenteric artery (Windscheif et al., 1994). However. PPADS (100 |iM) did 
not inhibit contractile responses to a,P-meATP or field stimulation and could not be used as 
a chemical tool to study purinergic receptors in the bovine tail artery. 
We studied contractile responses to field stimulation in the presence of 300 fiM 
suramin alone and in combination with ICQ nM prazosin. Suramin (300 fiM) inhibited 
frequency-dependent contraction in the bovine tail artery (Fig. 7) and inhibition became 
significant at higher fi-equencies (8 -32 Hz). Unfortunately, suramin's effect on field 
stimulation may not be the result of inhibition of only purinergic receptors because it 
inhibited contractions to norepinephrine and because it may inhibit G-protein mediated 
contraction (Freissmuth et al., 1996; Hohenegger et al.. 1997). Suramin (300 (iM) in 
combination with prazosin (100 nM) significantly, but not completely, inhibited contraction 
to field stimulation and it was not different fi-om the inhibitory effect of prazosin (100 nM) 
alone. These findings suggest the possibility of ATP co-transmission in sympathetic nerves 
in the bovine tail artery. To solve this issue the measurement of ATP release under field 
stimulation of sympathetic nerve terminals using the methods described by Levitt and 
Westfall (1982) may be helpful. The possibility that neuropeptide Y may be acting as a 
sympathetic co-transmitter should be also examined. It has been reported recently that 
neuropeptide Y and norepinephrine are sympathetic co-transmitters and mediate contraction 
in guinea pig small cutaneous artery (Morris, 1999) while in human saphenous vein. ATP, 
neuropeptide Y and norepinephrine are involved in contractile responses to field stimulation 
(Racchi et al., 1999). 
In conclusion, our data suggest that there are fimctional purinergic (Pjx) receptors in 
the bovine tail artery and their activation causes contractile responses. The lack of potent 
125 
selective purinergic antagotiists has not permitted us to conclude that ATP is definitely a co-
transmitter but data were obtained which point in this direction. The development of potent 
and selective purinergic antagonists and the measurements of ATP release in response to 
field stimulation will help to resolve the issue of whether ATP acts as a co-transmitter in the 
bovine tail arter\'. 
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Figure 1. Contractile responses to (A) field stimulation and (B) exogenous norepinephrine 
in the bovine tail artery in control (•), time-matched control tissues (O) and in the presence 
of 1 mM tetrodotoxin (•). A. Each line is a mean of three consecutively (with 15-min 
interval between everj'^ two frequency-response relationships) obtained frequency-response 
relationships (1-32 Hz) to electrical field stimulation. Data arrived from 4 animals. 
B. Concentration-response relationships to exogenous norepinephrine obtained for the same 
tissues (see A. above) prior to and after field stimulation. Each point represents mean ± 
S.E.M.. n=4. 
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Figure 2. Contractile responses to (A) field stimulation and (B) exogenous norepinephrine 
in the bovine tail artery in (•) control. (O) time-matched control tissues and in the presence 
of (•) 1 |J.M. (V) 30 JJ.M and (•) 100 fiM phentolamine. A. Frequency-response 
relationship to field stimulation in the bovine tail arter>'. Data plotted as percent of maximal 
contraction to norepinephrine. Data obtained from 7-13 animals. Each point represents the 
mean ± S.E.M. B. Concentration-response relationships to exogenous norepinephrine 
obtained prior to and after field stimulation. Each point represents mean ± S.E.M., n=5 - 7. 
Figure 3. Contractile responses to (A) field stimulation and (B) exogenous norepinephrine 
in the bovine tail artery in (•) control, (O) time-matched control tissues and in the presence 
of (•) 10 nM. (V) 30 nM. and (•) 100 nM prazosin. A. Frequency-response relationship to 
field stimulation in the bovine tail artery. Data plotted as percent of maximal contraction to 
norepinephrine. Each point represents mean ± S.E.M.. n=7. B. Concentration-response 
relationships to exogenously added norepinephrine obtained prior to and after field 
stimulation. Each point represents mean ± S.E.M.. n=7. 
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Figure 4. Concentration-response relationship to a,P-meATP applied cumulatively (•) and 
in single increasing concentrations (non-cumulatively, see Methods) (•) in the isolated 
bovine tail artery. Data plotted as percentage of maximum contraction to norepinephrine. 
Each point represents mean ± S.E.M., n=4. 
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Figure 5. Concentration-response relationships to a,P-meATP in the isolated bovine tail 
arter\- in the absence of antagonists (control ( •) tissue) and in the presence of (V) 100 nM 
prazosin. (") 300 jiM suramin and (•) combination of 100 nM prazosin and 300 |iM 
suramin. Data plotted as a percentage of the maximum contraction to 30 |iM a,p-meATP. 
Each point represents mean ± S.E.M.. n=6. 
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Figure 6. Concentration-response relationships to KCI (A) and to norepinephrine (B) in the 
isolated bovine tail artery in (•) control tissue. (O) time-matched control tissue and in the 
presence of (•) 300 fiM suramin. Data plotted as a percentage of the maximum contraction 
to norepinephrine. Each point represents mean ± S.E.M., n=5. (*) - Indicates responses in 
the presence of suramin (300 ^M) are significantly different from those in the time-control 
tissues (P < 0.05). 
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Figure 7. Frequency-response relationships to field stimulation in the isolated bovine tail 
artery in control tissue (•) and time-matched control tissues (O) and in the presence of 
(A) 100 nM prazosin, (•) 300 suramin and (•) a combination of 100 nM prazosin 
and 300 |aM suramin. Data plotted as a percentage of the maximum contraction to 
30 nM a,P-meATP. Each point represents mean ± S.E.M., n=6. (*) - Indicates 
contractile responses that are statistically different {P < 0.05) from those to in time-
matched control tissues. 
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CHAPTER VI. GENERAL CONCLUSIONS 
General Discussion 
This chapter contains a discussion of all the major conclusions from the 
present study. 
a-Adrenoceptors mediating contractile responses in the bovine tail arter>' 
It was shown earlier that adrenergic agonists induced contractile responses in the 
isolated bovine tail artery primarily through ai-adrenoceptors and not through az-
adrenoceptors (Hill and Dyer, 1997). No attempt was made to identify the a i-adrenoceptor 
subtypes involved in vasoconstriction responses in the bovine tail artery. In the present study 
contractile responses were investigated using isolated tissue bath methods similar to those 
used by Hill and Dyer (1997). Characterization of a i-adrenoceptor subtypes was done on the 
endothelium denuded bovine tail artery in order to avoid the possible effect by the 
endothelium (MacLean. et al., 1993; Zschauer et al.. 1997) on contractile responses to 
adrenergic agonists. 
The presence of aiA-adrenoceptors was demonstrated in experiments with the Oia-
adrenoceptor subtype selective agonist, A61603 (Buckner et al.. 1996). A61603 caused 
concentration-dependent contractions and was more potent than the non-selective ai-
adrenoceptor agonists norepinephrine and phenylephrine. The potency order was: A61603 > 
norepinephrine > phenylephrine, based on a comparison of EC50 values. Similar data were 
found for the bovine cloned au-adrenoceptor in radioligand binding experiments (Buckner et 
al.. 1996). The affinity (pKi) of A61603 for cloned hamster aib-adrenoceptors or cloned rat 
aid-adrenoceptors was less than that for norepinephrine and phenylephrine (Buckner et al.. 
1996). 
The affinity (pAi) of the a 1-adrenoceptor antagonists (5-methyIurapidil. WB 4101, 
BMY 7378 and ARC 239) against A6I603 and phenylephrine in the bovine tail artery was 
compared with literature (pKj) values obtained for the same antagonists for cloned receptors. 
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All four antagonists exhibited competitive antagonism against A61603. There was a 
significant correlation of pAi values from our study with pKi values reported by Zhu and 
colleagues (1997) for the cloned au-adrenoceptor. but not with cloned aib- or aid-
adrenoceptors. suggesting the presence of functional aiA-adrenoceptors in the bovine tail 
artery. 
The affmit>' of BMY 7378, a selective aip-adrenoceptor antagonist (Goetz et al.. 
1995; Zhu et al.. 1997), was found to be significantly higher against the non-subtype 
selective agonist phenylephrine than against a selective aiA-adrenoceptor agonist. A61603. 
A higher potency of BMY 7378 against phenylephrine can be taken as evidence (Fagura et 
al.. 1997; Villalobos-Molina et al.. 1997; Zhu et al.. 1997) for the presence of fionctional aip-
adrenoceptors in the bovine tail artery. 
Determination of the presence of aie-adrenoceptors in the bovine tail artery was done 
in experiments using the irreversible antagonist chlorethyiclonidine (O'Rourke et al.. 1995). 
Chloroe thy lc lon id ine  has  been  used  to  d i s t ingu i sh  be tween  a i A - ad renocep to r s  and  a i e -
adrenoceptors (Teng et al.. 1994; Testa et al.. 1995; Hattori and Kanno. 1997). The 
alkylating rate of chlorethyiclonidine is significantly lower for aiA-adrenoceptors than that 
for a IB- or aio-adrenoceptors (Xiao and Jeffries. 1997). In the bovine tail arter\'. 
preireaiment of tissues with a low concentration of chloroethylclonidine (50 ^M) for 10 min 
significantly inhibited contractile responses to phenylephrine but had no effect on the 
concentration-response relationship to A61603. A higher concentration of 
chloroethylclonidine and a longer incubation time significantly inhibited contractions 
produced by both phenylephrine and A61603, probably by an inactivation of all ai-
adrenoceptor subtypes. However, chlorethyiclonidine cannot discriminate between aiB- and 
aiD-adrenoceptor subtypes because it alkylates aiB- and aio-adrenoceptor subtypes at the 
same rate (Xiao and Jeffries, 1997). Whether the bovine tail artery possesses functional ais-
adrenoceptor subtypes is unclear since this possibility could not be excluded. 
The possible involvement of a2-adrenoceptors in mediating contractile responses in 
the isolated endothelium denuded bovine tail artery was studied using the ai-adrenoceptor 
selective agonist UK 14,304. UK 14,304 caused very small contractile responses which were 
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only 6% (or about 0.4 g) of that to 120 mM KCl. Idazoxan. an a^-adrenoceptor antagonist, 
inhibited contractile responses to norepinephrine in the isolated endothelium denuded bovine 
tail artery with potency (pKe) significantly lower than the affinity (pKi or pKo) reported from 
radioligand binding studies for ai-adrenoceptors (Blaxall et al.. 1991. MacLeiman et al.. 
1997; Renouard et al., 1994). A low pKe value for idazoxan in the bovine tail arter>-
determined against norepinephrine may be an indication of idazoxan blocking a.\-
adrenoceptors and not a2-adrenoceptors. 
These experiments extend the earlier findings of Hill and Dyer (1997) and support 
their conclusion for lack of a significant ai-adrenoceptor involvement in adrenergic 
mediating contractions in the bovine tail artery. 
In summary, in isolated endothelium denuded bovine tail arteries, ai-adrenoceptors 
but not a2-adrenoceptors were found to play a role in contractile responses to adrenergic 
agonists, a ia-Adrenoceptors plays a dominant role in contractile responses to adrenergic 
agonists compared to that of aio-adrenoceptors. Evidence for the presence of functional aiB-
adrenoceptors is more equivocal but it is likely that aiB-adrenoceptors also co-exist in the 
bovine tail artery (Table 1). 
a-Adrenoceptors mediating contractile responses in the bovine tail vein 
In contrasts to artery, a fewer number of studies have reported on the functional role 
of a 1-adrenoceptors in vein (Schuiz and Westfall. 1982; Leech and Faber, 1996; Elliot. 1997; 
Marshall et al., 1996; Hu and Dyer, 1997; Low et al.. 1999). 
Investigation of the presence of a i A -adrenoceptors in the bovine tail vein was studied 
using an experimental design similar to that for the study of a i-adrenergic receptors in the 
bovine tail artery. The adrenergic agonists norepinephrine, phenylephrine and A61603 
caused concentration dependent contractions in the endothelium denuded bovine tail vein and 
A61603 had a significantly greater potency (pDi) than that of norepinephrine or 
phenylephrine. Their potency (pD2) order (A61603 > norepinephrine > phenylephrine) 
indicates the presence of aiA-adrenoceptors (Buckner et al., 1996). However, the 
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dissociation constant for the receptor-agonist complex (KA) for norepinephrine in the 
endothelium denuded bovine tail vein was not significantly different from that for A61603. 
Interestingly, the affinity (1/KA) of norepinephrine and its pDi value were higher in the 
bovine tail vein than in the bovine tail artery. The differences in affinity of norepinephrine in 
the vein and artery may be explained by differences in the a-adrenoceptor types and subt>'pes 
present in each tissue (Bevan et al.. 1988; Bevan et al., 1986). 
The potency (pKs) of a i-adrenoceptor antagonists, WB 4101. BMY 7378. 5-
methylurapidil and prazosin was evaluated against phenylephrine and A61603. In addition, a 
new and novel aiB-adrenoceptor subtype selective competitive antagonist. L-765.314 (4-
amino-2-[4-[l -(benz\'loxycarbonyl)-2(S)-[[( 1,1 -dimethylethyl)amino] carbonyl]-
piperazinyl]-6,7-dimethoxyquinazoline) (Patane, et al.. 1998) became available for our use 
and was used to help determine whether aie-adrenoceptors are present in the tail vein. 
The presence of fimctional aiA-adrenoceptors in the bovine tail vein was strongly 
indicated by a higher affinity of the a i A-adrenoceptor selective antagonists. 5-methylurapidil 
and WB 4101 against A61603-mediated contraction than that of phenylephrine-mediated 
contraction. 
There are some differences in the a i-adrenoceptor subtype(s) composition in the 
bovine tail vein as compared to that in the artery. In contrast to the artery, no evidence for 
the presence of the aio-adrenoceptor subtype was found in the bovine tail vein. This 
conclusion is based on a low potency of the aio-adrenoceptor subtype selective antagonist 
BMY 7378 in inhibiting contractile response to A61603 and phenylephrine in the bovine tail 
vein. In addition, the presence of aiB-adrenoceptor subtypes in the bovine tail vein was 
demonstrated by using L-765,314, an ais-adrenoceptor subtype selective antagonist and 
chloroethylclonidine. Both antagonists were more potent in inhibiting contractile responses 
to phenylephrine than those mediated by A61602. In summary, two ai-adrenoceptor 
subtypes, aiA- and aiB-adrenoceptors, play a role in contractile responses to adrenergic 
agonists in the bovine tail vein (Table 1). 
Differences in types of functional a-adrenoceptors were found in bovine tail vein in 
comparison to the tail artery. The presence of the a2-adrenoceptor involvement in contractile 
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responses in the isolated endothelium denuded bovine tail vein was determined by using a 
non-subtype selective ai-adrenergic agonist. UK 14.304. (Renouard et al.. 1994; Uhlen et al.. 
1992). UK 14.304 produced a significant (about 63% of the maximal contraction to 120 mM 
KCl) contractile response in the endothelium denuded bovine tail vein. 
Table 1. a - Adrenoceptors characterized in the isolated endothelium denuded bovine tail 
artery and vein. 
Bovine tail vessels 
Artery Vein 
ar adrenoceptors Contraction Contraction 
Ct|A Present, predominant subtype Present 
CtlB Presence can not be excluded Present 
aiD Present Not present 
o-z- adrenoceptors Little role in contraction Contraction 
tt2B Not applicable Presence can not be excluded 
CX2C Not applicable Present 
tt2D Not applicable Presence can not be excluded 
ai-Adrenoceptor antagonists, prazosin, idazoxan. ARC 239. WB 4101. rauwolscine 
and yohimbine inhibited contractile responses to UK 14.304 and their potency was calculated 
as a pKe value. A relatively high potency of prazosin, as an a2-adrenoceptor antagonist, in 
inhibiting UK 14.304 induced contraction suggests the presence of a2B- and/or a^c-
adrenoceptor subtypes rather than a2D-adrenoceptors (Uhlen et al.. 1994. MacLenann et al., 
1997; Trendelenburg et al.. 1994. Bohmann et al.. 1994. Limberger et al.. 1995. Wahl et al.. 
1996). In order to discriminate between a2B- and a2c-adrenoceptor subtypes, the relative 
potencies (Blaxall et al.. 1991. Fuder and Selbach. 1993) of ARC 239 and rauwolscine were 
compared. The rationale for this comparison is based on the fact that ARC 239 has a slightly 
greater selectivity for a2B-adrenoceptors (Blaxall et al., 1991, Uhlen et al., 1994, Renouard et 
al., 1994) while rauwolscine is more selective for a2c-adrenoceptors (Blaxall et al., 1991, 
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Uhlen et al.. 1994). Relative potency was calculated as a ratio of potency based on pKe 
\ alues for (.^RC 239/ rauwolscine) and compared to the literature values obtained from a 
number of radioligand binding experiments (pKjOr pKo) (Blaxall et al.. 1991. Uhlen et al.. 
1992, Uhlen et al., 1994, Uhlen et al.. 1995. Renouard et al.. 1994) for a2B- and aic* 
adrenoceptors. The relative potency ratio of ARC 239/rauwolscine calculated for the bovine 
tail vein was similar to that calculated for literature values for aic-adrenoceptor subtypes and 
this suggests the presence of fimctional a2c-adrenoceptors in the bovine tail vein. However, 
the possibility that 0.23- and a^o-adr^noceptor subtypes are present in the tail vein cannot be 
excluded (Table 1). 
Investigation of nerve-mediated contraction in tiie bovine tail artery in response to 
electrical Held stimulation 
Investigation of ner\'e-mediating contraction and an evaluation of possible co-
transmission from sympathetic nerve terminals in the bovine tail arter%'^ in response to 
electrical field stimulation was a part of the research project. Electrical field stimulation with 
a constant current between two parallel platinum electrodes was used in all experiments 
(Duckies and Silverman, 1980). Contractile responses to field stimulation in the bovine tail 
arier\' were blocked by tetrodotoxin (1 mM). a voltage-gated Na'- channel blocker and this 
indicated that the contraction observed was due to neurotransmitter(s) release and not the 
result of direct stimulation of vascular smooth muscle. 
The working hypothesis was that if norepinephrine is the only neurotransmitter 
released from sympathetic nerve terminals then equal responses should be produced when an 
equal number of adrenoceptors are occupied, regardless of whether the norepinephrine comes 
from sympathetic neurons or is added exogenously to the tissue bath. Therefore, an 
equivalent concentration of norepinephrine at the receptor region would produce an 
equivalent contractile response due to the activation of the same number of receptors. In 
order to test this hypothesis contractile responses to norepinephrine and field stimulation 
were compared in the presence of a-adrenergic sintagonists, prazosin and phentolamine. 
Prazosin and phentolamine, as expected, significantly inhibited contractile responses to 
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exogenous norepinephrine in a concentration-dependent manner and caused a right shift of 
the concentration-response relationship curve for norepinephrine. However, prazosin and 
phentolamine were relatively less potent in inhibiting contractile responses to field 
stimulation than those to exogenously added norepinephrine. These findings suggested that 
there was a possibility of more than one neurotransmitter, besides norepinephrine, being 
involved in the contractile response to sympathetic nerve terminal stimulation. The possible 
involvement of ATP being a co-transmitter was evaluated. 
The presence of fimctional purinergic receptors (Pzx) was demonstrated with a 
synthetic stable ATP analogue. a,p-meATP. which produced concentration-dependent 
contraction of the bovine tail artery (Windschief et al.. 1994; O'Connor et al.. 1990; Bo and 
Bumstock. 1996). 
Contractile responses to a,P-meATP were significantly inhibited by the purinergic 
(P2X receptor) competitive antagonist, suramin (Bao and Stjame. 1993; Leff et al.. 1990; 
Ziyal et al., 1997; Morris, 1999) but not by prazosin. In addition, suramin slightly but 
significantly inhibited contractile responses to field stimulation in the bovine tail artery. 
However, these results were not easy to interpret because suramin, unexpectedly, slightly but 
significantly inhibited contractions to norepinephrine. Another purinergic (Pzx) receptor 
antagonist PPADS which has been reported to effectively inhibit contractile responses to 
a,P-meATP in some vascular tissue preparations was evaluated for its ability to antagonize 
a,p-meATP (Ziganshin et al., 1994; Ren and Bumstock. 1997; Windscheif et al.. 1994). 
However. PPADS did not inhibit contractile responses to a,P-meATP or field stimulation in 
the bovine tail artery. The desensitization approach of inactivating purinergic receptors 
(Ralevic and Bumstock. 1998) was attempted but was futile since the desensitization process 
did not last long enough. 
In searching for an explanation of suramin's inhibitory effect on norepinephrine-
induced contraction we discovered that suramin has been reported to have an inhibitory 
effect on the a subunit of G protein (Freissmuth et al.. 1996; Hohenegger et al., 1997). Since 
contractions to norepinephrine are mediated via G protein (and if this occurs in the artery) 
then suramin would be expected to inhibit contractions to norepinephrine regardless of its 
source (nerve or exogenously added to the bath). 
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In conclusion, our data suggest that there are functional purinergic (P2x) receptors in 
the bovine tail artery and their activation causes contractile responses. The lack of potent 
selective purinergic antagonists has hampered this research. The possibilit\' of sympathetic 
ATP co-transmission occurring in the bovine tail arter>- cannot be excluded and will be more 
convincing when experiments measuring ATP release under field stimulation are carried out. 
The possibility of neuropeptide Y involvement in the co-transmission process should be also 
examined in future studies. 
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